Following The Patents: Covid-19 & Medical Tyranny
Over the past two decades, a company named M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In their 2003-2004 Global Technology Assessment: Vector Weaponization, M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, they have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and many other research institutions, and their commercial affiliations.
The
National Institute of Health’s grant AI23946-08, issued to Dr. Ralph Baric at
the University of North Carolina at Chapel Hill (officially classified as
affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for
the express purpose of general research, pathogenic enhancement, detection,
manipulation, and potential therapeutic interventions targeting the same. As
early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of
the coronavirus family for their commercial benefit. (Source: U.S. Provisional
Application No. 60/206,537, filed May 21, 2000) In one of the several papers
derived from work sponsored by this grant, Dr. Baric published what he reported
to be the full-length cDNA of SARS CoV in which it was clearly stated that SAR
CoV was based on a composite of DNA segments.
“Using
a panel of contiguous cDNAs that span the entire genome, we have assembled a
full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly
cloned SARS viruses (infectious clone SARS-CoV) that contained the expected
marker mutations inserted into the component clones.”
(Source: https://www.pnas.org/content/100/22/12995)
On
April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher
M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent
7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an
infectious, replication defective, coronavirus.” This work was supported by the
NIH grant referenced above and GM63228. In short, the U.S. Department of Health
and Human Services was involved in the funding of amplifying the infectious
nature of coronavirus between 1999 and 2002 before SARS was
ever detected in humans!
Against
this backdrop, they noted the unusual patent prosecution efforts of the CDC,
when on April 25, 2003 they sought to patent the SARS coronavirus isolated from
humans that had reportedly transferred to humans during the 2002-2003 SARS
outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This
legality did not deter CDC in their efforts. Their application, updated in
2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not
licensed by their patent from manipulating SARS CoV, developing tests or kits
to measure SARS coronavirus in humans or working with their patented virus for
therapeutic use. Work associated with this virus by their select collaborators
included considerable amounts of chimeric engineering, gain-of-function
studies, viral characterization, detection, treatment (both vaccine and
therapeutic intervention), and weaponization inquiries.
In
short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852
patent (Claim 1), no research in the United States could be conducted
without permission or infringement.
It
was noted that gain-of-function specialist, Dr. Ralph Baric, was both the
recipient of millions of dollars of U.S. research grants from several federal
agencies but also sat on the World Health Organization’s International
Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study
Group (CSG). In this capacity, he was both responsible for determining
“novelty” of clades of virus species but directly benefitted from determining
declarations of novelty in the form of new research funding authorizations and
associated patenting and commercial collaboration. Together with CDC, NIAID, WHO,
academic and commercial parties (including Johnson & Johnson; Sanofi and
their several coronavirus patent holding biotech companies; Moderna; Ridgeback;
Gilead; Sherlock Biosciences; and, others), a powerful group of interests
constituted what we would suggest are “interlocking directorates” under U.S.
anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.
35 U.S.C. § 101
Section
101 of the Patent Act: "Whoever
invents or discovers any new and useful ... composition of matter, or any new
and useful improvement thereof, may obtain a patent therefor, subject to the
conditions and requirements of this title." 35 U.S.C. § 101.
We
have "long held that this provision contains an important implicit
exception[:] Laws of nature, natural phenomena, and abstract ideas are not
patentable." Mayo, 566 U.S., at , 132 S.Ct., at 1293 (internal
quotation marks and brackets omitted). Rather, "`they are the basic tools
of scientific and technological work'" that lie beyond the domain of
patent protection. Id., at ,
132 S.Ct., at 1293. As the Court has explained, without this exception, there
would be considerable danger that the grant of patents would "tie up"
the use of such tools and thereby "inhibit future innovation premised upon
them." Id., at _, 132
S.Ct., at 1301. This would be at odds with the very point of patents, which
exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct.
2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and
"`manifestations... of nature [are] free to all men and reserved
exclusively to none'").(Source: Association
for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013))
In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.” (Source: U.S. Patent 7,220,852) No “causal” data was provided for this statement.
When
they filed their patent application on April 25, 2003, their first claim (and
the only one that survived to ultimate issuance over the objection of the
patent examiner in 2006 and 2007) was the genome for SARS CoV.
While
this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC
insist on its granting over non-final and final rejections, but they also
continued to pay maintenance fees on the patent after the 2013 Supreme Court
decision confirmed that it was illegal.
In
addition, the CDC patented the detection of SARS CoV using a number of methods
including reverse transcription polymerase chain reaction (RT-PCR). With this
patent, they precluded anyone outside of their licensed or conspiring interest
from legally engaging in independent verification of their claim that they had
isolated a virus, that it was a causative agent for SARS, or that any therapy
could be effective against the reported pathogen.
It
is important to note that the CDC’s patent applications were also rejected in
non-final and final rejections for ineligibility under 35 U.S.C. § 102 for
being publicly disclosed prior to their own filing.
In the first non-final rejection, the USPTO stated that the CDC’s genome was
published in four Genbank accession entries on April 14, 18, and 21, 2003 with
identity ranging from 96.8% to 99.9% identical sequences. (Source: USPTO
Non-Final Rejection File #10822904, September 7, 2006, page 4.) Dr. Fauci knew,
and failed to disclose evidence that the CDC patent was illegal, based on work
he had funded in the years leading up to the SARS outbreak.
After
seeking an illegal patent, petitioning to override the decision of an examiner
to reject it, and ultimately prevailing with the patent’s grant, the CDC lied
to the public by stating they were controlling the patent so that it would be
“publicly available”. (Source: https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0)
Tragically, this public statement is falsified by the simple fact that their
own publication in Genbank had, in fact, made it public domain and thereby
unpatentable. This fact, confirmed by patent examiners, was overridden by CDC
in a paid solicitation to override the law.
While
not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is
detailed below. Of note, however, is his willful and deceptive use of the term
“vaccine” in patents and public pronouncements to pervert the meaning of the
term for the manipulation of the public.
In the 1905 Jacobson v. Mass case, the court was clear that a
PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor
Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts,
197 U.S. 11 (1905), the court held that the context for their opinion rested on
the following principle:
“This court has more than once recognized it as a fundamental
principle that 'persons and property are subjected to all kinds of restraints
and burdens in order to secure the general comfort, health, and prosperity of
the state…”
The Moderna and Pfizer “alleged vaccine” trials have explicitly
acknowledged that their gene therapy technology has no impact on viral
infection or transmission whatsoever and merely conveys to the recipient the
capacity to produce an S1 spike protein endogenously by the introduction of a
synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and
the Supreme Court’s determination is moot in this case.
Further, the USPTO, in its REJECTION of Anthony Fauci's HIV
vaccine made the following statement supporting their rejection of his bogus
"invention"
18 U.S.C. §2339 C et seq. – Funding and Conspiring to
Commit Acts of Terror
Indirectly, unlawfully, and willfully provides or collects funds
with the intention that such funds be used, or with the knowledge that such
funds are to be used, in full or in part, in order to carry out—
- an act
which constitutes an offense within the scope of a treaty specified in
subsection (e)(7), as implemented by the United States, or
- any
other act intended to cause death or serious bodily injury to a civilian,
or to any other person not taking an active part in the hostilities in a
situation of armed conflict, when the purpose of such act, by its nature
or context, is to intimidate a population, or to compel a government or
an international organization to do or to abstain from doing any act….
By
no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the
association of SARS with bioterror potential. Leveraging the fear of the
anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic
terror had directed towards his budget. He specifically stated that NIAID was
actively funding research on a “SARS Chip” DNA microarray to rapidly detect
SARS (something that was not made available during the current “pandemic”) and
two candidate vaccines focused on the SARS CoV spike protein. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/ ) Led by three Chinese researchers under his
employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least
one DNA vaccine in animal trials by 2004. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/
) This team, part of the Vaccine Research Center at NIAID, was primarily
focused on HIV vaccine development but was tasked to identify SARS vaccine
candidates as well. Working in collaboration with Sanofi, Scripps Institute,
Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as
a primary intervention for several designated “infectious diseases” precluded proven
therapies from being applied to the sick and dying.(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)
The
CDC and NIAID led by Anthony Fauci entered into trade among States (including,
but not limited to working with EcoHealth Alliance Inc.) and with foreign
nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences) through the 2014 et seq National Institutes of Health Grant
R01AI110964 to exploit their patent rights. This research was known to
involve surface proteins in coronavirus that had the capacity to directly
infect human respiratory systems. In flagrant violation of the NIH
moratorium on gain of function research, NIAID and Ralph Baric persisted in
working with chimeric coronavirus components specifically to amplify the
pathogenicity of the biologic material.
By
October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein
was described in NIAID’s funded work in China.
This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth
Alliance. This work, funded under R01AI079231, was pivotal in isolating and
manipulating viral fragments selected from sites across China which contained
high risk for severe human response. (Source: Ge, XY., Li, JL., Yang, XL. et
al. Isolation and characterization of a bat SARS-like coronavirus that uses
the ACE2 receptor. Nature 503, 535–538 (2013).)
By
March 2015, both the virulence of the S1 spike protein and the ACE II receptor
was known to present a considerable risk to human health. NIAID,
EcoHealth Alliance and numerous researchers lamented the fact that the public
was not sufficiently concerned about coronavirus to adequately fund their
desired research.(Source: Forum on Medical and Public Health Preparedness for
Catastrophic Events; Forum on Drug Discovery, Development, and Translation;
Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global
Health; Institute of Medicine; National Academies of Sciences, Engineering, and
Medicine. Rapid Medical Countermeasure Response to Infectious Diseases:
Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector
Partnerships: Workshop Summary. Washington (DC): National Academies Press (US);
2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/)
Dr.
Peter Daszak of EcoHealth Alliance offered the following assessment:
“Daszak
reiterated that, until an infectious disease crisis is very real, present, and
at an emergency threshold, it is often largely ignored. To sustain the funding
base beyond the crisis, he said, we need to increase public understanding of
the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key
driver is the media, and the economics follow the hype. We need to use that
hype to our advantage to get to the real issues. Investors will respond if they
see profit at the end of process, Daszak stated.”
Economics
will follow the hype.
The
CDC and NIAID entered into trade among States (including, but not limited to
working with University of North Carolina, Chapel Hill) and with foreign
nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric),
U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China
Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place
during a time when the work being performed was prohibited by the United States
National Institutes of Health.
The
public was clearly advised of the dangers being presented by NIAID-funded
research by 2015 and 2016 when the Wuhan Institute of Virology material was
being manipulated at UNC in Ralph Baric’s lab.
“The
only impact of this work is the creation, in a lab, of a new, non-natural
risk,” agrees Richard Ebright, a molecular biologist and biodefence expert at
Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are
long-standing critics of gain-of-function research.
In
their paper, the study authors also concede that funders may think twice about
allowing such experiments in the future. "Scientific review panels may
deem similar studies building chimeric viruses based on circulating strains too
risky to pursue," they write, adding that discussion is needed as to
"whether these types of chimeric virus studies warrant further
investigation versus the inherent risks involved”.
But
Baric and others say the research did have benefits. The study findings “move
this virus from a candidate emerging pathogen to a clear and present danger”,
says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the
EcoHealth Alliance, an international network of scientists, headquartered in
New York City, that samples viruses from animals and people in
emerging-diseases hotspots across the globe.
Studies
testing hybrid viruses in human cell culture and animal models are limited in
what they can say about the threat posed by a wild virus, Daszak agrees. But he
argues that they can help indicate which pathogens should be prioritized for
further research attention.”(Source: https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787 )
Knowing
that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID,
and their funded laboratories and commercial partners) had patents on each
proposed element of medical counter measures and their funding, Dr. Fauci, Dr.
Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to
commit acts of terror on the global population – including the citizens of the
United States – when, in September 2019, they published the following mandate:
“Countries,
donors and multilateral institutions must be prepared for the worst. A
rapidly spreading pandemic due to a lethal respiratory pathogen (whether
naturally emergent or accidentally or deliberately released) poses
additional preparedness requirements. Donors and multilateral institutions must
ensure adequate investment in developing innovative vaccines and therapeutics,
surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical
interventions. All countries must develop a system for immediately sharing
genome sequences of any new pathogen for public health
purposes along with the means to share limited medical countermeasures across
countries.
Progress
indicator(s) by September 2020
A. Donors and countries commit and
identify timelines for: financing and development of a universal influenza
vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its
Member States develop options for standard procedures and timelines for sharing
of sequence data, specimens, and medical countermeasures for pathogens other
than influenza.
B. Donors, countries and multilateral
institutions develop a multi-year plan and approach for strengthening R&D
research capacity, in advance of and during an epidemic.
C. WHO, the United Nations Children’s
Fund, the International Federation of Red Cross and Red Crescent Societies,
academic and other partners identify strategies for increasing capacity and
integration of social science approaches and researchers across the entire
preparedness/response continuum.”(Source: https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf
(page 8) )
As
if to confirm the utility of the September 2019 demand for “financing and development
of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019,
Dr. Fauci began gloating that his fortunes for additional funding were likely
changing for the better. In a February 2020 interview in STAT, he
was quoted as follows:
““The
emergence of the new virus is going to change that figure, likely considerably,
Fauci said. “I don’t know how much it’s going to be. But I think it’s going to
generate more sustained interest in coronaviruses because it’s very clear that
coronaviruses can do really interesting things.””(Source: https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/)
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting
in death of American Citizens
Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded
the definition of terrorism to cover "domestic," as opposed to
international, terrorism. A person engages in domestic terrorism if they do an
act "dangerous to human life" that is a violation of the criminal
laws of a state or the United States, if the act appears to be intended to: (i)
intimidate or coerce a civilian population; (ii) influence the policy of a
government by intimidation or coercion;
Dr.
Anthony Fauci has intimidated and coerced a civilian population and sought to
influence the policy of a government by intimidation and coercion.
With
no corroboration, Dr. Anthony Fauci promoted (Source: https://www.cato.org/blog/did-mitigation-save-two-million-lives
) Professor Neil Ferguson’s computer simulation derived claims that,
“The
world is facing the most serious public health crisis in generations. Here we
provide concrete estimates of the scale of the threat countries now face.
“We
use the latest estimates of severity to show that policy strategies which aim
to mitigate the epidemic might halve deaths and reduce peak healthcare demand
by two-thirds, but that this will not be enough to prevent health systems being
overwhelmed. More intensive, and socially disruptive interventions will
therefore be required to suppress transmission to low levels. It is likely such
measures – most notably, large scale social distancing – will need to be in
place for many months, perhaps until a vaccine becomes available.” (Source: https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/)
Reporting
to the President that as many as 2.2 million deaths may result from a pathogen
that had not yet been isolated and could not be measured with any accuracy, Dr.
Fauci intimidated and coerced the population and the government into reckless,
untested, and harmful acts creating irreparable harm to lives and livelihoods. (Source:
https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline)
Neither the Imperial College nor the “independent” Institute for Health
Metrics and Evaluation (principally funded by the Bill and Melinda Gates
Foundation) (Source: https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement)
had any evidence of success in estimating previous burdens from
coronavirus but, without consultation or peer-review, Dr. Fauci adopted their
terrifying estimates as the basis for interventions that are explicitly against
medical advice.
a. The imposition of social
distancing was based on computer simulation and environmental models with NO
disease transmission evidence whatsoever.
b. The imposition of face mask
wearing was directly against controlled clinical trial evidence and against the
written policy in the Journal of the American Medical Association.
“Face
masks should not be worn by healthy individuals to protect themselves from
acquiring respiratory infection because there is no evidence to suggest that
face masks worn by healthy individuals are effective in preventing people from
becoming ill.”(Source: https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo)
c. In both the Imperial College and
the IHME simulations, quarantines were modeled for the sick, not the
healthy.
Insisting
on vaccines while blockading the emergency use of proven pharmaceutical
interventions may have contributed to the death of many patients and otherwise healthy
individuals.(Source: https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/)
Using
the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively
suppressed proven medical countermeasures used by, and validated in scientific
proceedings, that offered alternatives to the products funded by his conspiring
entities for which he had provided direct funding and for whom he would receive
tangible and intangible benefit.
18 U.S.C. § 1001 – Lying to Congress
Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—
- falsifies, conceals, or covers up by any trick, scheme, or
device a material fact;
- makes any materially false, fictitious, or fraudulent
statement or representation; or
- makes or uses any false writing or document knowing the
same to contain any materially false, fictitious, or fraudulent
statement or entry;
shall
be fined under this title, imprisoned not more than 5 years or, if the offense
involves international or domestic terrorism (as defined in section 2331),
imprisoned not more than 8 years, or both. If the matter relates to an offense
under chapter 109A, 109B, 110, or 117, or section 1591, then the term of
imprisonment imposed under this section shall be not more than 8 years.
On
October 22, 2020, the United States Government Accountability Office (GAO)
published a report entitled: BIOMEDICAL RESEARCH: NIH Should Publicly
Report More Information about the Licensing of Its Intellectual Property.
In this document, the
authors reported that the National Institutes of Health (NIH) received, “up to
$2 billion in royalties from its contributions to 34 drugs sold from
1991-2019.”(Source: https://www.gao.gov/products/GAO-21-52)
A
casual review of the NIH Office of Technology Transfer report of active
licenses (Source: https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics)
appears to conflict with the GAO report on several important facts.
Conspicuously absent from the GAO report are over 30 patents associated with
active compounds generating billions of dollars in revenue. Why would it be
that the GAO and the NIH couldn’t agree on something as simple as drugs
generating income for NIH?
Since
the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally
funded research has been an economic bonanza for U.S. universities, federal
agencies, and their selected patronage. For the first decade following Bayh
Dole, NIH funding
doubled from $3.4 billion to $7.1 billion. A decade later, it
doubled again to $15.6 billion. In the wake of September 2001, the
National Institute for Allergy and Infectious Diseases (NIAID) saw its direct
budget increase over 300%, without accounting for DARPA, funds of as much as
$1.7 billion annually from 2005 forward. In 2020, NIH’s budget was over $41
billion.
What
has become of the $763 billion of taxpayer funds allocated to making America
healthier since inventors have been commercially incentivized? Who has been
enriched?
The
answer, regrettably, is that no accountability exists to answer these questions.
The NIH is the named owner of at least 138 patents since 1980.
The
United States Department of Health and Human Services is the named owner of at
least 2,600 patents.
NIAID
grants or collaboration have resulted in 2,655 patents and patent applications
of which only 95 include an assignment to the Department of Health and Human
Services as an owner. Most of these patents are assigned to universities
thereby making the ultimate commercial beneficiaries entirely opaque. One
of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly
reporting close affiliation with NIAID, is not referenced in the NIH GAO
report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing
its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before
exiting to commercial ventures. While their technology is clearly derived
from NIAID science, the company reports revenue from NIAID but no royalty or
commercial payments to NIH or any of its programs.
NIAID’s
Director, Dr. Anthony Fauci, is listed as an inventor on 8 granted U.S. patents.
None of them are reported in NIAID, NIH, or GAO reports of active licensing
despite the fact that Dr. Fauci reportedly was compelled to get paid for his
interleukin-2 “invention” – payments he reportedly donated to an unnamed
charity. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/)
Of
the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange
book, itemized in the GAO report, none of Dr. Anthony Fauci’s patents are
listed. Furthermore, none of the NIAID patents are listed despite clear
evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of
Johnson & Johnson) have generated over $2 billion annually from sales that
were the direct result of NIAID funded science. Missing from the GAO report
are 2 patents for Velclade® which has been generating sales in excess of $2.18
billion annually for several years. None of the patents for Yescarta® are
listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO
report. None of the Kepivance® patents are listed in the GAO report. In
violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in
the GAO report fail to disclose government interest despite being the direct
result of NIH funding.
Dr.
Anthony Fauci’s Own Patent Track Record:
US
Patent 6,190,656 and 6,548,055 - Immunologic enhancement with intermittent
interleukin-2 therapy:
A
method for activating a mammalian immune system entails a series of IL-2
administrations that are affected intermittently over an extended period. Each
administration of IL-2 is sufficient to allow spontaneous DNA synthesis in
peripheral blood or lymph node cells of the patient to increase and peak, and
each subsequent administration follows the preceding administration in the
series by a period of time that is sufficient to allow IL-2 receptor expression
in peripheral or lymph node blood of the patient to increase, peak and then
decrease to 50% of peak value. This intermittent IL-2 therapy can be combined
with another therapy which targets a specific disease state, such as an anti-retroviral
therapy comprising, for example, the administration of AZT, ddI or interferon
alpha. In addition, IL-2 administration can be employed to facilitate in situ
transduction of T-cells in the context of gene therapy. By this approach the
cells are first activated in vivo via the aforementioned IL-2 therapy, and
transduction then is affected by delivering a genetically engineered retroviral
vector directly to the patient.
This
application is a continuation of U.S. patent application Ser. No. 08/487,075,
filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S.
patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S.
Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May
26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage
filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of
which are incorporated herein by reference.
Filed
May 19, 1993
Issued
a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998
and April 12, 1999. Reduced and modified claims granted May 8, 2000.
This
family of patents was the basis of Fauci’s lie to the British Medical
Journal in which he falsely stated:
“Dr
Anthony Fauci told the BMJ that as a government employee he was required by law
to put his name on the patent for the development of interleukin 2 and was also
required by law to receive part of the payment the government received for use
of the patent. He said that he felt it was inappropriate to receive payment and
donated the entire amount to charity.”
US Patent 6,911,527 - HIV related peptides:
This
invention is the discovery of novel specific epitopes and antibodies associated
with long term survival of HIV-1 infections. These epitopes and antibodies have
use in preparing vaccines for preventing HIV-1 infection or for controlling
progression to AIDS.
Filed
May 6, 1999
Rejected
as unpatentable January 22, 2003. Issued with a final rejection on July 15,
2004 after submitting reconsideration requests. Modified and restricted claims
allowed September 29, 2004.
US
Patent 7,368,114 - Fusion protein including of CD4:
Novel
recombinant polypeptides are disclosed herein that include a CD4 polypeptide
ligated at its C-terminus with a portion of an immunoglobulin comprising a
hinge region and a constant domain of a mammalian immunoglobulin heavy chain.
The portion or the IgG is fused at its C-terminus with a polypeptide comprising
a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara
tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also
disclosed herein are methods for using these CD4 fusion proteins.
Filed
October 24, 2002
Rejected
as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings
February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants
further narrowed the construction of what was clearly not a patent and the
USPTO granted less than half the claims that had been sought in the original
filing.
US
Patent 9,896,509, 9,193,790 and 9,441,041 - Use of antagonists of the
interaction between HIV GP120 and .alpha.4.beta.7 integrin:
Methods
are provided for the treatment of a HIV infection. The methods can include
administering to a subject with an HIV infection a therapeutically effective
amount of an agent that interferes with the interaction of gp120 and .alpha.4
integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist,
thereby treating the HIV infection. In several examples, the .alpha.4 integrin
antagonist is a monoclonal antibody that specifically binds to a .alpha.4,
.beta.1 or .beta.7 integrin subunit, or a cyclic hexapeptide, with the amino
acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or
infection. The methods include contacting a cell with an effective amount of an
agent that interferes with the interaction of gp120 and .alpha.4 integrin, such
as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods
are provided for determining if an agent is useful to treat HIV.
Rejected
May 22, 2017 as Double Patenting. In their response, the applicants acknowledge
the illegal act and seek only those components of their application that extend
beyond the life of the issued patents. On October 11, 2017, the limited claims
were issued.
A
sample of the convoluted flow of funds that evades public disclosure.
U.S.
Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby,
British Columbia. In their patent, they disclose that their research was
supported by a grant from the National Institute of Allergy and Infectious
Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was
awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.(Source: Alnylam
Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics |
Technology Networks)
In
2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes
including a $1 billion damages claim for “relentless and egregious”
misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest
priority of November 10, 2008, there is no public record stating Tekmira as the
beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle
technology developed from this grant is the technology now used in the Moderna
COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a
license to technology from Arbutus – formerly Tekmira – which has accused
Acuitas of misappropriating trade secrets and licensing them to Moderna and
Pfizer’s collaboration with BioNTech.
Additional
references can be found at:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22
15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity
Every
contract, combination in the form of trust or otherwise, or conspiracy, in
restraint of trade or commerce among the several States, or with foreign
nations, is declared to be illegal. Every person who shall make any contract or
engage in any combination or conspiracy hereby declared to be illegal shall be
deemed guilty of a felony, and, on conviction thereof, shall be punished by
fine not exceeding $100,000,000 if a corporation, or, if any
other
person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said
punishments, in the discretion of the court.
The
National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at
the University of North Carolina at Chapel Hill (officially classified as
affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for
the express purpose of general research, pathogenic enhancement, detection,
manipulation, and potential therapeutic interventions targeting the same. As
early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of
the coronavirus family for their commercial benefit.(Source: U.S. Provisional
Application No. 60/206,537, filed May 21, 2000) In one of the several papers
derived from work sponsored by this grant, Dr. Baric published what he reported
to be the full length cDNA of SARS CoV in which it was clearly stated that SAR
CoV was based on a composite of DNA segments.
“Using
a panel of contiguous cDNAs that span the entire genome, we have assembled a
full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly
cloned SARS viruses (infectious clone SARS-CoV) that contained the expected
marker mutations inserted into the component clones.”(Source: https://www.pnas.org/content/100/22/12995)
On
April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher
M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent
7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an
infectious, replication defective, coronavirus.” This work was supported by the
NIH grant referenced above and GM63228. In short, the U.S. Department of Health
and Human Services was involved in the funding of amplifying the infectious
nature of coronavirus between 1999 and 2002 before SARS was ever
detected in humans.
Against
this backdrop, we noted the unusual patent prosecution efforts of the CDC, when
on April 25, 2003 they sought to patent the SARS coronavirus isolated from
humans that had reportedly transferred to humans during the 2002-2003 SARS
outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did
not deter CDC in their efforts. Their application, updated in 2007, ultimately
issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their
patent from manipulating SARS CoV, developing tests or kits to measure SARS
coronavirus in humans or working with their patented virus for therapeutic use.
Work associated with this virus by their select collaborators included
considerable amounts of chimeric engineering, gain-of-function studies, viral
characterization, detection, treatment (both vaccine and therapeutic intervention),
and weaponization inquiries.
In
short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852
patent (Claim 1), no research in the United States could be conducted without
permission or infringement.
We
noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient
of millions of dollars of U.S. research grants from several federal agencies
but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In
this capacity, he was both responsible for determining “novelty” of clades of
virus species but directly benefitted from determining declarations of novelty
in the form of new research funding authorizations and associated patenting and
commercial collaboration. Together with CDC, NIAID, WHO, academic and
commercial parties (including Johnson & Johnson; Sanofi and their several
coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead;
Sherlock Biosciences; and, others), a powerful group of interests constituted
what we would suggest are “interlocking directorates” under U.S. anti-trust
laws.
·
1986-1990 NIAID Grant AI
23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant
Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru
The
paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
·
1990 Pfizer files U.S.
Patent 6,372,224 on a vaccine for the S-protein on coronavirus November
14, 2000 which was abandoned April 2010 making it public domain.
· 1990s Work focused on CoV association with cardiomyopathy (see above)
Early
reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
·
2000 Ralph Baric AI23946
and GM63228 from the National Institutes of Health actively working recombinant
CoV
·
2001 National Institute
of Health, Allergy and Infectious diseases. “Reverse Genetics with a
Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total
costs/yr. RS Baric, PI
·
2002 Asia CoV SARS
outbreak
· 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.
Dr.
Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand
Challenges Scientific Advisory Board (served through 2010).
·
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response
and patent US7,151,163 https://www.sbir.gov/node/305319
· July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2
Dana
Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to
neutralize SARS CoV. This research is supported by several NIH grants including
National Institutes of Health Grants A128785, A148436, and A1053822.
·
2004 January 6, 2004 – SARS
and Bioterrorism linked at Bioterrorism and Emerging Infectious
Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706
At
this conference, the term “The New Normal” was introduced by Merck
FAUCI
AND BARIC start making money!!! National Institutes of Health,
Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7
million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project
develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV
replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV
to mice, producing a pathogenic mouse model for SARS-CoV infection.
National
Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS
Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09.
$2.1 million
·
November 22, 2004
University of Hong Kong patents SARS associated spike protein on CoV and
pursues patent US 7,491,489
·
2005 DARPA gets in on the
game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies,
June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Review
timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U
and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf
·
2008 Biodefense Grant U54
AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
·
2009 Biodefense Grant U54
AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant
from NIAID)
· 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)
Patent
issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued
patents.
·
August 6, 2010, Moderna (prior to its establishment) files U.S.
Patent 9,447,164 which attracted the investment of (and “inventorship” for)
venture capitalists at Flagship Ventures. This patent grew out of the work of
Dr. Jason P. Schrum of Harvard Medical School supported by National Science
Foundation Grant #0434507. While the application claims priority to August 2010, the application
didn’t get finalized until October, 2015. On November 4, 2015, the USPTO
issued a non-final rejection on this original patent rejecting all claims.
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507
with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
·
2011 Crucell joined the
Janssen Pharmaceutical Companies of Johnson & Johnson in February taking
with it all of its SARS technology.
Biodefense
Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill
(non-competitive grant from NIAID)
·
2012 MERS isolated in
Egypt
Biodefense
Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive
grant from NIAID)
·
2013 Biodefense Grant U54
AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant
from NIAID)
· 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435
·
2015 Moderna signs a
vaccine development agreement with NIAID and executes it with the lead on the
mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html
·
2016 NIH through Scripps
Institute and Dartmouth College file patent application WO 2018081318A1
“Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology
that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en
Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person
at NIH that Moderna “e-mailed” to get the sequence for SARS
CoV-2
according to Moderna’s report here (“In January
2020, once it was discovered that the infection in Wuhan was caused by a novel
coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the
Vaccine Research Center at the National Institutes of Health, asking him to
send the genetic sequence for the virus.”)
https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html
In
addition, co-inventor Jason McLellan worked with Graham on a vaccine patent
jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
·
2017 August – Sanofi buys
Protein Science Corp with considerable SARS patent holdings
·
2018 June – Sanofi buys
Ablynx with considerable SARS patent holdings
·
2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create- affordable-molecular-diagnostics/ funded by
Open Philanthropy – the same organization that would be the financial sponsor
of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan
in October 2019.
15 U.S.C. §8 – Market Manipulation and Allocation
Every combination, conspiracy, trust, agreement, or contract is
declared to be contrary to public policy, illegal, and void when the same is
made by or between two or more persons or corporations, either of whom, as
agent or principal, is engaged in importing any article from any foreign
country into the United States, and when such combination, conspiracy, trust,
agreement, or contract is intended to operate in restraint of lawful trade, or
free competition in lawful trade or commerce, or to increase the market price
in any part of the United States of any article or articles imported or
intended to be imported into the United States, or of any manufacture into
which such imported article enters or is intended to enter. Every person who
shall be engaged in the importation of goods or any commodity from any foreign
country in violation of this section, or who shall combine or conspire with
another to violate the same, is guilty of a misdemeanor, and on conviction
thereof in any court of the
United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.
Through
non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of
the Bio-Safety Level 4 laboratory locations, to the setting of prices for
Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S.
Department of Health and Human Services have been involved in allocating
Federal funds to conspiring parties without independent review.
Around
March 12, 2020, in an effort to enrich their own economic interests by way of
securing additional funding from both Federal and Foundation actors, the CDC
and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by
capricious symptom presentation alone. Forcing the public to rely on The
COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates
Foundation and presented by a media outlet (The Atlantic) – not a public health agency – Dr. Fauci used
fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive
PCR tests in the living while insisting that COVID deaths be counted by
symptoms alone. This perpetuated a market demand for his desired vaccine agenda
which was recited by him and his conspiring parties around the world until the
present. Not surprisingly, this was necessitated by the apparent fall in cases
that constituted Dr. Fauci’s and others’ criteria for depriving citizens of
their 1st Amendment rights.
15 U.S.C. § 19 – Interlocking Directorates
No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—
- engaged in whole or in part in commerce; and
- by virtue of their business and location of operation,
competitors, so that the elimination of competition by agreement between
them would constitute a violation of any of the antitrust laws; if each
of the corporations has capital, surplus, and undivided profits
aggregating more than $10,000,000 as adjusted pursuant to paragraph (5)
of this subsection.
Dr. Fauci is on the Leadership Council
of the Bill and Malinda Gates Global Vaccine Action Plan
Dr.
Fauci while controlling the economic dispensation of Federal research funding,
Dr. Fauci has been, and continues to be, on the World Health Organization’s
Global Preparedness Monitoring Board. He is joined on this board by the
conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias
and the State Council of China’s Dr. George
F.
Gao of the Chinese CDC. This GPMB stipulated that all member states must take
part in a global simulation of the release of a respiratory pathogen.
Dr.
Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4
facility and sits on the International Committee on Taxonomy of Virus Coronaviridae
Working Group tasked to confirm the presence of absence of the pathogen for
which he is directly compensated.
As
referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous
undisclosed commercial relationships exist between funded researchers, their
funding agencies, and commercial interests in which disclosed and undisclosed
commercial terms exist. A complete list of all potential implicated parties
is listed in the section below entitled “The Commercial Actors”.
It
appears that during the period of patent enforcement and after the Supreme
Court ruling confirming that patents on genetic material were illegal, the CDC
and National Institute of Allergy and Infectious Diseases led by Anthony Fauci
(hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade
among States (including, but not limited to working with Ecohealth Alliance
Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology
and the Chinese Academy of Sciences) through the 2014 et seq National
Institutes of Health Grant R01AI110964 to exploit their patent rights.
It
further appears that during the period of patent enforcement and after the
Supreme Court ruling confirming that patents on genetic material was illegal,
the CDC and National Institute of Allergy and Infectious Diseases (hereinafter
“NIAID”) entered into trade among States (including, but not limited to working
with University of North Carolina, Chapel Hill) and with foreign nations
(specifically, the Wuhan Institute of Virology and the Chinese Academy of
Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric),
U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China
Award 81290341 (Zheng-Li Shi) et al. 2015-2016.
It
further appears that during the period of patent enforcement and after the
Supreme Court ruling confirming that patents on generic material was illegal,
the CDC and NIAID entered into trade among States (including, but not limited
to working with University of North Carolina, Chapel Hill) and with foreign
nations to conduct chimeric construction of novel coronavirus material with
specific virulence properties prior to, during, and following the determination
made by the National Institutes for Health in October 17, 2014 that this work
was not sufficiently understood for its biosecurity and safety standards.
In
this inquiry, it is presumed that the CDC and its associates were: a) fully
aware of the work being performed using their patented technology; b) entered
into explicit or implicit agreements including licensing, or other consideration;
and, c) willfully engaged one or more foreign interests to carry forward the
exploitation of their proprietary technology when the U.S. Supreme Court
confirmed that such patents were illegal and when the National Institutes of
Health issued a moratorium on such research.
Reportedly,
in January 2018, the U.S. Embassy in China sent investigators to Wuhan
Institute of Virology and found that, “During interactions with scientists
at the WIV laboratory, they noted the new lab has a serious shortage of
appropriately trained technicians and investigators needed to safely operate
this high-containment laboratory.” The Washington Post reported that this
information was contained in a cable dated 19 January 2018. Over a year later,
in June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army
Medical Research Institute of Infectious Diseases (hereinafter “USAMRIID”) and
ordered it closed after alleging that their inspection found biosafety hazards.
A report in the journal Nature in 2003 (423(6936): 103) reported cooperation
between CDC and USAMRIID on coronavirus research followed by considerable
subsequent collaboration. The CDC, for what appear to be the same type of
concern identified in Wuhan, elected to continue work with the Chinese
government while closing the U.S. Army facility.
The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability.
35 U.S.C. §200 - 206 – Disclosure of Government Interest
35 U.S.C. §202 (c)(6)
An
obligation on the part of the contractor, in the event a United States patent
application is filed by or on its behalf or by any assignee of the contractor,
to include within the specification of such application and any patent issuing
thereon, a statement specifying that the invention was made with Government
support and that the Government has certain rights in the invention.
Over 5000 patents and patent
applications have included reference to SARS Coronavirus dating back to
priority dates of 1998. They are summarized below.
On
July 23, 2020, the Patent Trial and Appeal Board of the United States Patent
and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent
8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by
Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver
an mRNA vaccine. Some of the core technology was based on work originally done
at the University of British Columbia and was first licensed in 1998.
mRNA-1273
– the experimental vaccine developed by Moderna for COVID-19 – uses the LNP
technology that Moderna thought it had licensed from Acuitas Therapeutics Inc.,
a firm developed by a former principal of Arbutus’ prior company Tekmira. That
license did not authorize Moderna to use the technology for the COVID-19
vaccine.
M·CAM
and Knowledge Ecology International have independently confirmed that Moderna
has violated U.S. law in failing to disclose the U.S. government’s funding
interest in their patents and patent applications.
While this negligence impacts all of Moderna’s over 130 granted U.S. patents,
it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the
patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open
reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein
subunit formulated in a lipid nanoparticle.” The specific claims addressing the
pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS
CoV-2 outbreak! Both the patent and the DARPA funding
for the technology were disclosed in scientific publication (New England
Journal of Medicine) but the government funds were not acknowledged in the
patent.
In 2013, the Autonomous Diagnostics to Enable Prevention and
Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for
the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was
W911NF-13-1-0417. The company used that technology to develop its
COVID-19 vaccine, currently undergoing clinical trials in conjunction with NIH.(Source:
https://crsreports.congress.gov/product/pdf/IN/IN11446)
Under
the Federal Acquisition Regulation (FAR) rules, contractor to the Federal
Government must provide information regarding intellectual property
infringement issues as part of their contract. Under FAR §27.201-1(c) and (d),
the Government both requires a notice of infringement or potential infringement
as well as retention of economic liability for patent infringements. Specifically,
in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its
officers, agents, and employees against liability, including costs for
infringement of any United States Patent…”. In addition to the patents cited by
the USPTO in their examination of ‘600, M·CAM has identified fourteen other
issued patents preceding the ‘600 patent which were used by patent examiners to
limit patents arising from the same funded research including patents sought by
CureVac.
In
short, while Moderna enjoys hundreds of millions of dollars of funding,
allegiance, and advocacy from Anthony Fauci and his NIAID, since its inception,
it has been engaged in illegal patent activity and demonstrated contempt for
U.S. Patent law. To make matters worse, the U.S. Government has given it
financial backing in the face of undisclosed infringement risks potentially
contributing to the very infringement for which they are indemnified.
21 C.F.R. § 50.24 et seq., Illegal Clinical Trial
It
is unlawful to conduct medical research (even in the case of emergency) without
a series of steps taken to:
- Establish
the research with a duly authorized and independent institutional review
board;
- Secure
informed consent of all participants including a statement of risks and
benefits; and,
- Engage
in consultation with the community in which the study is to be conducted.
Dr.
Anthony Fauci has forced upon the healthy population of the United States an
unlawful clinical trial in which the U.S. Department of Health and Human
Services are extrapolating epidemiologic data. No informed consent has been
sought or secured for any of the “medical countermeasures” forced upon the
population and no independent review board – as defined by the statute – has
been empaneled.
Through
April 2020, the official recommendation by the Journal of the American
Medical Association was unambiguous.
“Face
masks should not be worn by healthy individuals to protect themselves from
acquiring respiratory infection because there is no evidence to suggest that
face masks worn by healthy individuals are effective in preventing people from
becoming ill.”(Source: Medical Masks
| Infectious Diseases | JAMA | JAMA Network)
Part
of that lack of evidence in fact showed that cloth facemasks actually increased
influenza-linked illness. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)
In
contravention to established science, States, municipalities, and
businesses have violated the legal requirements for the promulgation of medical
counter measures during a public health emergency stating a “belief” that face
masks limit the spread of SARS CoV-2. To date, not a single study has confirmed
that a mask prevented the transmission of, or the infection by SARS CoV-2.
All
parties mandating the use of facemasks are not only willfully ignoring
established science but are engaging in what amounts to a whole population clinical
trial. This conclusion is reached by the fact that facemask use and COVID-19
incidence are being reported in scientific opinion pieces promoted by the
United States Centers for Disease Control and Prevention and others.(Source: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)
Social
distancing of up to 6 feet has been promoted as a means of preventing
person-to-person transmission of influenza-like viruses. While one study
hypothesized that infection could happen in a 6 foot range, the study
explicitly states that person-to-person transfer was not tested and
viability of the virus at 6 feet was not even a subject of the investigation.(Source:
Werner E. Bischoff, Katrina Swett, Iris Leng,
Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient
Care, The Journal of Infectious Diseases,
Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773)
That did not stop the misrepresentation of the study to be used as the basis
for an unverified medical counter measure of social distancing. To date, no
study has established the efficacy of social distancing to modify the
transmission of SARS CoV-2. Public health officials have referenced:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.
|
|
It
is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a
product or service can prevent, treat, or cure human disease unless you possess
competent and reliable scientific evidence, including, when appropriate, well-
controlled human clinical studies, substantiating that the claims are true at
the time they are made. As a result, every party promoting the use of face
masks is violating the FTC Act.
The Commercial Actors
SARS coronavirus is a new topic for many individuals. Since 1999,
the ability to manipulate and exploit coronavirus for a variety of purposes has
attracted the attention of individuals, institutions and commercial
organizations in public, private, and not-for-profit sectors.
The following is a list of over 4,000 patents and patent
applications filed for the express purpose of controlling some aspect of the
SARS coronavirus.
PATENT |
Title |
Owner |
Priority |
File Date |
Issue Date |
US9995706 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
30- Sep -14 |
12- Jun- 18 |
US9995705 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
30- Sep -14 |
12- Jun- 18 |
US9994558 |
Multicyclic
compounds and methods of using same |
Karyopharm
Therapeutics Inc. |
20- Sep- 13 |
19- Sep -14 |
12- Jun- 18 |
US9994550 |
Heterocyclic
modulators of lipid synthesis for use against cancer and viral infections |
3-V
Biosciences, Inc. |
7- Jan- 14 |
7- Jan -15 |
12- Jun- 18 |
US9993543 |
Immunogenic
compositions comprising silicified virus and methods of use |
Portland
State University |
31- Jan- 13 |
31- Jan -14 |
12- Jun- 18 |
US9982257 |
Chiral
control |
WAVE
LIFE SCIENCES LTD. |
13- Jul-12 |
12- Jul- 13 |
29- May -18 |
US9982241 |
Recombinant
HCMV and RHCMV vectors and uses thereof |
Oregon
Health & Science University |
14- May- 10 |
1- Oct -15 |
29- May -18 |
US9982025 |
Monomeric
griffithsin tandemers |
The
United States of America, as represented by the Secretary, Department of Health
and Human Services |
5- Jun-
13 |
5- Jun -14 |
29- May -18 |
US9981036 |
Compositions,
comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics
and methods of using the same |
THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
12- Dec- 11 |
26- Feb -16 |
29- May -18 |
US9975885 |
Broad-spectrum
non-covalent coronavirus protease inhibitors |
PURDUE
RESEARCH FOUNDATION |
28- Apr- 16 |
28- Apr -17 |
22- May -18 |
US9974850 |
Immunogenic
compositions and uses thereof |
BOARD
OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
25- Mar- 15 |
25- Mar -16 |
22- May -18 |
US9974848 |
Tetanus
toxoid and CCL3 improve DC vaccines |
Duke
University |
14- Nov- 13 |
14- Nov -14 |
22- May -18 |
US9974845 |
Combination
of vaccination and inhibition of the PD-1 pathway |
CureVac
AG |
22- Feb- 13 |
21- Feb -14 |
22- May -18 |
US9970061 |
Bioagent
detection oligonucleotides |
IBIS
BIOSCIENCES, INC. |
27- Dec- 11 |
27- Dec -12 |
15- May -18 |
US9969793 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
Biologics, Inc. |
28- Oct- 14 |
13- Nov -17 |
15- May -18 |
US9963718 |
LCMV-GP-VSV-pseudotyped
vectors and tumor-infiltrating virus- producing cells for the therapy of
tumors |
VIRATHERAPEUTICS
GMBH |
8- Oct-
08 |
7- Apr -17 |
8- May -18 |
US9963611 |
Composition
for use in decreasing the transmission of human pathogens |
Innonix
Technologies, Incorporated |
29- May- 09 |
21- May -10 |
8- May -18 |
US9963427 |
Dithiol
mucolytic agents |
PARION
SCIENCES, INC. |
23- Aug- 13 |
11- Mar -16 |
8- May -18 |
US9962439 |
Injectable
vaccine composition |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
8- May -18 |
US9957302 |
Treating
cancer with viral nucleic acid |
Mayo
Foundation for Medical Education and Research |
20- Feb- 07 |
6- Jul- 15 |
1- May -18 |
US9957300 |
Virus-like
particles, methods of preparation, and immunogenic compositions |
Emory
University |
17- May- 02 |
4- May -15 |
1- May -18 |
US9957238 |
Arylalkyl-and
aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
1- Mar -17 |
1- May -18 |
US9951317 |
Highly
efficient influenza matrix (M1) proteins |
NOVAVAX,
INC. |
11- Jul-03 |
6- Oct -16 |
24- Apr- 18 |
US9951124 |
Antibody
producing non-human mammals |
MERUS
N.V. |
27- Jun- 08 |
25- Jan -13 |
24- Apr- 18 |
US9951122 |
Antibodies
against influenza virus and methods of use thereof |
BURNHAM
INSTITUTE FOR MEDICAL RESEARCH |
6- Dec-
07 |
12- Aug -13 |
24- Apr- 18 |
US9950062 |
Compounds
and compositions as TLR activity modulators |
GLAXOSMITHKLINE
BIOLOGICALS SA |
2- Sep-
09 |
1- Sep -10 |
24- Apr- 18 |
US9945856 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
AMSTERDAM
INSTITUTE OF VIRAL GENOMICS B.V. |
18- Aug- 03 |
13- Aug -14 |
17- Apr- 18 |
US9945780 |
Use of a
fluorescent material to detect failure or deteriorated performance of a
fluorometer |
GEN-PROBE
INCORPORATED |
14- Jun- 12 |
7- Jun -13 |
17- Apr- 18 |
US9944928 |
Construction
of pool of interfering nucleic acids covering entire RNA target sequence and
related compositions |
York
Yuan Yuan Zhu |
23- Jul-07 |
2- Jul- 15 |
17- Apr- 18 |
US9944695 |
Antibody
producing non-human mammals |
Merus
N.V. |
27- Jun- 08 |
30- Apr -14 |
17- Apr- 18 |
US9944686 |
Treatment
of tumors with recombinant interferon alpha |
SUPERLAB
FAR EAST LIMITED |
28- Feb- 01 |
5- Sep -13 |
17- Apr- 18 |
US9944649 |
Compounds
and compositions as toll-like receptor 7 agonists |
Novartis
Ag |
1- May-
14 |
29- Apr -15 |
17- Apr- 18 |
US9943614 |
Cationic
steroid antimicrobial diagnostic, detection, screening and imaging methods |
BRIGHAM
YOUNG UNIVERSITY |
17- Jun- 08 |
16- Jun -09 |
17- Apr- 18 |
US9938300 |
Isothiazolopyrimidinones,
pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific
protease 7 inhibitors |
Forma
Therapeutics, Inc. |
5- Feb- 15 |
4- Feb -16 |
10- Apr- 18 |
US9938275 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
23- Jan -17 |
10- Apr- 18 |
US9938258 |
Substituted
2,3-dihydrobenzofuranyl compounds and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Nov- 12 |
27- Nov -13 |
10- Apr- 18 |
US9932351 |
Thienopyrimidinones
as ubiquitin-specific protease 7 inhibitors |
Forma
Therapeutics, Inc. |
5- Feb-
15 |
4- Feb -16 |
3- Apr-
18 |
US9932323 |
Therapeutic
hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
Rutgers,
The State University of New Jersey |
11- Sep- 12 |
13- Jan -17 |
3- Apr-
18 |
US9931316 |
Antiviral
activity from medicinal mushrooms and their active constituents |
Not
Available |
31- Mar- 15 |
14- Sep -15 |
3- Apr-
18 |
US9926340 |
NAD
analogs and methods of using said NAD analogs in determining ribosylation of
proteins with PARP mutants |
Biolog
Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH |
8- Apr-
15 |
1- Apr -16 |
27- Mar -18 |
US9925215 |
Anionically
modified polyallylamine derivative, use of anionically modified
polyallylamine derivative as medicine, particularly for propylaxis and
treatment of infections of respiratory tract caused by human metapneumovirus
(hMPV), human rhinoviruses (HRV), and infection by influenza virus type A
(IAV) and pharmaceutical composition comprising the anionically modified
polyallylamine derivative |
UNIWERSYTET
JAGIELLONSKI |
29- Jul-14 |
25- Oct -17 |
27- Mar -18 |
US9920314 |
Compositions
for and methods of identifying antigens |
President
and Fellows of Harvard College |
21- Feb- 06 |
6- May -15 |
20- Mar -18 |
US9920128 |
Synthetic
antiserum for rapid-turnaround therapies |
The
Johns Hopkins University |
28- Jan- 15 |
20- Jan -16 |
20- Mar -18 |
US9919034 |
Methods
of treating and prophylactically protecting mammalian patients infected by
viruses classified in Baltimore group V |
TAMIR
BIOTECHNOLOGY, INC. |
28- Mar- 14 |
10- Jun -15 |
20- Mar -18 |
US9915613 |
Systems
and methods for distinguishing optical signals of different modulation
frequencies in an optical signal detector |
GEN-PROBE
INCORPORATED |
24- Feb- 11 |
21- Mar -14 |
13- Mar -18 |
US9914976 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA AGRICULTURAL
AND MECHANICAL UNIVERSITY (FA |
25- Mar- 11 |
27- May -16 |
13- Mar -18 |
US9913801 |
Treatment
of evolving bacterial resistance diseases including Klebsiella pneumoniae
with liposomally formulated glutathione |
YOUR
ENERGY SYSTEMS, LLC |
15- Feb- 13 |
15- Mar -13 |
13- Mar -18 |
US9909176 |
Efficient
deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq) |
The
Johns Hopkins University |
8- Sep-
14 |
1- Sep -15 |
6- Mar -18 |
US9908946 |
Generation
of binding molecules |
Merus
N.V. |
26- Sep- 11 |
16- Sep -15 |
6- Mar -18 |
US9908675 |
Powdered
pouch and method of making same |
MONOSOL,
LLC |
16- Apr- 12 |
19- Jul- 16 |
6- Mar -18 |
US9907796 |
Methods
of treating tumoral diseases, or bacterial or viral infections |
INHIBIKASE
THERAPEUTICS, INC. |
4- Oct-
12 |
15- Sep -16 |
6- Mar -18 |
US9895692 |
Sample-to-answer
microfluidic cartridge |
Micronics,
Inc. |
29- Jan- 10 |
5- Aug -15 |
20- Feb -18 |
US9895411 |
Analogs
of C5a and methods of using same |
BOARD
OF REGENTS OF THE UNIVERSITY OF NEBRASKA |
29- Jun- 10 |
29- Jun -11 |
20- Feb -18 |
US9895341 |
Inflammation
and immunity treatments |
Ocean
Spray Cranberries, Inc. |
1- Apr-
11 |
30- Mar -12 |
20- Feb -18 |
US9894888 |
Transgenic
immunodeficient mouse expressing human SIRP-alpha |
INSTITUT
PASTEUR |
26- Mar- 12 |
26- Mar -13 |
20- Feb -18 |
US9890419 |
Nanoreporters
and methods of manufacturing and use thereof |
NanoString
Technologies, Inc. |
23- Dec- 05 |
20- May -16 |
13- Feb -18 |
US9890408 |
Multiple
displacement amplification |
IBIS
BIOSCIENCES, INC. |
15- Oct- 09 |
15- Oct -10 |
13- Feb -18 |
US9890362 |
Compositions,
methods and uses for inducing viral growth |
Takeda
Vaccines, Inc. |
5- Dec-
08 |
19- Sep -14 |
13- Feb -18 |
US9890361 |
Methods
for increasing the infectivity of viruses utilizing alkyne- modified fatty acids |
LIFE
TECHNOLOGIES CORPORATION |
26- Jan- 12 |
25- Jan -13 |
13- Feb -18 |
US9890206 |
H1N1
flu virus neutralizing antibodies |
Medigen
Biotechnology Corporation |
20- Aug- 15 |
20- Aug -15 |
13- Feb -18 |
US9890169 |
Triazolinone
compounds as HNE inhibitors |
CHIESI
FARMACEUTICI S.P.A. |
14- Dec- 15 |
12- Dec -16 |
13- Feb -18 |
US9890124 |
Benzazepine
sulfonamide compounds |
Hoffmann-La
Roche Inc. |
15- Dec- 15 |
14- Jun -17 |
13- Feb -18 |
US9889194 |
Immunogenic
composition for MERS coronavirus infection |
New
York Blood Center, Inc. |
1- Mar-
13 |
28- Feb -14 |
13- Feb -18 |
US9885092 |
Materials
and methods for detection of HPV nucleic acids |
QIAGEN
GAITHERSBURG INC. |
24- Feb- 11 |
23- Feb -12 |
6- Feb -18 |
US9885082 |
Embodiments
of a probe and method for targeting nucleic acids |
University
of Idaho |
19- Jul-11 |
19- Jul- 12 |
6- Feb -18 |
US9885037 |
Chiral
control |
WAVE
LIFE SCIENCES LTD. |
13- Jul-12 |
12- Jul- 13 |
6- Feb -18 |
US9884895 |
Methods
and compositions for chimeric coronavirus spike proteins |
The
University of North Carolina at Chapel Hill |
20- Mar- 14 |
20- Mar -15 |
6- Feb -18 |
US9884876 |
Anti-viral
compounds, pharmaceutical compositions, and methods of use thereof |
Kineta,
Inc. |
9- May-
14 |
8- May -15 |
6- Feb -18 |
US9884129 |
Release
of agents from cells |
The
Brigham and Women's Hospital, Inc. |
15- Oct- 09 |
5- Jan -15 |
6- Feb -18 |
US9884032 |
Esters of
short chains fatty acids for use in the treatment of immunogenic disorders |
PROPONENT
BIOTECH GMBH |
3- Oct-
12 |
3- Mar -16 |
6- Feb -18 |
US9884026 |
Modular
particles for immunotherapy |
YALE
UNIVERSITY |
1- Nov-
13 |
31- Oct -14 |
6- Feb -18 |
US9880151 |
Method of
determining, identifying or isolating cell-penetrating peptides |
Phylogica
Limited |
23- May- 11 |
23- May -12 |
30- Jan- 18 |
US9879026 |
Substituted
spirocycles |
Boehringer
Ingelheim International GmbH |
12- Sep- 14 |
29- Nov -16 |
30- Jan- 18 |
US9879003 |
Host
targeted inhibitors of dengue virus and other viruses |
Dana-Farber
Cancer Institute, Inc. |
11- Apr- 12 |
15- Mar -13 |
30- Jan- 18 |
US9878988 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
PARION
SCIENCES, INC. |
29- May- 12 |
5- Jan -16 |
30- Jan- 18 |
US9873678 |
Chemical
compounds |
AstraZeneca
AB |
18- Mar- 14 |
17- Mar -15 |
23- Jan- 18 |
US9873674 |
C-Rel
inhibitors and uses thereof |
CORNELL
UNIVERSITY |
21- Sep- 12 |
19- Sep -13 |
23- Jan- 18 |
US9872900 |
Nucleic
acid vaccines |
ModernaTX,
Inc. |
23- Apr- 14 |
5- Apr -16 |
23- Jan- 18 |
US9872898 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Founation |
24- Apr- 12 |
3- Oct -16 |
23- Jan- 18 |
US9872895 |
TLR5
ligands, therapeutic methods, and compositions related thereto |
Emory
University |
24- Sep- 10 |
20- Sep -11 |
23- Jan- 18 |
US9868952 |
Compositions
and methods for “resistance-proof†SiRNA therapeutics for influenza |
Sirnaomics,
Inc. |
8-Jul- 12 |
7- Jul- 13 |
16- Jan- 18 |
US9868740 |
Pyrimidinone
compounds which are HNE inhibitors |
CHIESI
FARMACEUTICI S.p.A. |
12- Jun- 14 |
12- Jun -14 |
16- Jan- 18 |
US9868736 |
Deubiquitinase
inhibitors and methods for use of the same |
THE
REGENTS OF THE UNIVERSITY OF MICHIGAN |
10- Oct- 13 |
10- Oct -14 |
16- Jan- 18 |
US9867882 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
25- Aug -15 |
16- Jan- 18 |
US9867877 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
22- Nov -16 |
16- Jan- 18 |
US9862706 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
31- May- 16 |
26- May -17 |
9- Jan-
18 |
US9861614 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
23- Jun -15 |
9- Jan-
18 |
US9856254 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
13- Jun -16 |
2- Jan-
18 |
US9856241 |
Substituted
benzofuranyl and benzoxazolyl compounds and uses thereof |
Karyopharm
Therapeutics Inc. |
3-Jul- 13 |
3- Jul- 14 |
2- Jan-
18 |
US9856228 |
Peptidyl
nitril compounds as dipeptidyl peptidase I inhibitors |
PROZYMEX
A/S |
9- Sep-
13 |
8- Sep -14 |
2- Jan-
18 |
US9856224 |
Stable
sodium channel blockers |
PARION
SCIENCES, INC. |
30- Jun- 14 |
30- Jan -17 |
2- Jan-
18 |
US9855287 |
Anti-viral
azide containing compounds |
LIFE
TECHNOLOGIES CORPORATION |
28- Jul-10 |
20- Aug -15 |
2- Jan-
18 |
US9855284 |
Pharmaceutical
compositions and methods |
Pop
Test Oncology LLC |
3- Aug-
15 |
6- Dec -16 |
2- Jan-
18 |
US9849143 |
Broad
spectrum antiviral and methods of use |
The
Burlington HC Research Group, Inc. |
17- Apr- 06 |
16- Feb -17 |
26- Dec -17 |
US9845342 |
Fusion
proteins, recombinant bacteria, and methods for using recombinant bacteria |
Spogen
Biotech Inc. |
17- Sep- 14 |
17- Sep -15 |
19- Dec -17 |
US9840731 |
Preservation
of biological materials in non-aqueous fluid media |
Gentegra,
LLC |
14- Mar- 13 |
14- Mar -14 |
12- Dec -17 |
US9840719 |
Variant
AAV and compositions, methods and uses for gene transfer to cells, organs and
tissues |
The
Children's Hospital of Philadelphia |
22- Jul-13 |
22- Jul- 14 |
12- Dec -17 |
US9840491 |
Quinazolinones
and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
FORMA
Therapeutics, Inc. |
5- Feb-
15 |
4- Feb -16 |
12- Dec -17 |
US9839687 |
Acetylenedicarboxyl
linkers and their uses in specific conjugation of a cell-binding molecule |
SUZHOU
M-CONJ BIOTECH CO., LTD. |
15- Jul-15 |
15- Jul- 15 |
12- Dec -17 |
US9834812 |
Probe
kit for detecting a single strand target nucleotide sequence |
Fondazione
Istituto Italiano Di Tecnologia |
27- Dec- 12 |
27- Dec -13 |
5- Dec -17 |
US9834791 |
CRISPR-related
methods and compositions with governing gRNAS |
Editas
Medicine, Inc. |
7- Nov-
13 |
7- Nov -14 |
5- Dec -17 |
US9834757 |
Hand,
foot, and mouth vaccines and methods of manufacture and use thereof |
Takeda
Vaccines, Inc. |
7- Nov-
14 |
6- Nov -15 |
5- Dec -17 |
US9834595 |
Amino
acid sequences directed against envelope proteins of a virus and polypeptides
comprising the same for the treatment of viral diseases |
Ablynx
N.V. |
5- Jun- 08 |
29- Oct -15 |
5- Dec -17 |
US9833504 |
Virus-like
particles and process for preparing same |
Folia
Biotech Inc. |
13- May- 11 |
1- May -12 |
5- Dec -17 |
US9833492 |
Combinations
of a caspase inhibitor and an antiviral agent |
Centre
National de la Recherche Scientifique |
2- Nov-
07 |
15- May -15 |
5- Dec -17 |
US9832998 |
Antiviral
compositions |
Long
Island University |
30- May- 07 |
19- Mar -15 |
5- Dec -17 |
US9828382 |
Pyrimidinone
compounds as human neutrophil elastase inhibitors |
Chiesi
Farmaceutici S.p.A. |
18- Dec- 12 |
10- May -16 |
28- Nov -17 |
US9828379 |
Pyrrolo-pyrrole
carbamate and related organic compounds, pharmaceutical compositions, and
medical uses thereof |
ABIDE
THERAPEUTICS, INC. |
3-Jul- 13 |
1- Jul- 14 |
28- Nov -17 |
US9828370 |
Compositions
and methods for inhibiting kinases |
INHIBIKASE
THERAPEUTICS, INC. |
23- Apr- 15 |
22- Apr -16 |
28- Nov -17 |
US9828346 |
N-myristoyl
transferase inhibitors |
University
of Dundee |
2- Sep-
08 |
31- Aug -15 |
28- Nov -17 |
US9828342 |
Isatin
derivatives, pharmaceutical compositions thereof, and methods of use thereof |
CITY
OF HOPE |
24- Feb- 12 |
25- Feb -13 |
28- Nov -17 |
US9827190 |
Intradermal
delivery of immunological compositions comprising toll- like receptor 7
agonists |
GLAXOSMITHKLINE
BIOLOGICALS SA |
1- Feb-
13 |
30- Jan -14 |
28- Nov -17 |
US9822339 |
Means and
methods for influencing the stability of antibody producing cells |
ACADEMISCH
MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM |
9- Dec-
05 |
26- Aug -15 |
21- Nov -17 |
US9822173 |
Heterodimeric
immunoglobulins |
AMGEN
INC. |
21- Nov- 12 |
21- Nov -13 |
21- Nov -17 |
US9822165 |
Hydrocarbon
stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external
region |
DANA-FARBER
CANCER INSTITUTE, INC. |
18- Jun- 09 |
18- Jun -10 |
21- Nov -17 |
US9822155 |
Method of
preventively treating a subject at the risk of developing infections of a
respiratory virus |
Xiangxue
Group (Hong Kong) Company Limited |
9- May-
13 |
23- Aug -16 |
21- Nov -17 |
US9822127 |
GAK
modulators as antivirals |
The Board
of Trustees of the Leland Stanford Junior University |
23- Jul-14 |
23- Jul- 15 |
21- Nov -17 |
US9822065 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
14- Feb -17 |
21- Nov -17 |
US9821052 |
Reverse
genetics systems |
Seqirus
UK Limited |
31- Jul-09 |
30- Jul- 10 |
21- Nov -17 |
US9821051 |
Reducing
hospitalization in elderly influenza vaccine recipients |
Seqirus
UK Limited |
28- Oct- 10 |
21- Oct -11 |
21- Nov -17 |
US9816078 |
Compositions
for increasing polypeptide stability and activity, and related methods |
SOLIS
BIODYNE OÜ |
19- Nov- 09 |
11- Mar -16 |
14- Nov -17 |
US9815886 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
8- Jan -15 |
14- Nov -17 |
US9815805 |
Certain
(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as
dipeptidyl peptidase 1 inhibitors |
ASTRAZENECA
AB |
24- Jan- 14 |
8- Nov -16 |
14- Nov -17 |
US9814777 |
Targeting
lipids |
Arbutus
Biopharma Corporation |
4- Dec-
07 |
22- Oct -13 |
14- Nov -17 |
US9810683 |
Use of
live cell inteferometry with reflective floor of observation chamber to
determine changes in mass of mammalian cells |
The
Regents of the University of California |
6- May-
09 |
25- Nov -13 |
7- Nov -17 |
US9809845 |
Methods
and reagents for amplifying nucleic acids |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
6- Aug-
12 |
6- Aug -12 |
7- Nov -17 |
US9809796 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
18- May -17 |
7- Nov -17 |
US9809632 |
Universal
protein tag for double stranded nucleic acid delivery |
University
of Washington Through its Center for Commercialization |
23- Oct- 13 |
22- Oct -14 |
7- Nov -17 |
US9809591 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
5- Oct -15 |
7- Nov -17 |
US9808490 |
Induced
hepatocytes and uses thereof |
ACCELERATED
BIOSCIENCES CORP. |
26- Nov- 14 |
25- Nov -15 |
7- Nov -17 |
US9803236 |
Microarray-based
assay integrated with particles for analyzing molecular interactions |
CapitalBio
Corporation |
6- Aug-
10 |
6- Aug -10 |
31- Oct- 17 |
US9803197 |
Particle-nucleic
acid conjugates and therapeutic uses related thereto |
Emory
University |
25- Jun- 12 |
27- Feb -13 |
31- Oct- 17 |
US9802937 |
Substituted
pyrazolo{4,3-D}pyrimidines as kinase inhibitors |
ORIGENIS
GMBH |
21- Apr- 11 |
23- Apr -12 |
31- Oct- 17 |
US9802919 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
31- May- 16 |
26- May -17 |
31- Oct- 17 |
US9801948 |
Antimicrobial
compositions and methods of use thereof |
Yale
University |
21- Sep- 11 |
21- Sep -12 |
31- Oct- 17 |
US9801947 |
Methods
and compositions for enhancing immune response |
3M
INNOVATIVE PROPERTIES COMPANY |
10- Apr- 03 |
6- Oct -14 |
31- Oct- 17 |
US9801935 |
Soluble
needle arrays for delivery of influenza vaccines |
SEQIRUS
UK LIMITED |
20- Aug- 10 |
11- Oct -16 |
31- Oct- 17 |
US9801897 |
Delivery
of RNA to trigger multiple immune pathways |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
6- Jul- 11 |
31- Oct- 17 |
US9797000 |
Non-target
amplification method for detection of RNA splice-forms in a sample |
QIAGEN
GAITHERSBURG INC. |
1- May-
09 |
30- Apr -10 |
24- Oct- 17 |
US9796979 |
Oligonucleotide
modulators of the toll-like receptor pathway |
Quark
Pharmaceuticals Inc. |
3- Mar-
11 |
28- Jul- 16 |
24- Oct- 17 |
US9796735 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
20- Jun- 07 |
7- Nov -14 |
24- Oct- 17 |
US9795669 |
Lipidated
immune response modifier compound compositions, formulations, and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
17- Aug- 10 |
15- Dec -15 |
24- Oct- 17 |
US9795668 |
Delivery
of self-replicating RNA using biodegradable polymer particles |
GlaxoSmithKline
Biologicals S.A. |
6-Jul- 10 |
23- Nov -15 |
24- Oct- 17 |
US9795666 |
High-yield
transgenic mammalian expression system for generating virus-like particles |
Academia
Sinica |
5- Sep-
06 |
11- Feb -15 |
24- Oct- 17 |
US9791437 |
Multianalyte
assay |
Nexus
Dx, Inc. |
30- Apr- 07 |
15- Jun -15 |
17- Oct- 17 |
US9789180 |
D-amino
acid derivative-modified peptidoglycan and methods of use thereof |
The
Regents of the University of California |
30- Nov- 12 |
31- Mar -16 |
17- Oct- 17 |
US9786050 |
Stain-free
histopathology by chemical imaging |
The
Board of Trustees of the University of Illinois |
15- Mar- 13 |
14- Mar -14 |
10- Oct- 17 |
US9783595 |
Neutralizing
GP41 antibodies and their use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
7- Nov-
11 |
2- Aug -16 |
10- Oct- 17 |
US9782470 |
Method
of obtaining thermostable dried vaccine formulations |
Merck
Sharp & Dohme Corp. |
16- Oct- 13 |
13- Oct -14 |
10- Oct- 17 |
US9782434 |
Methods
of treating or preventing inflammation and hypersensitivity with oxidative
reductive potential water solution |
Sonoma
Pharmaceuticals, Inc. |
20- Jan- 06 |
7- Jul- 15 |
10- Oct- 17 |
US9770504 |
Generating
peptoid vaccines |
The
Board of Regents of the University of Texas System |
3- May-
13 |
2- May -14 |
26- Sep -17 |
US9770463 |
Delivery
of RNA to different cell types |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
7- Jun -11 |
26- Sep -17 |
US9765395 |
System
and method for DNA sequencing and blood chemistry analysis |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
10- Apr -15 |
19- Sep -17 |
US9765133 |
Antibody
producing non-human mammals |
Merus
N.V. |
27- Jun- 08 |
29- Apr -14 |
19- Sep -17 |
US9765071 |
Substituted
imidazo ring systems and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
25- Nov- 03 |
14- Mar -16 |
19- Sep -17 |
US9764027 |
Outer
membrane vesicles |
GLAXOSMITHKLINE
BIOLOGICALS SA |
18- Sep- 12 |
18- Sep -13 |
19- Sep -17 |
US9759723 |
B-cell
antigen presenting cell assay |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
8- Apr-
10 |
21- Mar -16 |
12- Sep -17 |
US9758840 |
Parasite
detection via endosymbiont detection |
IBIS
BIOSCIENCES, INC. |
14- Mar- 10 |
11- Mar -11 |
12- Sep -17 |
US9758820 |
Organism
identification panel |
BioFire
Diagnostics, LLC |
2- Apr-
07 |
1- Apr -08 |
12- Sep -17 |
US9758775 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
14- Apr -14 |
12- Sep -17 |
US9758568 |
Oligopeptide-free
cell culture media |
Baxalta
GmbH |
4- Jan- 06 |
16- Nov -15 |
12- Sep -17 |
US9758553 |
Yeast
strain for the production of proteins with terminal alpha-1,3- linked
galactose |
MERCK
SHARP & DOHME CORP. |
30- May- 08 |
2- Jul- 14 |
12- Sep -17 |
US9757478 |
Mutant
protease biosensors with enhanced detection characteristics |
Promega
Corporation |
11- May- 10 |
7- Jan -16 |
12- Sep -17 |
US9757470 |
Peptides
for assisting delivery across the blood brain barrier |
Children's
Medical Center Corporation |
22- May- 06 |
30- Apr -14 |
12- Sep -17 |
US9757446 |
Influenza
virus vectors and uses therefor |
FLUGEN,
INC. |
17- Mar- 14 |
13- Mar -15 |
12- Sep -17 |
US9757407 |
Treatment
of viral infections by modulation of host cell metabolic pathways |
The
Trustees of Princeton University |
1- Jun-
07 |
21- Dec -15 |
12- Sep -17 |
US9751945 |
Sortase-modified
VHH domains and uses thereof |
Whitehead
Institute for Biomedical Research |
13- Apr- 12 |
15- Apr -13 |
5- Sep -17 |
US9750798 |
Bunyaviruses
with segmented glycoprotein precursor genes and methods for generating these
viruses |
STICHTING
WAGENINGEN RESEARCH |
21- May- 13 |
21- May -14 |
5- Sep -17 |
US9750797 |
Sustained
release vaccine composition |
VIRBAC
CORPORATION |
16- Jun- 04 |
16- Jun -05 |
5- Sep -17 |
US9750690 |
Circulation
of components during microfluidization and/or homogenization of emulsions |
NOVARTIS
AG |
3- Dec-
09 |
5- Sep -14 |
5- Sep -17 |
US9746985 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
25- Feb- 08 |
20- Apr -11 |
29- Aug -17 |
US9746459 |
Antigen
presenting cell assay |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
8- Apr-
10 |
11- Oct -13 |
29- Aug -17 |
US9745306 |
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-
D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one
derivatives and their use as phosphoinositide 3-kinase inhibitors |
Respivert
Limited |
15- Mar- 13 |
14- Mar -14 |
29- Aug -17 |
US9744231 |
Quality
control methods for oil-in-water emulsions containing squalene |
NOVARTIS
AG |
8- Nov-
06 |
27- Aug -13 |
29- Aug -17 |
US9744229 |
Vaccines
and immunotherapeutics using IL-28 and compositions and methods of using the
same |
THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
4- Apr-
08 |
28- Apr -14 |
29- Aug -17 |
US9744183 |
Nucleic
acid prodrugs and methods of use thereof |
WAVE
LIFE SCIENCES LTD. |
6-Jul- 09 |
6- Jul- 10 |
29- Aug -17 |
US9738894 |
Short
interfering RNA (siRNA) analogues |
Roche
Innovation Center Copenhagen A/S |
21- Mar- 03 |
28- Mar -16 |
22- Aug -17 |
US9738624 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
21- Jun- 13 |
20- Jun -14 |
22- Aug -17 |
US9737618 |
Adeno-associated
virus (AAV) glades, sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
30- Sep- 03 |
20- Jul- 15 |
22- Aug -17 |
US9737593 |
Carbon
nanotube compositions and methods of use thereof |
Yale
University |
19- Mar- 08 |
15- Mar -13 |
22- Aug -17 |
US9730997 |
Alphavirus
vectors for respiratory pathogen vaccines |
Novartis
Vaccines and Diagnostics, Inc. |
21- May- 04 |
20- Aug -14 |
15- Aug -17 |
US9730912 |
Pharmaceutical
compounds |
ASTEX
THERAPEUTICS LIMITED |
12- Oct- 06 |
12- Oct -07 |
15- Aug -17 |
US9727810 |
Spatially
addressable molecular barcoding |
Cellular
Research, Inc. |
27- Feb- 15 |
26- Feb -16 |
8- Aug -17 |
US9726607 |
Systems
and methods for detecting multiple optical signals |
GEN-PROBE
INCORPORATED |
10- Mar- 05 |
3- Mar -14 |
8- Aug -17 |
US9725770 |
Methods
and compositions for identification of source of microbial contamination in a
sample |
The
Regents of the University of California |
6- Mar-
12 |
6- Mar -13 |
8- Aug -17 |
US9725487 |
Compositions
and methods for measles virus inhibition |
Autoimmune
Technologies, LLC |
4- Nov-
03 |
13- May -15 |
8- Aug -17 |
US9719106 |
Tissue
preferential codon modified expression cassettes, vectors containing same,
and uses thereof |
The
Trustees of the University of Pennsylvania |
29- Apr- 13 |
29- Apr -14 |
1- Aug -17 |
US9719083 |
Bioagent
detection methods |
IBIS
BIOSCIENCES, INC. |
8- Mar-
09 |
8- Mar -10 |
1- Aug -17 |
US9718774 |
Indole
carboxamide derivatives as P2X7 receptor antagonist |
IDORSIA
PHARMACEUTICALS LTD |
12- Dec- 12 |
11- Dec -13 |
1- Aug -17 |
US9717755 |
Method
of treating inflammation |
Cytosorbents
Corporation |
1- Apr-
10 |
1- Apr -11 |
1- Aug -17 |
US9717749 |
Production
of stable non-polyadenylated RNAs |
Massachusetts
Institute of Technology |
16- Oct- 12 |
16- Oct -13 |
1- Aug -17 |
US9717732 |
Drug
combination |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
1- Aug -17 |
US9714411 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
30- Nov -15 |
25- Jul- 17 |
US9714283 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
2- Jul- 15 |
25- Jul- 17 |
US9714226 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
13- Nov -15 |
25- Jul- 17 |
US9713641 |
Anti-TIGIT
antigen-binding proteins and methods of use thereof |
Potenza
Therapeutics, Inc. |
13- Feb- 17 |
13- Feb -17 |
25- Jul- 17 |
US9713606 |
Methods
for treating pulmonary emphysema using substituted 2-
Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
1- Dec -15 |
25- Jul- 17 |
US9708375 |
Inhibitory
polypeptides specific to WNT inhibitors |
Amgen
Inc. |
15- Mar- 13 |
14- Mar -14 |
18- Jul- 17 |
US9707278 |
Methods
of modulating immune responses by modifying Akt3 bioactivity |
Augusta
University Research Institute, Inc. |
17- Apr- 14 |
17- Apr -15 |
18- Jul- 17 |
US9701736 |
Influenza
hemagglutinin-specific monoclonal antibodies for preventing and treating
influenza virus infection |
New
York Blood Center, Inc. |
20- Oct- 10 |
9- Oct -14 |
11- Jul- 17 |
US9701638 |
Therapeutic
hydroxyquinolones |
Rutgers,
The State University of New Jersey |
9- Nov-
12 |
8- Nov -13 |
11- Jul- 17 |
US9700616 |
Arranging
interaction and back pressure chambers for microfluidization |
NOVARTIS
AG |
3- Dec-
09 |
22- Mar -16 |
11- Jul- 17 |
US9700614 |
Intranasal
vaccination dosage regimen |
Eurocine
Vaccines AB |
17- Dec- 12 |
17- Dec -13 |
11- Jul- 17 |
US9700558 |
Drug
combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
11- Jul- 17 |
US9696247 |
Sample
fixation and stabilisation |
RNASSIST
LTD. |
1- Mar-
13 |
28- Feb -14 |
4- Jul- 17 |
US9695445 |
Method
for production of reprogrammed cell using chromosomally unintegrated virus
vector |
ID
Pharma Co., Ltd. |
16- Jul-08 |
29- Jul- 15 |
4- Jul- 17 |
US9695135 |
Therapeutic
catechols |
Rutgers,
The State University of New Jersey |
12- May- 14 |
11- May -15 |
4- Jul- 17 |
US9695134 |
3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-
2-carboxamide compounds |
Parion
Sciences, Inc. |
17- Dec- 12 |
8- Jan -15 |
4- Jul- 17 |
US9689018 |
Mixed
cell diagnostic systems for detection of respiratory, herpes and enteric
viruses |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
4- Aug -14 |
27- Jun- 17 |
US9688982 |
Methods
and compositions for the treatment of cancer or other diseases |
CITY
OF HOPE |
26- Jan- 07 |
11- Oct -13 |
27- Jun- 17 |
US9687536 |
Methods
and compositions for intranasal delivery |
SHIN
NIPPON BIOMEDICAL LABORATORIES, LTD. |
15- Apr- 10 |
15- Apr -11 |
27- Jun- 17 |
US9683256 |
Biological
specimen collection and transport system |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
15- Dec -15 |
20- Jun- 17 |
US9683017 |
Inhibitory
peptides of viral infection |
UNIVERSITY
TENNESSEE RESEARCH FOUNDATION |
17- Jul-14 |
16- Jul- 15 |
20- Jun- 17 |
US9682133 |
Disrupted
adenovirus-based vaccine against drugs of abuse |
CORNELL
UNIVERSITY |
17- Mar- 10 |
17- Mar -11 |
20- Jun- 17 |
US9677089 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
30- Mar -16 |
13- Jun- 17 |
US9676867 |
Chimeric
T cell receptor comprising carbonic anhydrase IX (G250) antibody |
Dana-Farber
Cancer Institute Inc. |
2- Dec-
05 |
8- May -13 |
13- Jun- 17 |
US9676857 |
Soluble
engineered monomeric Fc |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
16- Mar- 12 |
14- Mar -13 |
13- Jun- 17 |
US9676727 |
Myxovirus
therapeutics, compounds, and uses related thereto |
Children's
Healthcare of Atlanta, Inc. |
24- Oct- 11 |
7- Jul- 16 |
13- Jun- 17 |
US9675550 |
Methods
for inducing an immune response via buccal and/or sublingual administration
of a vaccine |
BOARD
OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
26- Jul-10 |
25- Jan -13 |
13- Jun- 17 |
US9670507 |
Directed
evolution and in vivo panning of virus vectors |
The
University of North Carolina at Chapel Hill |
30- Apr- 08 |
28- Jun -16 |
6- Jun-
17 |
US9670166 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
6- Feb-
13 |
5- Aug -16 |
6- Jun-
17 |
US9669092 |
Antagonism
of the VIP signaling pathway |
Emory
University |
2- Feb-
11 |
31- Jan -12 |
6- Jun-
17 |
US9669089 |
Nucleic
acid comprising or coding for a histone stem-loop and a poly(A) sequence or a
polyadenylation signal for increasing the expression of an encoded pathogenic
antigen |
CureVac
AG |
15- Feb- 12 |
15- Feb -13 |
6- Jun- 17 |
US9669088 |
Vaccination
with multiple clades of H5 influenza A virus |
Seqirus
UK Limited |
26- Nov- 07 |
25- Nov -08 |
6- Jun-
17 |
US9661856 |
Synergy
of plant antimicrobials with silver |
The
Arizona Board of Regents on Behalf of The University of Arizona |
24- Aug- 12 |
26- Aug -13 |
30- May -17 |
US9657278 |
Methods
to produce bunyavirus replicon particles |
Stichting
Dienst Landbouwkundig Onderzoek |
20- Sep- 10 |
10- Jul- 15 |
23- May -17 |
US9657076 |
GM-CSF
and IL-4 conjugates, compositions, and methods related thereto |
Children's
Healthcare of Atlanta, Inc. |
23- Oct- 12 |
23- Oct -13 |
23- May -17 |
US9657048 |
Enantiomers
of the 1′,6′-isomer of neplanocin A |
Auburn
University |
4- Aug-
14 |
4- Aug -15 |
23- May -17 |
US9657015 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
23- May -17 |
US9655896 |
Chemically
and metabolically stable dipeptide possessing potent sodium channel blocker
activity |
PARION
SCIENCES, INC. |
27- Jun- 11 |
12- Jan -15 |
23- May -17 |
US9655845 |
Oil-in-water
emulsions that contain nucleic acids |
GlaxoSmithKline
Biologicals, S.A. |
6-Jul- 11 |
6- Jul- 12 |
23- May -17 |
US9655367 |
Disinfecting
composition and wipes with reduced contact time |
LONZA,
INC. |
6- Nov-
13 |
4- Nov -14 |
23- May -17 |
US9651543 |
Malaria
antigen screening method |
The
United States of America as Represented by the Secretary of the Navy |
31- Aug- 05 |
19- Apr -13 |
16- May -17 |
US9650685 |
Selective
detection of human rhinovirus |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
5- Dec-
08 |
15- Dec -14 |
16- May -17 |
US9650649 |
LCMV-GP-VSV-pseudotyped
vectors and tumor-infiltrating virus- producing cells for the therapy of
tumors |
VIRATHERAPEUTICS
GMBH |
8- Oct-
08 |
8- Oct -09 |
16- May -17 |
US9649324 |
Use
of tylvalosin as antiviral agent |
CAMBRIDGE
UNIVERSITY TECHNICAL SERVICES |
13- Jul-06 |
8- Jun -15 |
16- May -17 |
US9649309 |
Therapeutic
uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
16- May -17 |
US9644180 |
Synthetic
membrane-receiver complexes |
RUBIUS
THERAPEUTICS, INC. |
18- Nov- 13 |
12- Jun -15 |
9- May -17 |
US9642876 |
Method of
preventing or treating sinusitis with oxidative reductive potential water
solution |
SONOMA
PHARMACEUTICALS, INC. |
30- Dec- 03 |
27- Oct -15 |
9- May -17 |
US9642873 |
Combinations
of TGFβ and COX-2 inhibitors and methods for their therapeutic application |
Sirnaomics,
Inc. |
4- May-
10 |
4- May -11 |
9- May -17 |
US9637524 |
Proteolysis-resistant
capsid of chimeric hepatitis E virus as an oral delivery vector |
The
Regents of the University of California |
27- Feb- 09 |
5- Nov -14 |
2- May -17 |
US9637491 |
Pyrazolo[4,3-D]pyrimidines
as kinase inhibitors |
ORIGENIS
GMBH |
19- Oct- 12 |
18- Oct -13 |
2- May -17 |
US9636410 |
Cationic
oil-in-water emulsions |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 11 |
6- Jul- 12 |
2- May -17 |
US9636397 |
Adjuvant
compositions and related methods |
Vaxliant,
LLC |
24- Mar- 15 |
24- Mar -16 |
2- May -17 |
US9636370 |
AAV
vectors targeted to oligodendrocytes |
The
University of North Carolina at Chapel Hill |
28- Sep- 12 |
27- Sep -13 |
2- May -17 |
US9629907 |
Compositions
for and methods of inducing mucosal immune responses |
The
Trustees of the University of Pennsylvania |
19- Nov- 04 |
28- Oct -11 |
25- Apr- 17 |
US9624173 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
19- Mar -15 |
18- Apr- 17 |
US9623040 |
Immunomodulation
by controlling expression levels of microRNAs in dendritic cells |
The Board
of Trustees of the Leland Stanford Junior University |
14- Jul-14 |
10- Jul- 15 |
18- Apr- 17 |
US9618508 |
Flow
cytometry analysis of materials adsorbed to metal salts |
GlaxoSmithKline
Biologicals SA |
14- Dec- 10 |
14- Dec -11 |
11- Apr- 17 |
US9618476 |
System
and method for electronic biological sample analysis |
NANOMEDICAL
DIAGNOSTICS, INC. |
28- Apr- 14 |
28- Apr -14 |
11- Apr- 17 |
US9618429 |
Polymer
stabilization of chromogen solutions |
Ventana
Medical Systems, Inc. |
23- Jan- 12 |
18- Jan -13 |
11- Apr- 17 |
US9611481 |
Chimeric
polynucleotides and polypeptides enabling the secretion of a polypeptide of
interest in combination with exosomes and uses thereof |
UNIVERSITE
DE MONTPELLIER |
24- Sep- 09 |
23- Sep -10 |
4- Apr- 17 |
US9611474 |
Double-stranded
oligonucleotide molecules to DDIT4 and methods of use thereof |
QUARK
PHARMACEUTICALS, INC. |
12- Sep- 12 |
12- Sep -13 |
4- Apr-
17 |
US9605276 |
Replication
defective adenovirus vector in vaccination |
Etubics
Corporation |
24- Aug- 12 |
15- Mar -13 |
28- Mar -17 |
US9603864 |
Substituted
nucleosides, nucleotides and analogs thereof |
Alios
BioPharma, Inc. |
24- Jun- 14 |
22- Jun -15 |
28- Mar -17 |
US9603850 |
MerTK-specific
pyrazolopyrimidine compounds |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
28- Mar -17 |
US9599606 |
ADP-ribose
detection reagents |
The
Board of Regents of the University of Texas System |
10- Jun- 14 |
9- Jun -15 |
21- Mar -17 |
US9598459 |
Pharmaceutical
compositions and methods |
Pop
Test Oncology LLC |
3- Aug-
15 |
28- Jul- 16 |
21- Mar -17 |
US9597333 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
28- Sep -16 |
21- Mar -17 |
US9593334 |
Use of
the chromosome 19 microRNA cluster (C19MC) for treating viral disease and
promoting authophagy |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
7- Mar-
12 |
6- Mar -13 |
14- Mar -17 |
US9593331 |
Double-stranded
nucleic acid molecule for gene expression control |
Osaka
City University |
2- Nov-
11 |
1- Nov -12 |
14- Mar -17 |
US9593084 |
Chloro-pyrazine
carboxamide derivatives with epithelial sodium channel blocking activity |
Parion
Sciences, Inc. |
17- Dec- 12 |
13- Dec -13 |
14- Mar -17 |
US9592284 |
Immunization
regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boost |
The
Trustees of the University of Pennsylvania |
28- Apr- 04 |
27- Apr -05 |
14- Mar -17 |
US9592277 |
Compositions
with modified nucleases targeted to viral nucleic acids and methods of use
for prevention and treatment of viral diseases |
Avirid,
Inc. |
14- Apr- 04 |
14- Apr -05 |
14- Mar -17 |
US9588069 |
Methods
for performing thermal melt analysis |
GEN-PROBE
INCORPORATED |
31- Jul-12 |
31- Jul- 13 |
7- Mar -17 |
US9587250 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
Trustees
of the University of Pennsylvania |
17- Dec- 01 |
16- Jan -15 |
7- Mar -17 |
US9586998 |
Methods
of propagating monkey adenoviral vectors |
GenVec,
Inc. |
9- Nov-
09 |
4- Aug -15 |
7- Mar -17 |
US9586911 |
Arylalkyl-
and aryloxyalkyl-substituted epthelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
19- Dec -14 |
7- Mar -17 |
US9586910 |
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-
pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra
zine-2-carboxamide |
Parion
Sciences, Inc. |
27- Jun- 11 |
18- Dec -13 |
7- Mar -17 |
US9585968 |
Hydrazino
1H-imidazoquinolin-4-amines and conjugates made therefrom |
3M
Innovative Properties Company |
3- Jun-
11 |
14- Aug -15 |
7- Mar -17 |
US9585953 |
Immunogenic
compositions in particulate form and methods for producing the same |
MUCOSIS
B.V. |
22- Mar- 11 |
22- Mar -12 |
7- Mar -17 |
US9585874 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
6- Jan -16 |
7- Mar -17 |
US9585849 |
Broad
spectrum antiviral and methods of use |
The
Burlington HC Research Group, Inc. |
17- Apr- 06 |
17- Apr -07 |
7- Mar -17 |
US9580474 |
Polyionic
papilloma virus-like particle (VLP) vaccines |
THE
JOHNS HOPKINS UNIVERSITY |
8- Sep-
10 |
8- Sep -11 |
28- Feb -17 |
US9580468 |
Methods
and reagents for efficient and targeted delivery of therapeutic molecules to
CXCR4 cells |
CENTRE
DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA
(CIBER BBN) |
13- Jan- 11 |
13- Jan -12 |
28- Feb -17 |
US9580429 |
Pyrrolo[3,2-D]pyrimidin-4-one
derivatives and their use in therapy |
AstraZeneca
AB |
6- Dec-
04 |
15- Sep -14 |
28- Feb -17 |
US9574189 |
Enzymatic
encoding methods for efficient synthesis of large libraries |
Nuevolution
A/S |
1- Dec-
05 |
1- Dec -06 |
21- Feb -17 |
US9574181 |
Influenza
virus reassortment method |
Seqirus
UK Limited |
21- May- 10 |
24- Oct -14 |
21- Feb -17 |
US9573955 |
Compounds |
Chiese
Farmaceutici S.p.A. |
16- Dec- 13 |
16- Dec -14 |
21- Feb -17 |
US9573938 |
Therapeutic
hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
Rutgers,
The State University of New Jersey |
11- Sep- 12 |
11- Sep -13 |
21- Feb -17 |
US9572899 |
Compositions
for enhancing transport of molecules into cells |
AVI
BIOPHARMA, INC. |
29- Apr- 03 |
5- Nov -08 |
21- Feb -17 |
US9572864 |
Compositions
and uses of lectins |
Emory
University |
12- Feb- 10 |
11- Dec -15 |
21- Feb -17 |
US9572823 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
5- Apr -16 |
21- Feb -17 |
US9567336 |
Conjugated
TLR7 and/or TLR8 and TLR2 agonists |
INVIVOGEN |
19- Nov- 12 |
15- Mar -13 |
14- Feb -17 |
US9566326 |
Adjuvanted
influenza vaccines for pediatric use |
Seqirus
UK Limited |
22- Feb- 08 |
21- Jun -13 |
14- Feb -17 |
US9566291 |
Nutritional
composition comprising indigestible oligosaccharides |
N.V.
Nutricia |
24- Aug- 04 |
24- Aug -05 |
14- Feb -17 |
US9566290 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
20- Apr -16 |
14- Feb -17 |
US9566289 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
17- Feb -16 |
14- Feb -17 |
US9565857 |
Antimicrobial
solutions |
Board
of Regents, The University of Texas System |
10- Sep- 10 |
9- Sep -11 |
14- Feb -17 |
US9562110 |
Bispecific
antibody |
Wuhan
YZY Biopharma Co., Ltd. |
21- Nov- 12 |
21- Nov -12 |
7- Feb -17 |
US9561263 |
Treatment
of inflammatory illnesses with ACE2 |
Apeiron
Biologics AG |
18- Dec- 07 |
18- Dec -08 |
7- Feb -17 |
US9556237 |
Antiviral
rift valley fever virus peptides and methods of use |
The
United States of America, as represented by the Secretary of the Army, on
behalf of the U.S. Army Medical Research
Institute of Infectious Diseases |
6- Dec-
12 |
4- Jun -15 |
31- Jan- 17 |
US9556229 |
Modification
of peptides using a bis(thioether)arylbridge approach |
The
Regents of the University of California |
18- May- 12 |
17- May -13 |
31- Jan- 17 |
US9556184 |
Phosphoinositide
3-kinase inhibitors |
Respivert,
Ltd. |
15- Mar- 13 |
4- Dec -15 |
31- Jan- 17 |
US9556117 |
Indole
carboxamide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
18- Dec- 12 |
17- Dec -13 |
31- Jan- 17 |
US9555031 |
Therapeutic
uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
31- Jan- 17 |
US9555030 |
Therapeutic
uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase
activity |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
31- Jan- 17 |
US9550773 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
13- Apr -15 |
24- Jan- 17 |
US9550757 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
5- Mar-
10 |
28- Jun -13 |
24- Jan- 17 |
US9549949 |
Antiviral
agent |
NBC
MESHTEC, INC. |
3- Sep-
08 |
31- Aug -09 |
24- Jan- 17 |
US9549938 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
11- Mar -16 |
24- Jan- 17 |
US9546371 |
Chimeric
polynucleotides and polypeptides enabling secretion of a polypeptide of
interest in association with exosomes and use thereof for the production of
immunogenic compositions |
CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
18- Mar- 08 |
18- Mar -09 |
17- Jan- 17 |
US9546184 |
Alkyloxy
substituted thiazoloquinolines and thiazolonaphthyridines |
3M
INNOVATIVE PROPERTIES COMPANY |
13- Aug- 08 |
8- Jun -15 |
17- Jan- 17 |
US9546150 |
Substituted
quinazolin-4-ones for inhibiting ubiquitin specific protease 7 |
HYBRIGENICS
SA |
2- Sep-
11 |
29- Aug -12 |
17- Jan- 17 |
US9545440 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
23- Oct -15 |
17- Jan- 17 |
US9540373 |
Substituted
spirocycles |
Boehringer
Ingelheim International GmbH |
12- Sep- 14 |
10- Sep -15 |
10- Jan- 17 |
US9539321 |
HMGB1-derived
peptides enhance immune response to antigens |
The
Regents of the University of California |
27- Jul-10 |
9- Mar -15 |
10- Jan- 17 |
US9539217 |
Nanoparticle
compositions |
Allertein
Therapeutics, LLC |
3- Apr-
13 |
3- Apr -14 |
10- Jan- 17 |
US9533978 |
Pyrimidine
derivatives and their use in the treatment of cancer and further diseases |
Sumitomo
Dainippon Pharma Co., Ltd |
21- May- 09 |
26- Aug -14 |
3- Jan-
17 |
US9533037 |
Methods
for designing and preparing vaccines comprising directed sequence polymer
compositions via the directed expansion of epitopes |
Declion
Holdings LLC |
16- Oct- 07 |
16- Oct -08 |
3- Jan- 17 |
US9529974 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
25- Feb- 08 |
27- Jul- 11 |
27- Dec -16 |
US9527903 |
Engineered
antibody constant domain molecules |
The
United States of America, as represent by the Secretary, Department of Health
and Human Services |
31- Jan- 08 |
1- Oct -13 |
27- Dec -16 |
US9526803 |
Diagnostic
chewing gum for pathogens |
Julius-Maximilians-Universitaet
Wuerzburg |
8- Mar-
12 |
8- Mar -13 |
27- Dec -16 |
US9526700 |
Composition
for inactivating an enveloped virus |
VIROBLOCK
SA |
19- May- 06 |
17- Nov -14 |
27- Dec -16 |
US9522962 |
Peptides,
conjugates and method for increasing immunogenicity of a vaccine |
Academisch
Ziekenhuis Leiden h.o.d.n. LUMC |
15- Mar- 10 |
15- Mar -11 |
20- Dec -16 |
US9522894 |
Certain
(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as
dipeptidyl peptidase 1 inhibitors |
AstraZeneca
AB |
24- Jan- 14 |
21- Jan -15 |
20- Dec -16 |
US9522171 |
EV576 for
use in the treatment of viral infections of the respiratory tract |
Volution
Immuno Pharmaceuticals SA |
8- Jan- 10 |
2- Jan -15 |
20- Dec -16 |
US9518093 |
Topical
formulation of arginine-rich cyclic antimicrobial peptides |
NOVABIOTICS
LIMITED |
24- Feb- 06 |
9- Nov -15 |
13- Dec -16 |
US9518083 |
Gadd45beta
targeting agents |
Imperial
Innovations Limited |
22- Oct- 09 |
10- Feb -15 |
13- Dec -16 |
US9517263 |
Benzonaphthyridine-containing
vaccines |
GlaxoSmithKline
Biologicals SA |
10- Jun- 09 |
10- Jun -10 |
13- Dec -16 |
US9517205 |
Soluble
needle arrays for delivery of influenza vaccines |
Seqirus
UK Limited |
20- Aug- 10 |
19- Aug -11 |
13- Dec -16 |
US9512471 |
Methods
and kits for detecting human papillomavirus |
DIACARTA
Inc |
30- Jun- 10 |
30- Jun -10 |
6- Dec -16 |
US9512443 |
Recombinant
expression of multiprotein complexes using polygenes |
ETH
ZURICH |
8- Nov-
05 |
6- Nov -06 |
6- Dec -16 |
US9512181 |
Fusion
proteins of ciliate granule lattice proteins, granular protein particles
thereof, and uses therefor |
Tetragenetics,
Inc. |
27- May- 11 |
29- May -12 |
6- Dec -16 |
US9511070 |
Heterocyclyl
carboxamides for treating viral diseases |
NovaDrug,
LLC |
31- Aug- 12 |
30- Aug -13 |
6- Dec -16 |
US9506063 |
SiRNA
compositions and methods for treatment of HPV and other infections |
Sirnaomics,
Inc. |
29- Jul-10 |
29- Jan -13 |
29- Nov -16 |
US9504747 |
Lipids
and lipid compositions for the delivery of active agents |
Novartis
AG |
8- Mar-
13 |
7- Mar -14 |
29- Nov -16 |
US9504673 |
Agent for
the prophylaxis and treatment of highly pathogenic infectious diseases |
LTD
“Valenta-Intellekt†|
21- May- 09 |
10- May -10 |
29- Nov -16 |
US9504255 |
Physical
antimicrobial method |
NMS
TECHNOLOGIES CO., LTD. |
1- Aug-
12 |
16- Jul- 13 |
29- Nov -16 |
US9499799 |
Cells and
methodology to generate non-segmented negative-strand RNA viruses |
Centre
National De La Recherche Scientifique |
22- Dec- 06 |
15- Oct -13 |
22- Nov -16 |
US9499535 |
Kinase
inhibitors |
ORIGENIS
GMBH |
21- Apr- 11 |
23- Apr -12 |
22- Nov -16 |
US9499489 |
Myxovirus
therapeutics, compounds, and uses related thereto |
Children's
Healthcare of Atlanta, Inc. |
24- Oct- 11 |
24- Oct -12 |
22- Nov -16 |
US9498548 |
Method of
using oxidative reductive potential water solution in dental applications |
Oculus
Innovative Sciences, Inc. |
2- May-
05 |
2- May -06 |
22- Nov -16 |
US9498544 |
Genetically
modified human umbilical cord perivascular cells for prophylaxis against or
treatment of biological or chemical agents |
Tissue
Regeneration Therapeutics Inc. |
21- Apr- 08 |
13- Mar -15 |
22- Nov -16 |
US9498527 |
Vaccine
composition |
NITTO
DENKO CORPORATION |
4- Apr-
12 |
3- Apr -13 |
22- Nov -16 |
US9494571 |
Methods
of testing for intracellular pathogens |
Novartis
AG |
8- Mar-
10 |
7- Mar -11 |
15- Nov -16 |
US9493788 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
16- Jan -15 |
15- Nov -16 |
US9493572 |
GITR
antibodies and methods of inducing or enhancing an immune response |
GITR,
Inc. |
25- Mar- 05 |
23- Mar -15 |
15- Nov -16 |
US9493518 |
Compositions
and methods for treating clostridium difficile- associated diseases |
National
Health Research Institutes |
14- Mar- 13 |
13- Mar -14 |
15- Nov -16 |
US9492528 |
Influenza
virus-like particles (VLPS) comprising hemagglutinin |
MEDICAGO
INC. |
13- Jul-07 |
2- Jul- 09 |
15- Nov -16 |
US9492413 |
Use of
salt of an acetylsalicylic acid for the treatment of viral infections |
Ventaleon
GMBH |
14- Jan- 08 |
14- Jan -09 |
15- Nov -16 |
US9489495 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
GEORGETOWN
UNIVERSITY |
25- Feb- 08 |
28- Aug -08 |
8- Nov -16 |
US9487838 |
Oligonucleotide
probe for the detection of adenovirus |
QIAGEN
HAMBURG GMBH |
28- Dec- 10 |
28- Dec -10 |
8- Nov -16 |
US9487837 |
Exosome-mediated
diagnosis of hepatitis virus infections and diseases |
MOREHOUSE
SCHOOL OF MEDICINE |
6- Oct-
08 |
21- Jan -14 |
8- Nov -16 |
US9487778 |
Oligonucleotide
modulators of the toll-like receptor pathway |
QUARK
PHARMACEUTICALS, INC. |
3- Mar-
11 |
1- Mar -12 |
8- Nov -16 |
US9487749 |
Use
of methylsulfonylmethane (MSM) to modulate microbial activity |
Biogenic
Innovations, LLC |
30- Oct- 09 |
12- Aug -14 |
8- Nov -16 |
US9487528 |
Compounds |
Chiesi
Farmaceutici S.p.A. |
9- Jun-
14 |
5- Jun -15 |
8- Nov -16 |
US9486479 |
Antimicrobial
solutions containing dichloride monoxide and methods of making and using the
same |
Oculus
Innovative Sciences, Inc. |
13- Mar- 07 |
21- Jul- 14 |
8- Nov -16 |
US9481912 |
Compositions
and methods for detecting and identifying nucleic acid sequences in
biological samples |
Longhorn
Vaccines and Diagnostics, LLC |
12- Sep- 06 |
8- Oct -13 |
1- Nov -16 |
US9481724 |
hDC-sign
binding peptides |
Sloan-Kettering
Institute for Cancer Research |
19- Dec- 11 |
10- Dec -12 |
1- Nov -16 |
US9481630 |
Ingenane-type
diterpene compound, and pharmaceutical composition for treating or preventing
viral infectious diseases containing same |
KOREA
RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
19- Oct- 11 |
28- Sep -12 |
1- Nov -16 |
US9476090 |
Signal
propagation biomolecules, devices and methods |
STC.UNM |
21- May- 13 |
21- May -14 |
25- Oct- 16 |
US9476032 |
Attenuated
viruses useful for vaccines |
The Research
Foundation for The State University of New York |
30- Mar- 07 |
31- Mar -08 |
25- Oct- 16 |
US9475872 |
Nucleic
acid molecules encoding moonoclonal antibodies speceific for IL17F |
ImmunoQure
AG |
28- Dec- 11 |
2- Jan -13 |
25- Oct- 16 |
US9475862 |
Neutralizing
GP41 antibodies and their use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
7- Nov-
11 |
7- Nov -12 |
25- Oct- 16 |
US9475832 |
Phosphonates
with reduced toxicity for treatment of viral infections |
The
Regents of the University of California |
14- Apr- 10 |
29- Sep -14 |
25- Oct- 16 |
US9475804 |
Heterobifunctional
linkers with polyethylene glycol segments and immune response modifier
conjugates made therefrom |
3M
Innovative Properties Company |
3- Jun-
11 |
1- Jun -12 |
25- Oct- 16 |
US9475779 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
25- Oct- 16 |
US9475775 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
4- Mar -16 |
25- Oct- 16 |
US9474844 |
Methods
for pathogen inactivation in blood using UV irradiation while minimizing heat
transfer thereto |
Hemalux
LLC |
22- Oct- 14 |
29- Dec -15 |
25- Oct- 16 |
US9474759 |
Broad-spectrum
antivirals against 3C or 3C-like proteases of picornavirus-like supercluster:
picornaviruses, caliciviruses and coronaviruses |
Kansas
State University Research Foundation |
27- Sep- 11 |
27- Sep -12 |
25- Oct- 16 |
US9469876 |
Circulating
biomarkers for metastatic prostate cancer |
Caris
Life Sciences Switzerland Holdings GmbH |
6- Apr-
10 |
6- Apr -11 |
18- Oct- 16 |
US9464276 |
Highly
efficient influenza matrix (M1) proteins |
Novavax,
Inc. |
11- Jul-03 |
23- Feb -15 |
11- Oct- 16 |
US9464123 |
Peptides
having activity of inhibiting infections of respiratory viruses and use of
the same |
XIANGXUE
GROUP (HONG KONG) COMPANY LIMITED |
9- May-
13 |
21- Feb -14 |
11- Oct- 16 |
US9463240 |
Arranging
interaction and back pressure chambers for microfluidization |
NOVARTIS
AG |
3- Dec-
09 |
11- Jul- 14 |
11- Oct- 16 |
US9459247 |
Quantitative
measurement of nano/micro particle endocytosis with cell mass spectrometry |
Academia
Sinica |
29- Mar- 10 |
29- Mar -11 |
4- Oct-
16 |
US9459233 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
26- Feb -13 |
4- Oct-
16 |
US9458492 |
Methods
and cells for identifying RIG-I pathway regulators |
Kineta,
Inc. |
25- Feb- 11 |
23- Feb -12 |
4- Oct-
16 |
US9458470 |
Recombinant
influenza virus-like particles (VLPs) produced in transgenic plants
expressing hemagglutinin |
MEDICAGO
INC. |
21- Jan- 08 |
23- Jan -13 |
4- Oct-
16 |
US9458184 |
Compositions
of TLR7 and/or TLR8 agonists conjugated to lipids |
INVIVOGEN |
15- Jun- 12 |
15- Mar -13 |
4- Oct-
16 |
US9458113 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
4- Oct-
16 |
US9457074 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Foundation |
24- Apr- 12 |
23- Feb -15 |
4- Oct-
16 |
US9453043 |
Nucleic
acid chemical modifications |
ALNYLAM
PHARMACEUTICALS, INC. |
2- Mar-
09 |
22- Jan -15 |
27- Sep -16 |
US9452973 |
Modulators
of the relaxin receptor 1 |
THE
FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES |
4- May-
12 |
15- Mar -13 |
27- Sep -16 |
US9452210 |
Influenza
virus-like particles (VLPS) comprising hemagglutinin produced within a plant |
MEDICAGO
INC. |
13- Jul-07 |
4- Jan -13 |
27- Sep -16 |
US9447462 |
Methods
for concurrent identification and quantification of an unknown bioagent |
IBIS
BIOSCIENCES, INC. |
18- Feb- 04 |
27- Jan -14 |
20- Sep -16 |
US9447132 |
Highly
active nucleoside derivative for the treatment of HCV |
Achillion
Pharmaceuticals, Inc. |
12- Apr- 13 |
14- Apr -14 |
20- Sep -16 |
US9447097 |
4-amino-imidazoquinoline
compounds |
Hoffmann-La
Roche Inc. |
22- Apr- 14 |
7- Apr -16 |
20- Sep -16 |
US9446062 |
Methods
of treating ischemia-reperfusion injury with siRNAs |
Quark
Pharmaceuticals, Inc. |
25- Oct- 06 |
8- Jan -15 |
20- Sep -16 |
US9442107 |
Antibody-nanoparticle
conjugates and methods for making and using such conjugates |
Ventana
Medical Systems, Inc. |
27- Apr- 10 |
21- Apr -15 |
13- Sep -16 |
US9441247 |
TC-83-derived
alphavirus vectors, particles and methods |
ALPHAVAX,
INC. |
18- May- 04 |
6- Jul- 15 |
13- Sep -16 |
US9440960 |
Substituted
oxetanes and their use as inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
1- Aug-
14 |
31- Jul- 15 |
13- Sep -16 |
US9440930 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
13- Sep -16 |
US9435795 |
Enhanced
deposition of chromogens utilizing pyrimidine analogs |
Ventana
Medical Systems, Inc. |
30- Dec- 10 |
6- Oct -14 |
6- Sep -16 |
US9435000 |
Primate
T-lymphotropic viruses |
Johns
Hopkins University |
21- Feb- 05 |
20- Sep -13 |
6- Sep -16 |
US9434997 |
Methods,
compounds and systems for detecting a microorganism in a sample |
Lawrence
Livermore National Security, LLC |
24- Aug- 07 |
21- Aug -08 |
6- Sep -16 |
US9434769 |
Peptide
compositions and methods for inhibiting herpesvirus infection |
The
Administrators of the Tulane Educational Fund |
30- Oct- 09 |
9- Jul- 14 |
6- Sep -16 |
US9433672 |
Compositions
and methods for activating innate and allergic immunity |
ID
Biomedical Corporation of Quebec |
26- Apr- 12 |
28- Apr -14 |
6- Sep -16 |
US9430610 |
Re-sequencing
pathogen microarray |
The
United States of America, as represented by the Secretary of the Navy |
2-Jul- 04 |
10- Apr -08 |
30- Aug -16 |
US9428739 |
Norovirus
and Sapovirus antigens |
NOVARTIS
VACCINES AND DIAGNOSTICS, INC. |
24- Mar- 01 |
27- Nov -12 |
30- Aug -16 |
US9428574 |
Polypeptides
and uses thereof for treatment of autoimmune disorders and infection |
COMPUGEN
LTD. |
30- Jun- 11 |
1- Jul- 12 |
30- Aug -16 |
US9428571 |
Antibodies
and processes for preparing the same |
TAIGA
BIOTECHNOLOGIES, INC. |
16- May- 08 |
18- Mar -15 |
30- Aug -16 |
US9428490 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
26- Jul- 12 |
30- Aug -16 |
US9428439 |
Hydrobenzamide
derivatives as inhibitors of Hsp90 |
ASTEX
THERAPEUTICS LTD. |
12- Oct- 06 |
7- Jan -14 |
30- Aug -16 |
US9426989 |
Organic
peroxide compounds for microorganism inactivation |
NOVARTIS
AG |
6- May-
10 |
6- May -11 |
30- Aug -16 |
US9422367 |
Antigenic
GM-CSF peptides and antibodies to GM-CSF |
Morphotek,
Inc. |
7- Feb-
06 |
26- Nov -13 |
23- Aug -16 |
US9421254 |
Immunostimulatory
combinations of TLR ligands and methods of use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
24- Sep- 07 |
24- Sep -08 |
23- Aug -16 |
US9416416 |
Biological
specimen collection/transport compositions and methods |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
16- Dec -11 |
16- Aug -16 |
US9416409 |
Capture
primers and capture sequence linked solid supports for molecular diagnostic
tests |
IBIS
BIOSCIENCES, INC. |
31- Jul-09 |
30- Jul- 10 |
16- Aug -16 |
US9416396 |
Covalently
linked thermostable kinase for decontamination process validation |
The
Secretary of State for Health |
20- Feb- 08 |
18- Feb -09 |
16- Aug -16 |
US9415392 |
Slip
chip device and methods |
The
University of Chicago |
24- Mar- 09 |
23- Mar -10 |
16- Aug -16 |
US9415087 |
Compositions
and methods for treating coronavirus infection |
Ludwig-Maximilians-Universitaet
Muenchen |
11- Mar- 14 |
8- May -15 |
16- Aug -16 |
US9415033 |
Esters of
short chains fatty acids for use in the treatment of immunogenic disorders |
PROPONENT
BIOTECH GMBH |
3- Oct-
12 |
3- Oct -13 |
16- Aug -16 |
US9409987 |
Polypeptides
and polynucleotides, and uses thereof for treatment of immune related
disorders and cancer |
COMPUGEN
LTD |
15- Apr- 11 |
16- Apr -12 |
9- Aug -16 |
US9409917 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
20- Jan- 12 |
18- Jan -13 |
9- Aug -16 |
US9409870 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
15- Dec- 14 |
27- Nov -15 |
9- Aug -16 |
US9408908 |
Combination
adjuvant formulation |
Not
Available |
16- Oct- 08 |
15- Feb -13 |
9- Aug -16 |
US9408907 |
Homogenous
suspension of immunopotentiating compounds and uses thereof |
GlaxoSmithKline
Biologicals SA |
15- Dec- 09 |
15- Dec -10 |
9- Aug -16 |
US9404160 |
Methods
for the detection of microorganisms |
Becton,
Dickinson and Company |
22- Dec- 09 |
21- Dec -10 |
2- Aug -16 |
US9403868 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
5- Mar -15 |
2- Aug -16 |
US9402921 |
Directed
evolution and in vitro panning of virus vectors |
The
University of North Carolina at Chapel Hill |
30- Apr- 08 |
22- Oct -14 |
2- Aug -16 |
US9402878 |
Depsipeptide
and uses thereof |
NovoBiotic
Pharmaceuticals, LLC |
3- Dec-
12 |
1- Jul- 15 |
2- Aug -16 |
US9402812 |
Methods
for the preparation of liposomes |
Indu
Javeri |
23- Sep- 09 |
23- Sep -10 |
2- Aug -16 |
US9394092 |
Powdered
pouch and method of making same |
MONOSOL,
LLC |
16- Apr- 12 |
14- Mar -13 |
19- Jul- 16 |
US9393564 |
Bioagent
detection systems, devices, and methods |
IBIS
BIOSCIENCES, INC. |
30- Mar- 09 |
30- Mar -10 |
19- Jul- 16 |
US9393295 |
Nanoparticles
for use in pharmaceutical compositions |
Novartis
AG |
28- Apr- 08 |
28- Apr -09 |
19- Jul- 16 |
US9393215 |
Nanoparticles
for use in immunogenic compositions |
Novartis
AG |
2- Dec-
05 |
1- Dec -06 |
19- Jul- 16 |
US9388429 |
Method
for propagating adenoviral vectors encoding inhibitory gene products |
GenVec,
Inc. |
10- Nov- 05 |
28- May -14 |
12- Jul- 16 |
US9388234 |
Systems
and methods for identifying Replikin Scaffolds and uses of said Replikin
Scaffolds |
Not
Available |
6- Jun-
03 |
19- Jun -13 |
12- Jul- 16 |
US9388198 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
21- Jan- 14 |
21- Jan -14 |
12- Jul- 16 |
US9388197 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
22- Jan- 13 |
21- Jan -14 |
12- Jul- 16 |
US9387242 |
Chimeric
viruses presenting non-native surface proteins and uses thereof |
Icahn
School of Medicine at Mount Sinai |
2- Dec-
05 |
1- Dec -06 |
12- Jul- 16 |
US9382590 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA
AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU) |
25- Mar- 11 |
20- May -15 |
5- Jul- 16 |
US9382545 |
CpG
oligonucleotide analogs containing hydrophobic T analogs with enhanced
immunostimulatory activity |
COLEY
PHARMACEUTICAL GMBH |
27- Sep- 06 |
4- Oct -13 |
5- Jul- 16 |
US9382288 |
Derivatives
of steroid benzylamines, having an antiparasitic antibacterial, antimycotic
and/or antiviral action |
Justus-Liebig-Universitat
Giessen |
6- Oct-
10 |
6- Oct -11 |
5- Jul- 16 |
US9381244 |
VISTA
modulators for diagnosis and treatment of cancer |
KING'S
COLLEGE LONDON |
7- Sep-
12 |
9- Sep -13 |
5- Jul- 16 |
US9381239 |
VLPS
derived from cells that do not express a viral matrix or core protein |
Novavax,
Inc. |
25- May- 07 |
14- Apr -14 |
5- Jul- 16 |
US9381226 |
Methods
and compositions related to inhibition of viral entry |
UNIVERSITY
OF UTAH RESEARCH FOUNDATION |
8- Feb-
07 |
8- Feb -08 |
5- Jul- 16 |
US9381220 |
Sceletium
extract and uses thereof |
H.
L. Hall & Sons Limited |
20- Mar- 09 |
15- Jul- 14 |
5- Jul- 16 |
US9380785 |
Antiviral
resin member |
NBC
MESHTEC, INC. |
6-Jul- 11 |
6- Jul- 12 |
5- Jul- 16 |
US9376486 |
Human
monoclonal antibody with specificity for Dengue virus serotype 1 E protein
and uses thereof |
DSO
National Laboratories |
14- Dec- 10 |
14- Dec -11 |
28- Jun- 16 |
US9376398 |
Carboxylic
acid compounds |
Astrazeneca
Aktiebolag |
18- May- 12 |
17- May -13 |
28- Jun- 16 |
US9375465 |
Conjugates
of GM-CSF and IL-7, compositions and methods related thereto |
Children's
Healthcare of Atlanta, Inc. |
14- Nov- 11 |
13- Nov -12 |
28- Jun- 16 |
US9372156 |
System
for processing contents of a receptacle to detect an optical signal emitted
by the contents |
GEN-PROBE
INCORPORATED |
10- Mar- 05 |
22- Feb -11 |
21- Jun- 16 |
US9371563 |
Nanoreporters
and methods of manufacturing and use thereof |
NanoString
Technologies, Inc. |
23- Dec- 05 |
11- Mar -13 |
21- Jun- 16 |
US9370582 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
4- Dec-
07 |
11- Jul- 14 |
21- Jun- 16 |
US9370581 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
4- Dec-
07 |
11- Jul- 14 |
21- Jun- 16 |
US9370570 |
Polychlorinated
biphenyls and squalene-containing adjuvants |
Novartis
AG |
28- Dec- 07 |
10- Dec -13 |
21- Jun- 16 |
US9370531 |
Method of
providing patient specific immune response in amyloidoses and protein
aggregation disorders |
New
York University |
31- Aug- 07 |
1- Sep -08 |
21- Jun- 16 |
US9365577 |
Pyrimidinone
compounds as human neutrophil elastase inhibitors |
Chiesi
Farmaceutici S.p.A. |
18- Dec- 12 |
17- Dec -13 |
14- Jun- 16 |
US9365567 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
30- Sep -14 |
14- Jun- 16 |
US9365523 |
Imidazolyl
amide compounds and uses related thereto |
Children's
Healthcare of Atlanta, Inc. |
31- Mar- 11 |
28- Mar -12 |
14- Jun- 16 |
US9365506 |
Compounds
and compositions as TLR2 agonists |
NOVARTIS
AG |
23- Mar- 10 |
9- Jul- 14 |
14- Jun- 16 |
US9364511 |
Antiviral
preparations obtained from a natural cinnamon extract |
RAMOT
AT TEL-AVIV UNIVERSITY LTD. |
24- Dec- 03 |
22- Jun -06 |
14- Jun- 16 |
US9359360 |
TLR
agonists |
The
Regents of The University of California |
22- Aug- 05 |
20- Nov -12 |
7- Jun-
16 |
US9358280 |
Decreasing
potential iatrogenic risks associated with influenza vaccines |
Novartis
AG |
9- Sep-
04 |
11- Jan -13 |
7- Jun-
16 |
US9353133 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
7- Mar -14 |
31- May -16 |
US9352048 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
4- Dec-
07 |
22- Jul- 14 |
31- May -16 |
US9347055 |
Method
and kit for preparation of sample for use in nucleic acid amplification |
EIKEN
KAGAKU KABUSHIKI KAISHA |
5- Nov-
07 |
5- Nov -08 |
24- May -16 |
US9346866 |
Inhibition
of tace activity with cyclic peptides |
The
Regents of the University of California |
2- Jun-
11 |
19- Sep -14 |
24- May -16 |
US9346794 |
Substituted
4-pyridones and their use as inhibitors of neutrophil elastase activity |
Boehringer
Ingelheim International GmbH |
23- Aug- 12 |
29- Dec -15 |
24- May -16 |
US9346769 |
Tetrazolones
as inhibitors of fatty acid synthase |
Infinity
Pharmaceuticals, Inc. |
5- May-
10 |
23- Aug -13 |
24- May -16 |
US9346753 |
Dithiol
mucolytic agents |
PARION
SCIENCES, INC. |
23- Aug- 13 |
13- Aug -14 |
24- May -16 |
US9345760 |
IPNV-ISAV
bivalent vaccine using a virus-like particle-based platform and methods of
using the same |
Advanced
Bionutrition Corporation |
9- Sep-
11 |
7- Sep -12 |
24- May -16 |
US9340507 |
Substituted
4-pyridones and their use as inhibitors of neutrophil elastase activity |
Boehringer
Ingelheim International GmbH |
23- Aug- 12 |
2- Sep -15 |
17- May -16 |
US9339561 |
Mutant
protease biosensors with enhanced detection characteristics |
PROMEGA
CORPORATION |
11- May- 10 |
5- May -14 |
17- May -16 |
US9339525 |
Inhibition
of biofilm organisms |
Novabiotics
Limited |
31- Mar- 09 |
31- Mar -10 |
17- May -16 |
US9334268 |
4-amino-imidazoquinoline
compounds |
HOFFMAN-LA
ROCHE INC. |
22- Apr- 14 |
22- Apr -15 |
10- May -16 |
US9328110 |
Substituted
imidazo ring systems and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
25- Nov- 03 |
11- Mar -14 |
3- May -16 |
US9328093 |
Selective
inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions
thereof and their therapeutic applications |
HYBRIGENICS
SA |
15- Jan- 10 |
17- Sep -14 |
3- May -16 |
US9326972 |
Use
of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones
for the treatment of autoimmune/inflammatory diseases associated with
toll-like receptor overexpression |
Ohio
University |
16- Mar- 04 |
9- Feb -12 |
3- May -16 |
US9322827 |
B-cell
antigen presenting cell assay |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
8- Apr-
10 |
8- Apr -11 |
26- Apr- 16 |
US9321999 |
Compositions
for increasing polypeptide stability and activity, and related methods |
SOLIS
BIODYNE OÜ |
19- Nov- 09 |
19- Nov -10 |
26- Apr- 16 |
US9321847 |
Activatable
toxin complexes comprising a cleavable inhibitory peptide |
RAMOT
at Tel Aviv University Ltd. |
20- Sep- 10 |
22- Aug -11 |
26- Apr- 16 |
US9321831 |
RSV-specific
binding molecules and means for producing them |
MedImmune
Limited |
1- Jun-
07 |
13- Sep -13 |
26- Apr- 16 |
US9320784 |
Peptides
shared among lethal cancers and therapeutic compositions comprising said
peptides |
Not
Available |
7- Aug-
09 |
19- Jul- 12 |
26- Apr- 16 |
US9320748 |
Immunologically
useful arginine salts |
Novartis
AG |
7- Mar-
12 |
7- Mar -13 |
26- Apr- 16 |
US9315530 |
Adsorption
of immunopotentiators to insoluble metal salts |
Novartis
AG |
1- Sep-
10 |
1- Sep -11 |
19- Apr- 16 |
US9310375 |
Luminophore-labeled
molecules coupled with particles for microarray-based assays |
CapitalBio
Corporation |
27- Oct- 10 |
27- Oct -10 |
12- Apr- 16 |
US9310088 |
Device
and method for reducing spread of microorganisms and airborne health
hazardous matter and/or for protection from microorganisms and airborne
health hazardous matter |
Technical
University of Denmark |
17- Jul-09 |
14- Jul- 10 |
12- Apr- 16 |
US9309325 |
Antibodies
and methods of use thereof |
The
Regents of the University of California |
7- May-
09 |
4- May -10 |
12- Apr- 16 |
US9303068 |
D-amino
acid derivative-modified peptidoglycan and methods of use thereof |
The
Regents of the University of California |
30- Nov- 12 |
27- Nov -13 |
5- Apr-
16 |
US9303000 |
Olefin
containing nuclear transport modulators and uses thereof |
KARYOPHARM
THERAPEUTICS INC. |
17- Jan- 11 |
16- Jan -12 |
5- Apr-
16 |
US9297010 |
Short
interfering RNA (siRNA) analogues |
Roche
Innovation Center Copenhagen A/S |
21- Mar- 03 |
11- Feb -14 |
29- Mar -16 |
US9295732 |
Conjugated
TLR7 and/or TLR8 and TLR2 polycationic agonists |
INVIVOGEN |
22- Feb- 13 |
22- Feb -13 |
29- Mar -16 |
US9295708 |
Modified
release formulations for oprozomib |
Onyx
Therapeutics, Inc. |
24- Oct- 12 |
24- Oct -13 |
29- Mar -16 |
US9295646 |
Cationic
oil-in-water emulsions |
Novartis
AG |
6-Jul- 10 |
18- Sep -11 |
29- Mar -16 |
US9291628 |
Direct
clone analysis and selection technology |
Dublin
City University |
13- Jul-10 |
13- Jul- 11 |
22- Mar -16 |
US9291597 |
Detecting
targets using mass tags and mass spectrometry |
VENTANA
MEDICAL SYSTEMS, INC. |
2-Jul- 10 |
1- Jul- 11 |
22- Mar -16 |
US9290794 |
Mutant
protease biosensors with enhanced detection characteristics |
PROMEGA
CORPORATION |
11- May- 10 |
12- Nov -12 |
22- Mar -16 |
US9290786 |
Monoclonal
antibody production by EBV transformation of B cells |
Institute
for Research in Biomedicine |
26- Feb- 03 |
25- Apr -13 |
22- Mar -16 |
US9290760 |
Modified
iRNA agents |
ALNYLAM
PHARMACEUTICALS, INC. |
15- Sep- 10 |
14- Sep -11 |
22- Mar -16 |
US9290745 |
Luciferase
biosensor |
PROMEGA
CORPORATION |
10- Oct- 03 |
14- Feb -14 |
22- Mar -16 |
US9290545 |
Compositions
and methods for the treatment of viral infections |
Dana-Farber
Cancer Institute, Inc. |
23- Jan- 08 |
23- Jul- 10 |
22- Mar -16 |
US9290459 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
6- Feb-
13 |
9- Nov -15 |
22- Mar -16 |
US9290457 |
Substituted
dihydropyrimidinones and their use as inhibitors of neutrophil elastase
activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
22- Mar -16 |
US9289487 |
II-key/antigenic
epitope hybrid peptide vaccines |
Antigen
Express, Inc. |
14- Sep- 99 |
11- Jan -05 |
22- Mar -16 |
US9284560 |
Application
of highly conserved domain sequences from viral genome as template to design
therapeutic sliRNAs |
Biocross
Institute of Molecular Medicine (Nantong) Co., Ltd. |
19- Sep- 11 |
19- Sep -11 |
15- Mar -16 |
US9278128 |
Vaccines
and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid
molecules encoding the same, and methods for using the same |
The
Trustees of the University of Pennsylvania |
14- Sep- 09 |
6- Jan -14 |
8- Mar -16 |
US9278126 |
Influenza
vaccines with reduced amounts of squalene |
Seqirus
UK Limited |
10- Feb- 09 |
10- Feb -10 |
8- Mar -16 |
US9272024 |
Compositions,
comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics
and methods of using the same |
The
Trustees of the University of Pennsylvania |
12- Dec- 11 |
11- Dec -12 |
1- Mar -16 |
US9271494 |
Shelf
stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial
compositions |
Ecolab
USA, Inc. |
30- Aug- 07 |
30- Aug -07 |
1- Mar -16 |
US9266844 |
Suppression
of SARS replication by SARS helicase inhibitors |
The
Curators of the University of Missouri |
15- Jun- 12 |
17- Jun -13 |
23- Feb -16 |
US9266843 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
9- May -13 |
23- Feb -16 |
US9265876 |
Systems
and methods for pathogen inactivation in blood using UV irradiation while
minimizing heat transfer thereto |
Hemalux
Technologies LLC |
22- Oct- 14 |
22- Oct -14 |
23- Feb -16 |
US9260398 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
PARION
SCIENCES, INC. |
29- May- 12 |
9- Dec -14 |
16- Feb -16 |
US9255144 |
Anti-IL-18
antibodies and their uses |
MedImmune
Limited |
20- Dec- 10 |
20- Dec -11 |
9- Feb -16 |
US9255140 |
Adjuvancy
and immune potentiating properties of natural products of Onchocerca volvulus |
NEW
YORK BLOOD CENTER, INC. |
15- Jun- 04 |
23- Mar -09 |
9- Feb -16 |
US9254315 |
Systems
and methods for identifying replikin scaffolds and uses of said replikin
scaffolds |
Not
Available |
28- Apr- 04 |
3- Feb -10 |
9- Feb -16 |
US9254265 |
Small
liposomes for delivery of immunogen encoding RNA |
NOVARTIS
AG |
31- Aug- 10 |
31- Aug -11 |
9- Feb -16 |
US9249427 |
Recombinant
HCMV and RHCMV vectors and uses thereof |
Oregon
Health & Science University |
14- May- 10 |
14- Nov -12 |
2- Feb -16 |
US9249195 |
Reovirus
vaccines and methods of use therefor |
Vanderbilt
University |
7- Apr-
10 |
4- Apr -11 |
2- Feb -16 |
US9248201 |
Mutant
protease biosensors with enhanced detection characteristics |
PROMEGA
CORPORATION |
11- May- 10 |
5- May -14 |
2- Feb -16 |
US9248178 |
Different
serotypes of vesicular stomatitis virus as expression vectors for
immunization regimens |
Not
Available |
8- Jun-
09 |
8- Jun -10 |
2- Feb -16 |
US9242980 |
Lipidated
immune response modifier compound compositions, formulations, and methods |
3M
Innovative Properties Company |
17- Aug- 10 |
16- Aug -11 |
26- Jan- 16 |
US9238809 |
Compositions,
methods, and kits for isolating and analyzing nucleic acids using an anion
exchange material |
QIAGEN
GAITHERSBURG, INC. |
24- Sep- 09 |
5- Aug -10 |
19- Jan- 16 |
US9234175 |
Creating
bioengineered lymph nodes |
H.
Lee Moffitt Cancer Center and Research Institute, Inc. |
17- Nov- 09 |
16- Nov -10 |
12- Jan- 16 |
US9233148 |
Replikin-based
compounds for prevention and treatment of influenza and methods of
differentiating infectivity and lethality in influenza |
Not
Available |
9- Jan- 09 |
16- Oct -09 |
12- Jan- 16 |
US9227977 |
Phosphoinositide
3-kinase inhibitors |
Respivert
Ltd. |
15- Mar- 13 |
14- Mar -14 |
5- Jan-
16 |
US9222075 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
2- May -14 |
29- Dec -15 |
US9221832 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
22- Jul-11 |
20- Jul- 12 |
29- Dec -15 |
US9221807 |
Substituted
pyridones and pyrazinones and their use as inhibitors of neutrophil elastase
activity |
Boehringer
Ingelheim International GmbH |
21- Feb- 14 |
12- Feb -15 |
29- Dec -15 |
US9220768 |
Decreasing
potential iatrogenic risks associated with influenza vaccines |
Novartis
AG |
9- Sep-
04 |
14- Oct -11 |
29- Dec -15 |
US9217745 |
Arrayed
detector system for measurement of influenza immune response |
University
of Rochester |
2- May-
08 |
11- Jul- 13 |
22- Dec -15 |
US9217157 |
Recombinant
influenza viruses and uses thereof |
Icahn
School of Medicine at Mount Sinai |
27- Jul-09 |
27- Jul- 10 |
22- Dec -15 |
US9216192 |
Toll-like
receptor agonist formulations and their use |
VentiRx
Pharmaceuticals, Inc. |
1- Aug-
08 |
16- Jul- 12 |
22- Dec -15 |
US9213027 |
Lipoparticles
comprising proteins, methods of making, and using the same |
Integral
Molecular, Inc. |
30- Jul-03 |
1- Nov -13 |
15- Dec -15 |
US9212399 |
Biological
specimen collection and transport system and method of use |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
7- Jan -14 |
15- Dec -15 |
US9212205 |
Nucleic
acid binding compounds and methods of use |
University
of Rochester |
26- Jul-07 |
28- Jul- 08 |
15- Dec -15 |
US9206396 |
Methods
and devices for quantitative viral assays |
Wisconsin
Alumni Research Foundation |
16- Nov- 05 |
16- Nov -06 |
8- Dec -15 |
US9206158 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
10- Jun -15 |
8- Dec -15 |
US9200329 |
Rapid
epidemiologic typing of bacteria |
BioFire
Diagnostics, LLC |
19- May- 08 |
18- May -09 |
1- Dec -15 |
US9200287 |
Phosphate-modified
oligonucleotide analogs with enhanced immunostimulatory activity |
AdiuTide
Pharmaceuticals GmbH |
18- May- 07 |
15- May -08 |
1- Dec -15 |
US9200280 |
Methods
and compositions for the treatment of cancer or other diseases |
CITY
OF HOPE |
26- Jan- 07 |
9- Jun -14 |
1- Dec -15 |
US9200279 |
Methods
and compositions for the treatment of cancer or other diseases |
CITY
OF HOPE |
26- Jan- 07 |
14- Jan -14 |
1- Dec -15 |
US9200074 |
Antibodies
to IL-1 R1 and methods of making them |
MEDIMMUNE
LIMITED |
7- Nov-
08 |
16- Apr -14 |
1- Dec -15 |
US9199981 |
Compounds
and compositions as C-kit kinase inhibitors |
NOVARTIS
AG |
1- Sep-
11 |
27- Aug -12 |
1- Dec -15 |
US9199897 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
12- May -11 |
1- Dec -15 |
US9198927 |
Targeting
opposite strand replication intermediates of single- stranded viruses by RNAI |
ALNYLAM
PHARMACEUTICALS, INC. |
24- Sep- 04 |
1- Mar -10 |
1- Dec -15 |
US9193780 |
Amino
acid sequences directed against envelope proteins of a virus and polypeptides
comprising the same for the treatment of viral diseases |
Ablynx
N.V. |
5- Jun- 08 |
5- Jun -09 |
24- Nov -15 |
US9192661 |
Delivery
of self-replicating RNA using biodegradable polymer particles |
Novartis
AG |
6-Jul- 10 |
7- Jun -11 |
24- Nov -15 |
US9187748 |
Compositions
and methods for silencing ebola virus gene expression |
Not
Available |
20- Jul-09 |
28- Mar -14 |
17- Nov -15 |
US9187426 |
Organic
compounds |
Novartis
AG |
27- Jun- 08 |
25- Jun -09 |
17- Nov -15 |
US9186419 |
Directed
evolution and in vitro panning of virus vectors |
The
University of North Carolina at Chapel Hill |
30- Apr- 08 |
17- Jan -14 |
17- Nov -15 |
US9186399 |
Immune
stimulatory oligonucleotide analogs containing modified sugar moieties |
AdiutTide
Pharmaceuticals GmbH |
9- Oct-
07 |
29- Sep -08 |
17- Nov -15 |
US9181303 |
Treatment
of bacterial infections with cyclic antimicrobial peptides |
NovaBiotics
Limited |
22- Dec- 05 |
20- Jun -14 |
10- Nov -15 |
US9181290 |
Inhibition
of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranose |
CHANG
GUNG UNIVERSITY |
17- Jun- 11 |
19- Sep -11 |
10- Nov -15 |
US9175047 |
Peptidomimetic
macrocycles |
Aileron
Therapeutics, Inc. |
14- Jan- 09 |
14- Jan -10 |
3- Nov -15 |
US9174925 |
Phorbol
type diterpene compound, pharmaceutical composition for treatment or
prevention of viral infectious diseases including same |
KOREA
RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
26- Oct- 11 |
28- Sep -12 |
3- Nov -15 |
US9169318 |
Neutralizing
molecules to viral antigens |
Sea
Lane Biotechnologies, Inc. |
28- Mar- 08 |
18- Jul- 11 |
27- Oct- 15 |
US9168318 |
Oxidative
reductive potential water solution and methods of using the same |
Oculus
Innovative Sciences, Inc. |
30- Dec- 03 |
11- Aug -04 |
27- Oct- 15 |
US9168299 |
Methods
for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL)
antibodies |
LIPUM
AB |
8- Apr-
09 |
30- Oct -13 |
27- Oct- 15 |
US9168269 |
Inhibitors
of long and very long chain fatty acid metabolism as broad spectrum anti-virals |
THE
TRUSTEES OF PRINCETON UNIVERSITY |
18- Feb- 10 |
18- Feb -11 |
27- Oct- 15 |
US9163222 |
Mutations
in OAS1 genes |
Kineta
Two, LLC |
4- May-
05 |
14- Nov -12 |
20- Oct- 15 |
US9163065 |
Depsipeptide
and uses thereof |
NovoBiotic
Pharmaceuticals, LLC |
3- Dec-
12 |
3- Dec -13 |
20- Oct- 15 |
US9161976 |
Immunotherapy
comprising TLR9 ligand and CD40 ligand |
Trustees
of Dartmouth College |
30- Dec- 02 |
22- Oct -12 |
20- Oct- 15 |
US9156811 |
N-myristoyl
transferase inhibitors |
Univeristy
of Dundee |
2- Sep-
08 |
29- Aug -09 |
13- Oct- 15 |
US9155309 |
Virus
inactivating sheet |
NBC
MESHTEC, INC. |
2- Oct-
09 |
4- Oct -10 |
13- Oct- 15 |
US9149473 |
Targeted
whole genome amplification method for identification of pathogens |
IBIS
BIOSCIENCES, INC. |
14- Sep- 06 |
14- Sep -07 |
6- Oct-
15 |
US9149445 |
Inhibition
of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for
treatment of viral infections |
THE
TRUSTEES OF PRINCETON UNIVERSITY |
27- Jul-09 |
27- Jul- 10 |
6- Oct-
15 |
US9145588 |
Generation
of binding molecules |
MERUS
BIOPHARMACEUTICALS B.V. |
26- Sep- 11 |
26- Sep -12 |
29- Sep -15 |
US9145585 |
Method
for using permuted nucleic acid probes |
Ventana
Medical Systems, Inc. |
1- Sep-
06 |
5- Aug -14 |
29- Sep -15 |
US9145410 |
Pyrazolopyridines
and analogs thereof |
3M
Innovative Properties Company |
3- Oct-
03 |
26- Jan -12 |
29- Sep -15 |
US9144575 |
Anti-viral
azide containing compounds |
LIFE
TECHNOLOGIES CORPORATION |
28- Jul-10 |
28- Jul- 11 |
29- Sep -15 |
US9139833 |
Modified
small interfering RNA molecules and methods of use |
Arrowhead
Research Corporation |
26- Jul-02 |
12- Mar -13 |
22- Sep -15 |
US9139647 |
Diagnosis
and treatment of cancer using anti-TM4SF20 antibody |
FORERUNNER
PHARMA RESEARCH CO., LTD. |
25- Dec- 08 |
25- Dec -09 |
22- Sep -15 |
US9139620 |
Feline
morbillivirus and uses thereof |
THE
GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S
REPUBLIC OF CHINA |
20- Jan- 12 |
22- Jan -13 |
22- Sep -15 |
US9138472 |
CD40L
vaccines, compositions, and methods related thereto |
EMORY
UNIVERSITY |
28- Sep- 10 |
28- Sep -11 |
22- Sep -15 |
US9134247 |
Method
and apparatus for two-step surface-enhanced raman spectroscopy |
REAL-TIME
ANALYZERS, INC. |
16- Dec- 11 |
16- Dec -11 |
15- Sep -15 |
US9133248 |
Methods
of propagating monkey adenoviral vectors |
GenVec,
Inc. |
9- Nov-
09 |
9- Nov -10 |
15- Sep -15 |
US9132423 |
Sample-to-answer
microfluidic cartridge |
Micronics,
Inc. |
29- Jan- 10 |
28- Jan -11 |
15- Sep -15 |
US9132175 |
Bacillus
based delivery system and methods of use |
The
Curators of the University of Missouri |
18- Apr- 11 |
18- Apr -11 |
15- Sep -15 |
US9128101 |
Biomarkers
for theranostics |
Caris
Life Sciences Switzerland Holdings GmbH |
1- Mar-
10 |
1- Mar -11 |
8- Sep -15 |
US9127256 |
Method
for production of reprogrammed cell using chromosomally unintegrated virus
vector |
DNAVEC
CORPORATION |
16- Jul-08 |
16- Jul- 09 |
8- Sep -15 |
US9127251 |
Means and
methods for influencing the stability of antibody producing cells |
ACADEMISCH
MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM |
9- Dec-
05 |
8- Dec -06 |
8- Sep -15 |
US9127028 |
Substrates
for chromogenic detection and methods of use in detection assays and kits |
Ventana
Medical Systems, Inc. |
16- Aug- 10 |
12- Aug -11 |
8- Sep -15 |
US9125952 |
Immunostimulatory
compositions comprising liposome-encapsulated oligonucleotides and epitopes |
Industry
Academic Cooperation Foundation, Hallym University |
17- Jul-09 |
13- Aug -14 |
8- Sep -15 |
US9115093 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
4- Mar-
13 |
20- Feb -14 |
25- Aug -15 |
US9115065 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with Arenaviruses |
Kineta,
Inc. |
6- Dec- 04 |
26- Feb -13 |
25- Aug -15 |
US9109199 |
Methods
to produce bunyavirus replicon particles |
STICHTING
DIENST LANDBOUWKUNDIG ONDERZOEK |
20- Sep- 10 |
20- Sep -11 |
18- Aug -15 |
US9107970 |
Method
and a filter for capturing airborne agents |
Not
Available |
15- Jul-08 |
13- Jul- 09 |
18- Aug -15 |
US9107958 |
Hydrazino
1H-imidazoquinolin-4-amines and conjugates made therefrom |
3M
Innovative Properties Company |
3- Jun-
11 |
1- Jun -12 |
18- Aug -15 |
US9107906 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
8- Jan -15 |
18- Aug -15 |
US9107904 |
Immunostimulatory
compositions and methods of use thereof |
Massachusetts
Institute of Technology |
5- Apr-
12 |
15- Mar -13 |
18- Aug -15 |
US9102938 |
2′
and 5′ modified monomers and oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
31- Mar- 11 |
31- Mar -11 |
11- Aug -15 |
US9102911 |
High
density self-contained biological analysis |
BioFire
Diagnostics, LLC |
15- May- 09 |
28- Jan -13 |
11- Aug -15 |
US9102741 |
GAS57
mutant antigens and GAS57 antibodies |
Novartis
AG |
12- Sep- 07 |
13- Oct -14 |
11- Aug -15 |
US9102740 |
Cna-B
domain antigens in vaccines against gram positive bacteria |
NOVARTIS
AG |
12- Jan- 09 |
7- Jun -13 |
11- Aug -15 |
US9102633 |
Arylalkyl-
and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
13- Dec -13 |
11- Aug -15 |
US9102624 |
Substituted
4-pyridones and their use as inhibitors of neutrophil elastase activity |
Boehringer
Ingelheim International GmbH |
23- Aug- 12 |
20- Aug -13 |
11- Aug -15 |
US9101597 |
Immunoprotective
primary mesenchymal stem cells and methods |
Autoimmune
Technologies, LLC |
14- Mar- 13 |
14- Mar -13 |
11- Aug -15 |
US9101582 |
Use of a
pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen |
The
United States of America as represented by the Secretary of the Department of
Health and Human Services,
Centers for Disease Control and Prevention |
31- Jul-08 |
27- Mar -13 |
11- Aug -15 |
US9096585 |
Antiviral
compounds and uses thereof |
Icahn
School of Medicine at Mount Sinai |
28- May- 10 |
31- May -11 |
4- Aug -15 |
US9096543 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
9- May -13 |
4- Aug -15 |
US9090897 |
Production
of IFN-lambda by conventional dendritic cells |
Bavarian
Nordic A/S |
18- Dec- 09 |
17- Dec -10 |
28- Jul- 15 |
US9085641 |
Peptides
regulating the surface expression of the T cell receptor |
Max-Delbruck-Centrum
Fur Molekulare Medizin |
23- Jun- 06 |
23- Jun -07 |
21- Jul- 15 |
US9084808 |
Modified
small interfering RNA molecules and methods of use |
Arrowhead
Research Corporation |
1- Oct-
04 |
9- May -14 |
21- Jul- 15 |
US9084758 |
Antiviral
compositions comprising ethanol extract of Tetracera scandens and use thereof |
The Catholic
University of Korea Industry-Academic Cooperation Foundation |
24- Jul-12 |
25- Aug -14 |
21- Jul- 15 |
US9080209 |
Non-mass
determined base compositions for nucleic acid detection |
IBIS
BIOSCIENCES, INC. |
6- Aug-
09 |
6- Aug -10 |
14- Jul- 15 |
US9080204 |
Compositions
and methods for rapid, real-time detection of influenza a virus (H1N1) Swine
2009 |
Longhorn
Vaccines and Diagnostics, LLC |
12- Sep- 06 |
30- Dec -11 |
14- Jul- 15 |
US9079965 |
Bispecific
antibody |
Wuhan
YZY Biopharma Co., LTD. |
21- Nov- 12 |
13- Mar -14 |
14- Jul- 15 |
US9079943 |
TC-83-derived
alphavirus vectors, particles and methods |
ALPHAVAX,
INC. |
18- May- 04 |
28- Mar -14 |
14- Jul- 15 |
US9079865 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
29- Jul- 12 |
14- Jul- 15 |
US9078885 |
Respiratory
disease treatment |
Pulmagen
Therapeutics (Inflammation) Limited |
7- Aug-
08 |
7- Apr -14 |
14- Jul- 15 |
US9078868 |
Therapeutic
agent for accelerating recovery of animal under medical treatment |
DAIICHI
SANKYO COMPANY, LIMITED |
15- Jan- 10 |
14- Jan -11 |
14- Jul- 15 |
US9073869 |
Method
of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid
(benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
11- Sep -14 |
7- Jul- 15 |
US9072738 |
Chemically
and metabolically stable dipeptide possessing potent sodium channel blocker
activity |
PARION
SCIENCES, INC. |
27- Jun- 11 |
27- Jun -12 |
7- Jul- 15 |
US9072726 |
Methods
of treating or preventing inflammation and hypersensitivity with oxidative
reductive potential water solution |
Oculus
Innovative Sciences, Inc. |
20- Jan- 06 |
21- Dec -09 |
7- Jul- 15 |
US9072702 |
Reverse
genetics using non-endogenous pol I promoters |
Novartis
AG |
21- May- 09 |
21- May -10 |
7- Jul- 15 |
US9067873 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including infections
associated with arenaviruses |
Kineta
Four, LLC |
6- Dec- 04 |
19- Dec -13 |
30- Jun- 15 |
US9066964 |
Use
of tylvalosin as antiviral agent |
Cambridge
University Technical Services |
13- Jul-06 |
13- Jul- 07 |
30- Jun- 15 |
US9063150 |
Method for
detection of antigen-specific antibodies in biological samples |
The United States of America as represented
by the Secretary of the Department of Health and Human Services, Centers for
Disease Control Prevention |
2- Sep-
08 |
25- Aug -09 |
23- Jun- 15 |
US9061001 |
Combination
adjuvant formulation |
Dalhousie
University |
16- Oct- 08 |
15- Oct -09 |
23- Jun- 15 |
US9056900 |
Compositions
and methods for coronavirus inhibition |
Autoimmune
Technologies, LLC. |
4- Nov-
03 |
8- Aug -13 |
16- Jun- 15 |
US9056898 |
Attenuated
RNA virus and applications thereof |
Washington
University |
20- Sep- 07 |
22- Sep -08 |
16- Jun- 15 |
US9056071 |
Compounds
and methods for preventing or treating a viral infection |
CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) |
2- Nov-
07 |
19- Jun -13 |
16- Jun- 15 |
US9051619 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA
AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU) |
25- Mar- 11 |
23- Mar -12 |
9- Jun-
15 |
US9051564 |
Compositions
for and methods of identifying antigens |
President
and Fellows of Harvard College |
21- Feb- 06 |
21- Feb -07 |
9- Jun-
15 |
US9051353 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
24- Sep -13 |
9- Jun-
15 |
US9050376 |
Conjugates
of synthetic TLR agonists and uses therefor |
The
Regents of the University of California |
7- Feb-
07 |
19- Jun -14 |
9- Jun-
15 |
US9046523 |
Rapid
bioluminescence detection system |
THE
SECRETARY OF STATE FOR HEALTH |
7- Jan- 09 |
2- Aug -13 |
2- Jun-
15 |
US9045855 |
Anti-viral
member |
NBC
Meshtec, Inc. |
26- Dec- 08 |
28- Dec -09 |
2- Jun-
15 |
US9045727 |
Virus-like
particles, methods of preparation, and immunogenic compositions |
EMORY
UNIVERSITY |
17- May- 02 |
4- Apr -06 |
2- Jun-
15 |
US9045472 |
Imidazoquinoline
compounds |
ASTRAZENECA
AB |
16- Dec- 10 |
16- Dec -11 |
2- Jun-
15 |
US9045470 |
Compounds
and compositions as TLR activity modulators |
IRM
LLC |
2- Sep-
09 |
1- Sep -10 |
2- Jun-
15 |
US9044420 |
Immunogenic
compositions and methods of using the compositions for inducing humoral and
cellular immune responses |
IMMUNE
DESIGN CORP. |
8- Apr-
11 |
6- Apr -12 |
2- Jun-
15 |
US9040310 |
Antibody-nanoparticle
conjugates and methods for making and using such conjugates |
Ventana
Medical Systems, Inc. |
27- Apr- 10 |
27- Apr -11 |
26- May -15 |
US9034646 |
Virally-inactivated
growth factors-containing platelet lysate depleted of PDGF and VEGF and
preparation method thereof |
ZHENG
YANG BIOMEDICAL TECHNOLOGY CO., LTD. |
25- May- 10 |
26- Nov -12 |
19- May -15 |
US9034313 |
Nucleic
acid molecules encoding rantes, and compositions comprising and methods of
using the same |
Inovio
Pharmaceuticals, Inc. |
8- Feb-
10 |
8- Feb -11 |
19- May -15 |
US9029413 |
Treatment
of viral infections by modulation of host cell metabolic pathways |
The
Trustees of Princeton University |
1- Jun-
07 |
3- Apr -12 |
12- May -15 |
US9029382 |
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl)
pyrazine-2-carboxamide compounds |
Parion
Sciences, Inc. |
17- Dec- 12 |
13- Dec -13 |
12- May -15 |
US9029315 |
Soluble
PD-1 variants, fusion constructs, and uses thereof |
The
University of Hong Kong |
11- Nov- 10 |
11- Nov -11 |
12- May -15 |
US9028841 |
Synergistic
bacterial compositions and methods of production and use thereof |
Seres
Health, Inc. |
23- Nov- 12 |
20- Mar -14 |
12- May -15 |
US9028837 |
Methods
and compositions for poxvirus A35R protein |
East
Carolina University |
7- Jun-
12 |
20- Dec -12 |
12- May -15 |
US9028823 |
Methods
of inducing or enhancing an immune response in a subject by administering
agonistic GITR binding antibodies |
GITR,
Inc. |
25- Mar- 05 |
1- Mar -13 |
12- May -15 |
US9024001 |
Alphavirus
replicon packaging constructs |
Novartis
Vaccines and Diagnostics, Inc. |
25- May- 04 |
20- May -05 |
5- May -15 |
US9023855 |
Compounds |
Chiesi
Farmaceutici S.p.A. |
14- Sep- 11 |
11- Feb -14 |
5- May -15 |
US9023839 |
Compounds
and compositions as c-kit kinase inhibitors |
IRM
LLC |
1- Sep-
11 |
22- Apr -14 |
5- May -15 |
US9017699 |
Adjuvancy
and immune potentiating properties of natural products of Onchocerca volvulus |
New
York Blood Center, Inc. |
15- Jun- 04 |
18- Feb -10 |
28- Apr- 15 |
US9017696 |
Adenovirus
vectors |
Isis
Innovation Limited |
10- Apr- 07 |
10- Apr -08 |
28- Apr- 15 |
US9012622 |
Compositions
and methods using siRNA molecules and siRNA cocktails for the treatment of
breast cancer |
Not
Available |
31- Dec- 08 |
31- Dec -09 |
21- Apr- 15 |
US9011767 |
Transportable
vacuum assisted decontamination unit and decontamination process |
STERIS
Inc. |
1- Apr-
13 |
31- Mar -14 |
21- Apr- 15 |
US9006264 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
9- Sep -13 |
14- Apr- 15 |
US9006194 |
Compositions
and methods for diminishing viral infection and inflammation associated with
viral infection |
Drexel
University |
19- Dec- 08 |
17- Dec -09 |
14- Apr- 15 |
US9005974 |
Means
and methods for influencing the stability of cells |
Academish
Medisch Centrum Bij de Universiteit van Amsterdam |
9- Dec-
05 |
9- Dec -05 |
14- Apr- 15 |
US9005665 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Foundation |
24- Apr- 12 |
24- Apr -13 |
14- Apr- 15 |
US9005599 |
Genetically
modified human umbilical cord perivascular cells for prophylaxis against or
treatment of biological or chemical agents |
Tissue
Regeneration Therapeutics Inc. |
21- Apr- 08 |
20- Apr -09 |
14- Apr- 15 |
US8999996 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
19- Mar -14 |
7- Apr-
15 |
US8999975 |
Substituted
N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
19- Sep- 11 |
14- Sep -12 |
7- Apr-
15 |
US8999678 |
Method
of increasing the function of an AAV vector |
The
Trustees of the University of Pennsylvania |
7- Apr-
05 |
7- Apr -06 |
7- Apr-
15 |
US8999349 |
HMGB1-derived
peptides enhance immune response to antigens |
The
Regents of the University of California |
27- Jul-10 |
27- Jul- 11 |
7- Apr-
15 |
US8999316 |
Antiviral
compounds |
Long
Island University |
30- May- 07 |
30- May -08 |
7- Apr-
15 |
US8993717 |
Gadd45beta
targeting agents |
Imperial
Innovations Limited |
22- Oct- 09 |
22- Oct -10 |
31- Mar -15 |
US8993581 |
Methods
for treating viral disorders |
Trustees
of Boston University |
24- Sep- 09 |
11- Jun -13 |
31- Mar -15 |
US8993295 |
Methods, compositions,
and kits for the selective activation of protoxins through combinatorial
targeting |
The
General Hospital Corporation |
20- Jul-06 |
20- Jul- 07 |
31- Mar -15 |
US8992939 |
Highly
efficient influenza matrix (M1) proteins |
Novavax,
Inc. |
11- Jul-03 |
24- Oct -11 |
31- Mar -15 |
US8987249 |
Substituted
2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides
inhibitors of Cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
12- Mar -14 |
24- Mar -15 |
US8987191 |
Bioactive
peptides and methods of using same |
Compugen
Ltd. |
12- Jul-07 |
21- Jun -13 |
24- Mar -15 |
US8986933 |
Selective
detection of human rhinovirus |
The
United States of America as represented by the Secretary of the Department of
Health and Human Services,
Centers for Disease Control |
5- Dec-
08 |
5- Dec -08 |
24- Mar -15 |
US8986926 |
Compositions
comprising oriented, immobilized macromolecules and methods for their
preparation |
NanoString
Technologies, Inc. |
23- Dec- 05 |
22- Dec -06 |
24- Mar -15 |
US8986702 |
Antibodies
and processes for preparing the same |
Taiga
Biotechnologies, Inc. |
16- May- 08 |
18- May -09 |
24- Mar -15 |
US8980898 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
Parion
Sciences, Inc. |
29- May- 12 |
29- May -13 |
17- Mar -15 |
US8980338 |
Sceletium
extract and uses thereof |
H.L.
Hall & Sons Limited |
20- Mar- 09 |
16- Mar -10 |
17- Mar -15 |
US8980281 |
High-yield
transgenic mammalian expression system for generating virus-like particles |
Academia
Sinica |
5- Sep-
06 |
12- Feb -10 |
17- Mar -15 |
US8975389 |
Nucleic
acid chemical modifications |
Alnylam
Pharmaceuticals, Inc. |
2- Mar-
09 |
2- Mar -10 |
10- Mar -15 |
US8969362 |
9-substituted
8-oxoadenine compound |
AstraZeneca
Aktiebolag |
26- Mar- 04 |
21- Oct -13 |
3- Mar -15 |
US8969350 |
Pharmaceutical
product comprising a p38 kinase inhibitor and a second active ingredient |
Astrazeneca
AB |
18- Dec- 08 |
17- Dec -09 |
3- Mar -15 |
US8962580 |
Chemical
modifications of monomers and oligonucleotides with cycloaddition |
Alnylam
Pharmaceuticals, Inc. |
23- Sep- 08 |
23- Sep -09 |
24- Feb -15 |
US8962332 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
13- Sep -13 |
24- Feb -15 |
US8962330 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
31- Oct -07 |
24- Feb -15 |
US8961983 |
Mucosal
vaccine using cationic nanogel |
National
University Corporation Tokyo Medical and Dental University |
31- Oct- 08 |
5- Sep -14 |
24- Feb -15 |
US8961477 |
Delivery
of immune response modifier compounds |
3M
Innovative Properties Company |
25- Aug- 03 |
25- Aug -04 |
24- Feb -15 |
US8956863 |
Agents
from cells |
The
Brigham and Women's Hospital, Inc. |
15- Oct- 09 |
15- Oct -10 |
17- Feb -15 |
US8956616 |
Constructs
binding to phosphatidylserine and their use in disease treatment |
Board
of Regents, The University of Texas System |
24- Jan- 05 |
24- Jan -06 |
17- Feb -15 |
US8951768 |
Mutations
in OAS1 genes |
Kineta
Two, LLC |
4- May-
05 |
11- Jul- 11 |
10- Feb -15 |
US8951528 |
Immune
response modifier conjugates |
3M
Innovative Properties Company |
22- Feb- 06 |
21- Feb -07 |
10- Feb -15 |
US8945943 |
Personal
glucose meters for detection and quantification of a broad range of analytes |
The
Board of Trustees of the University of Illinois |
26- May- 10 |
26- May -11 |
3- Feb -15 |
US8945904 |
Influenza
virus reassortment |
Novartis
AG |
21- May- 10 |
20- May -11 |
3- Feb -15 |
US8945610 |
Condensation
products based on bicyclic or polycyclic aromatics or heteroaromatics |
BASF
SE |
14- Nov- 07 |
11- Nov -08 |
3- Feb -15 |
US8940864 |
Stabilized
therapeutic small helical antiviral peptides |
New
York Blood Center, Inc. |
5- Oct-
06 |
2- Oct -07 |
27- Jan- 15 |
US8940501 |
Methods
for ligation and uses thereof |
Whitehead
Institute for Biomedical Research |
30- Jan- 09 |
1- Feb -10 |
27- Jan- 15 |
US8937154 |
Stabilized
therapeutic small helical antiviral peptides |
New
York Blood Center, Inc. |
5- Oct-
06 |
2- Feb -12 |
20- Jan- 15 |
US8933210 |
Label-free
functional nucleic acid sensors for detecting target agents |
The
Board of Trustees of the University of Illinois |
6- Oct-
10 |
6- Oct -11 |
13- Jan- 15 |
US8933019 |
Antiviral
cell-penetrating peptides |
New
York Blood Center, Inc. |
6- May-
08 |
31- Oct -12 |
13- Jan- 15 |
US8916552 |
Pharmaceutical
combinations |
Astex
Therapeutics Limited |
12- Oct- 06 |
12- Oct -07 |
23- Dec -14 |
US8916340 |
Method
for identifying and validating dominant T helper cell epitopes using an
HLA-DM-assisted class II binding assay |
The
John Hopkins University |
6- Jan- 06 |
8- Jan -07 |
23- Dec -14 |
US8906872 |
Antisense
antiviral compound and method for treating ssRNA viral infection |
Sarepta
Therapeutics, Inc. |
16- Sep- 04 |
22- Dec -11 |
9- Dec -14 |
US8906863 |
Proteolysis-resistant
capsid of chimeric hepatitis E virus as an oral delivery vector |
The
Regents of the University of California |
27- Feb- 09 |
1- Sep -11 |
9- Dec -14 |
US8906862 |
Multiple
antigen delivery system using hepatitis E virus-like particle |
National
Institute of Infectious Disease |
27- Feb- 09 |
29- Aug -11 |
9- Dec -14 |
US8901071 |
Compounds
and their use |
Novabiotics
Limited |
31- Mar- 10 |
30- Mar -11 |
2- Dec -14 |
US8900585 |
Influenza
hemagglutinin-specific monoclonal antibodies for preventing and treating
influenza virus infection |
New
York Blood Center, Inc. |
20- Oct- 10 |
20- Oct -11 |
2- Dec -14 |
US8895629 |
Circulation
of components during homogenization of emulsions |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
25- Nov -14 |
US8895577 |
Compounds
and compositions as TLR activity modulators |
Not
Available |
3- Mar-
08 |
22- Apr -13 |
25- Nov -14 |
US8895570 |
Purine
derivatives |
AstraZeneca
AB |
17- Dec- 10 |
14- Dec -11 |
25- Nov -14 |
US8895534 |
Boron
containing small molecules |
Anacor
Pharmaceuticals, Inc. |
20- Jun- 07 |
30- Jul- 10 |
25- Nov -14 |
US8895295 |
High
density self-contained biological analysis |
Biofire
Diagnostics, LLC |
15- Nov- 06 |
14- Nov -07 |
25- Nov -14 |
US8889708 |
Substituted
bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of
cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
12- Mar -14 |
18- Nov -14 |
US8889692 |
Pyrazinone
derivatives, pharmaceutically acceptance salts thereof and their uses |
AstraZeneca
AB |
27- Jun- 07 |
14- Sep -12 |
18- Nov -14 |
US8889656 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
30- Apr -13 |
18- Nov -14 |
US8889398 |
Composition
for inactivating an enveloped virus |
Viroblock
SA |
19- May- 06 |
18- May -07 |
18- Nov -14 |
US8889181 |
Immunostimulatory
compositions comprising liposome-encapsulated oligonucleotides and epitopes |
Industry
Academic Cooperation Foundation, Hallym University |
17- Jul-09 |
16- Jun -10 |
18- Nov -14 |
US8889118 |
Anticancer
agent containing dendritic cell having RNA virus transferred thereinto |
DNA
VEC Research Inc. |
24- Jun- 04 |
28- Apr -05 |
18- Nov -14 |
US8889117 |
Modular
nanoparticles for adaptable vaccines |
Yale
University |
15- Feb- 07 |
15- Feb -08 |
18- Nov -14 |
US8884020 |
Indole
compounds |
Ironwood
Pharmaceuticals, Inc. |
7- Aug-
06 |
7- Aug -07 |
11- Nov -14 |
US8883790 |
Pharmaceutical
combinations |
Astex
Therapeutics Limited |
12- Oct- 06 |
12- Oct -07 |
11- Nov -14 |
US8883500 |
Method of
preparing adenosine-resistant anti-tumor T lymphocytes for adoptive
immunotherapy |
Northeastern
University |
5- Dec-
08 |
7- Dec -09 |
11- Nov -14 |
US8883481 |
Reverse
genetics methods for virus rescue |
Novartis
AG |
20- Oct- 09 |
20- Oct -10 |
11- Nov -14 |
US8883477 |
Oligoadenylate
synthetase (OAS) |
Kineta
Two, LLC |
23- Nov- 05 |
14- Jun -13 |
11- Nov -14 |
US8882484 |
Methods
and compositions for production of recombinant protein in HBX-expressing
mammalian cells |
Bayer
HealthCare LLC |
28- May- 08 |
27- May -09 |
11- Nov -14 |
US8881040 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
28- Aug- 08 |
2- Dec -09 |
4- Nov -14 |
US8877775 |
Substituted
2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
12- Mar -14 |
4- Nov -14 |
US8877187 |
Therapeutic
antibodies for treatment and prophylaxis of transmittable viral diseases |
Avianax,
LLC |
25- Jul-05 |
23- Nov -10 |
4- Nov -14 |
US8877060 |
Methods
for removing pathogens from a platelet preparation |
Biovec
Transfusion, LLC |
23- Nov- 10 |
31- Oct -11 |
4- Nov -14 |
US8871816 |
Methods
for producing vaccine adjuvants |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
28- Oct- 14 |
US8871790 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
8- Mar -12 |
28- Oct- 14 |
US8871783 |
Substituted
2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmBh |
14- Mar- 13 |
12- Mar -14 |
28- Oct- 14 |
US8871782 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
1- Oct -04 |
28- Oct- 14 |
US8871503 |
Construct |
Isis
Innovation Limited |
28- Mar- 06 |
28- Mar -07 |
28- Oct- 14 |
US8871487 |
Compositions,
methods and uses for inducing viral growth |
Takeda
Vaccines, Inc. |
5- Dec-
08 |
4- Dec -09 |
28- Oct- 14 |
US8871442 |
Enhanced
deposition of chromogens |
Ventana
Medical Systems, Inc. |
30- Dec- 10 |
28- Dec -11 |
28- Oct- 14 |
US8865865 |
N-terminally
modified tetrapeptide derivatives having a C-terminal arginine mimetic |
Philipps-Universitat
Marburg |
29- Oct- 08 |
29- Oct -09 |
21- Oct- 14 |
US8865166 |
Antibodies
to IL-17A and uses thereof |
MedImmune
Limited |
23- Jun- 06 |
22- Jun -07 |
21- Oct- 14 |
US8859568 |
Pyrrolo[3,2-D]pyrimidin-4-one
derivatives and their use in therapy |
Astrazeneca
AB |
6- Dec-
04 |
3- Nov -10 |
14- Oct- 14 |
US8859251 |
Oligoadenylate
synthetase (OAS) |
Kineta
Two, LLC |
23- Nov- 05 |
1- Jul- 13 |
14- Oct- 14 |
US8858958 |
Adjuvant
comprising aluminum, oligonucleotide and polycation |
Novartis
AG |
27- Aug- 09 |
27- Aug -10 |
14- Oct- 14 |
US8858957 |
GAS57
mutant antigens and GAS57 antibodies |
Novartis
AG |
12- Sep- 07 |
14- Mar -13 |
14- Oct- 14 |
US8854617 |
Compounds
and markers for surface-enhanced Raman scattering |
Julius-Maximilians-Universitat
Wurzburg |
24- Sep- 07 |
24- Sep -08 |
7- Oct-
14 |
US8853382 |
Expression
of antibody or a fragment thereof in lactobacillus |
Hera
Pharmaceuticals, Inc. |
5- Aug-
10 |
4- Aug -11 |
7- Oct-
14 |
US8846710 |
Method
of preferentially inducing the biosynthesis of interferon |
3M
Innovative Properties Company |
23- Feb- 05 |
22- Feb -06 |
30- Sep -14 |
US8846697 |
Purine
analogs |
The
Regents of the University of California |
31- May- 06 |
23- Apr -07 |
30- Sep -14 |
US8846643 |
Phosphonates
with reduced toxicity for treatment of viral infections |
The
Regents of the University of California |
14- Apr- 10 |
11- Oct -12 |
30- Sep -14 |
US8846051 |
Modulation
of replicative fitness by deoptimization of synonymous codons |
The United States of America as represented
by the Secretary of the Department of Health and Human Services, Centers for
Disease Control and Prevention |
8- Oct-
04 |
7- Oct -05 |
30- Sep -14 |
US8841100 |
Use
of methylsulfonylmethane (MSM) to modulate microbial activity |
Biogenic
Innovations, LLC |
30- Oct- 09 |
16- Feb -11 |
23- Sep -14 |
US8840899 |
Use
of mTOR inhibitors to enhance T cell immune responses |
Emory
University |
5- Aug-
08 |
5- Aug -09 |
23- Sep -14 |
US8840890 |
Rapid
expression cloning of human monoclonal antibodies from memory B cells |
University
of Maryland, Baltimore |
12- Nov- 08 |
12- Nov -09 |
23- Sep -14 |
US8840873 |
Method of
treating second and third degree burns using oxidative reductive potential
water solution |
Oculus
Innovative Sciences, Inc. |
23- Mar- 05 |
23- Mar -06 |
23- Sep -14 |
US8840774 |
Electrochemistry
and electrogenerated chemiluminescence with a single faradaic electrode |
Board
of Regents of the University of Texas System |
3- Jun-
05 |
28- Oct -13 |
23- Sep -14 |
US8835107 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
Amsterdam
Institute of Viral Genomics B.V. |
18- Aug- 03 |
26- Jul- 10 |
16- Sep -14 |
US8834445 |
Methods
of treating or preventing peritonitis with oxidative reductive potential
water solution |
Oculus
Innovative Sciences, Inc. |
20- Jan- 06 |
30- Mar -12 |
16- Sep -14 |
US8828962 |
SiRNA
compositions and methods for potently inhibiting viral infection |
Xiangxue
Group (Hong Kong) Company Limited |
11- Dec- 08 |
12- Dec -11 |
9- Sep -14 |
US8828956 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
4- Dec -12 |
9- Sep -14 |
US8828940 |
Method of
treating an ischemia-reperfusion injury-related disorder by administering
GPCR ligands |
Compugen
Ltd. |
18- Sep- 06 |
14- Dec -10 |
9- Sep -14 |
US8828929 |
Cytotoxic
T cell epitope peptide for SARS coronavirus, and use thereof |
Japan as
Represented by Director-General of National Institute of Infectious Diseases |
28- Nov- 08 |
27- Nov -09 |
9- Sep -14 |
US8828673 |
Mixed
cell diagnostic systems for detection of respiratory, herpes and enteric
viruses |
Diagnostic
Hybrids Inc |
24- Apr- 98 |
1- Mar -12 |
9- Sep -14 |
US8828659 |
Method
for producing nucleic acid probes |
Ventana
Medical Systems, Inc. |
1- Sep-
06 |
11- Mar -13 |
9- Sep -14 |
US8828407 |
Chimaeric
protein |
The
Pirbright Institute |
7-Jul- 09 |
5- Jul- 10 |
9- Sep -14 |
US8828406 |
Influenza
viruses and uses thereof |
Icahn
School of Medicine at Mount Sinai |
30- Jul-09 |
29- Jul- 10 |
9- Sep -14 |
US8822512 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
20- Sep -11 |
2- Sep -14 |
US8822409 |
Compositions
and uses thereof for the treatment of acute respiratory distress syndrome
(ARDS) and clinical disorders associated with therewith |
Phylogica
Limited |
20- Jun- 07 |
20- Jun -08 |
2- Sep -14 |
US8821897 |
Viral
adjuvants |
The
University of North Carolina at Chapel Hill |
9-Jul- 04 |
24- Nov -10 |
2- Sep -14 |
US8816089 |
Methods
for controlling SR protein phosphorylation, and antiviral agents whose active
ingredients comprise agents that control SR protein activity |
Masatoshi
Hagiwara |
26- Dec- 03 |
19- Nov -12 |
26- Aug -14 |
US8816053 |
Methods
for treating viral infection using IL-28 and IL-29 cysteine mutants |
ZymoGenetics,
Inc. |
2- Apr-
04 |
7- Sep -12 |
26- Aug -14 |
US8815837 |
Respiratory
disease treatment |
Pulmagen
Therapeutics (Inflammation) Limited |
7- Aug-
08 |
29- Jun -12 |
26- Aug -14 |
US8815831 |
Treatment
of Acinetobacter with alginate oligomers and antibiotics |
Algipharma
AS |
3- Jun-
09 |
3- Jun -10 |
26- Aug -14 |
US8815611 |
Surface
for label independent detection and method thereof |
Corning
Incorporated |
10- Apr- 08 |
3- Apr -09 |
26- Aug -14 |
US8815249 |
Ii-key/antigenic
epitope hybrid peptide vaccines |
Antigen
Express, Inc. |
4- Sep-
99 |
26- Jul- 10 |
26- Aug -14 |
US8815244 |
Method
for production of antibody using ostrich |
Japan
Science and Technology Agency |
29- Aug- 05 |
16- Aug -11 |
26- Aug -14 |
US8809377 |
Deubiquitinase
inhibitors and methods for use of the same |
The
Regents of the University of Michigan |
24- Sep- 10 |
23- Sep -11 |
19- Aug -14 |
US8808703 |
Compounds
(cystein based lipopeptides) and compositions as TLR2 agonists used for
treating infections, inflammations, respiratory diseases etc |
Not
Available |
23- Mar- 10 |
23- Mar -11 |
19- Aug -14 |
US8808686 |
Adjuvant-sparing
multi-dose influenza vaccination regimen |
Novartis
AG |
15- Jun- 06 |
19- Sep -11 |
19- Aug -14 |
US8802853 |
Arylalkenyl
and arylalkynyl substituted imidazoquinolines |
3M
Innovative Properties Company |
29- Dec- 03 |
17- Dec -04 |
12- Aug -14 |
US8802647 |
Materials
and methods for prevention and treatment of RNA viral diseases |
University
of South Florida |
30- Apr- 02 |
17- Sep -12 |
12- Aug -14 |
US8802106 |
Peptide
compositions and methods for inhibiting herpesvirus infection |
The
Administrators of the Tulane Educational Fund |
30- Oct- 09 |
29- Oct -10 |
12- Aug -14 |
US8796423 |
Anti-TSG101
antibodies and their uses for treatment of viral infections |
Eli
Lilly and Company |
15- Nov- 06 |
18- Apr -08 |
5- Aug -14 |
US8790655 |
Conjugates
of synthetic TLR agonists and uses therefor |
The
Regents of The University of California |
7- Feb-
07 |
8- Jan -13 |
29- Jul- 14 |
US8785408 |
Compositions
and methods for reducing or protecting against delayed graft function (DGF) |
Quark
Pharmaceuticals, Inc. |
27- Jun- 07 |
26- Jun -08 |
22- Jul- 14 |
US8785375 |
Cyclic
antimicrobial peptides for treating bacterial infections |
Novabiotics
Ltd. |
22- Dec- 05 |
22- Aug -12 |
22- Jul- 14 |
US8784900 |
Antimicrobial
solutions containing dichlorine monoxide and methods of making and using the
same |
Oculus
Innovative Sciences, Inc. |
13- Mar- 07 |
13- Mar -08 |
22- Jul- 14 |
US8779132 |
Pharmaceutical
compounds |
Astex
Therapeutics Limited |
12- Oct- 06 |
12- Oct -07 |
15- Jul- 14 |
US8778963 |
Hydroxylamine
and oxime substituted imidazoquinolines, imidazopyridines, and
imidazonaphthyridines |
3M
Innovative Properties Company |
25- Nov- 03 |
24- Nov -04 |
15- Jul- 14 |
US8778846 |
Composition,
device and associated method |
General
Electric Company |
4- Dec-
06 |
1- Mar -07 |
15- Jul- 14 |
US8778845 |
Composition,
device and associated method |
Genral
Electric Company |
15- Dec- 05 |
1- Mar -07 |
15- Jul- 14 |
US8778358 |
Immunogenic
compositions for gram positive bacteria such as Streptococcus agalactiae |
Novartis
Vaccines and Diagnostics, Inc. |
29- Jul-04 |
18- Oct -10 |
15- Jul- 14 |
US8778275 |
Methods
for producing vaccine adjuvants |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
15- Jul- 14 |
US8772471 |
Targeted
delivery of siRNA |
Immune
Disease Institute |
26- Jan- 07 |
25- Jan -08 |
8- Jul- 14 |
US8765939 |
Pyrimidline
derivatives having immune modulating properties that act via TLR7 for the
treatment of viral or allergic diseases and cancers |
AstraZeneca
AB |
22- Nov- 07 |
16- Aug -12 |
1- Jul- 14 |
US8765704 |
Modified
small interfering RNA molecules and methods of use |
Novartis
AG |
28- Feb- 08 |
14- Dec -11 |
1- Jul- 14 |
US8765643 |
Composition,
device and associated method |
General
Electric Company |
4- Dec-
06 |
1- Mar -07 |
1- Jul- 14 |
US8765146 |
Adenoviral
vector-based malaria vaccines |
GenVec,
Inc. |
31- Aug- 05 |
31- Aug -06 |
1- Jul- 14 |
US8765138 |
Antiviral
and antibacterial activity from medicinal mushrooms |
Not
Available |
6- Jan- 04 |
24- Sep -08 |
1- Jul- 14 |
US8765133 |
Method
of producing anti-CD166 antibody in ostrich |
Japan
Science and Technology Agency |
29- Aug- 05 |
16- Aug -11 |
1- Jul- 14 |
US8759307 |
Oligonucleotide
compound and method for treating nidovirus infections |
Sarepta
Therapeutics, Inc. |
24- Dec- 03 |
25- Apr -08 |
24- Jun- 14 |
US8758763 |
Archaeal
polar lipid aggregates for administration to animals |
National
Research Council of Canada |
15- Dec- 06 |
23- Jan -13 |
24- Jun- 14 |
US8758680 |
Method
and device for cleaning air |
Not
Available |
29- Sep- 10 |
27- Sep -11 |
24- Jun- 14 |
US8754071 |
Compounds
and compositions as c-kit kinase inhibitors |
Not
Available |
1- Sep-
11 |
19- Sep -13 |
17- Jun- 14 |
US8754015 |
Modified
phage for displaying post-translationally modified proteins and uses thereof |
University
of Rochester |
21- Nov- 06 |
20- Nov -07 |
17- Jun- 14 |
US8748567 |
Method
for delivery across the blood brain barrier |
Children's
Medical Center Corporation |
22- May- 06 |
22- May -07 |
10- Jun- 14 |
US8748464 |
Use of
SIRT1 activators or inhibitors to modulate an immune response |
The
J. David Gladstone Institutes |
7- Feb-
08 |
16- Jul- 10 |
10- Jun- 14 |
US8748405 |
Methods
and compositions for the treatment of cancer or other diseases |
City
of Hope |
26- Jan- 07 |
9- Sep -11 |
10- Jun- 14 |
US8748156 |
Animal
protein-free media for cultivation of cells |
Baxter
Healthcare SA |
29- Oct- 04 |
16- Apr -13 |
10- Jun- 14 |
US8741813 |
Composition,
device and associated method |
General
Electric Company |
15- Dec- 05 |
28- Feb -07 |
3- Jun-
14 |
US8741653 |
Single
recombination system and methods of use |
Emergent
Product Development GmbH |
22- Dec- 08 |
16- Dec -09 |
3- Jun-
14 |
US8741604 |
Nucleic
acid molecule encoding a specific IL-1R1 antibody |
Medimmune
Limited |
7- Nov-
08 |
14- Sep -12 |
3- Jun-
14 |
US8741564 |
Quantitative
nuclease protection assay (QNPA) and sequencing (QNPS) improvements |
HTG
Molecular Diagnostics, Inc. |
4- May-
11 |
26- Apr -12 |
3- Jun-
14 |
US8741311 |
Methods
and compositions for immunization against virus |
Academia
Sinica |
27- Mar- 09 |
26- Mar -10 |
3- Jun-
14 |
US8735567 |
Multi-targeted
RNAi therapeutics for scarless wound healing of skin |
Not
Available |
6- Nov-
07 |
6- Nov -08 |
27- May -14 |
US8735559 |
Mutant
protease biosensors with enhanced detection characteristics |
Promega
Corporation |
11- May- 10 |
11- May -11 |
27- May -14 |
US8735421 |
Imidazoquinolinyl
sulfonamides |
3M
Innovative Properties Company |
30- Dec- 03 |
23- Dec -04 |
27- May -14 |
US8735410 |
Quinazoline
derivatives as tyrosine kinase inhibitors |
AstraZeneca
AB |
26- Feb- 05 |
24- Feb -06 |
27- May -14 |
US8735348 |
Casein
derived peptides and uses thereof |
Peptera
Ltd. |
1- Mar-
00 |
5- Sep -12 |
27- May -14 |
US8734823 |
Device
including altered microorganisms, and methods and systems of use |
The
Invention Science Fund I, LLC |
14- Dec- 05 |
28- May -10 |
27- May -14 |
US8728793 |
Amphipathic
alpha-helical peptide compositions as antiviral agents |
The Board
of Trustees of the Leland Stanford Junior University |
19- Jul-07 |
14- Jul- 08 |
20- May -14 |
US8722917 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
23- Jan -12 |
13- May -14 |
US8722741 |
Biphenyloxyacetic
acid derivatives for the treatment of respiratory disease |
AstraZeneca
AB |
24- Aug- 04 |
6- Dec -11 |
13- May -14 |
US8722725 |
Caffeoylquinic
acid derivatives containing nitrogen, and preparation method, pharmaceutical
composition and usage thereof |
Zhejiang
Medicine Co., Ltd. Xinchang Pharmaceutical Factory |
23- Mar- 07 |
21- Mar -08 |
13- May -14 |
US8718948 |
Systems
and methods for distinguishing optical signals of different modulation
frequencies in an optical signal detector |
Gen-Probe
Incorporated |
24- Feb- 11 |
24- Feb -12 |
6- May -14 |
US8716464 |
Compositions
and methods for silencing Ebola virus gene expression |
Not
Available |
20- Jul-09 |
20- Jul- 10 |
6- May -14 |
US8716461 |
Human
parvovirus |
Blood
Systems, Inc. |
24- May- 04 |
24- May -05 |
6- May -14 |
US8710224 |
Heterocyclic
compounds as CCR2B antagonists |
AstraZeneca
AB |
24- Dec- 04 |
13- Sep -13 |
29- Apr- 14 |
US8709730 |
Methods
of preventing and treating viral infections by inhibiting the deISGylation
activity of OTU domain-containing viral proteins |
Icahn
School of Medicine at Mount Sinai |
5- Apr- 07 |
7- Apr -08 |
29- Apr- 14 |
US8709496 |
Use of
deuterium oxide for the treatment of virus-based diseases of the respiratory
tract |
D2
Bioscience Group Ltd. |
6- Jan- 10 |
23- May -12 |
29- Apr- 14 |
US8709447 |
Compositions
and methods for activating innate and allergic immunity |
ID
Biomedical Corporation of Quebec |
22- Oct- 03 |
26- Apr -12 |
29- Apr- 14 |
US8709441 |
TC-83-derived
alphavirus vectors, particles and methods |
Alphavax,
Inc. |
18- May- 04 |
6- Jul- 10 |
29- Apr- 14 |
US8704169 |
Direct
impact ionization (DII) mass spectrometry |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
11- Oct- 11 |
11- Oct -11 |
22- Apr- 14 |
US8703748 |
Cleaning
composition for treating tissue for transplantation derived from human/animal |
CG
BIO Co., Ltd. |
11- Feb- 09 |
10- Feb -10 |
22- Apr- 14 |
US8703467 |
Inactivation
of a pathogen in a sample by a treatment with formalin and UV light |
Baxter
Healthcare SA |
27- May- 04 |
26- May -05 |
22- Apr- 14 |
US8702958 |
Electrochemistry
and electrogenerated chemiluminescence with a single faradaic electrode |
Board
of Regents of the University of Texas System |
3- Jun-
05 |
31- May -12 |
22- Apr- 14 |
US8697873 |
Amide
substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
3M
Innovative Properties Company |
24- Mar- 04 |
24- Mar -05 |
15- Apr- 14 |
US8697853 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
10- Jan -13 |
15- Apr- 14 |
US8697659 |
Analogues
of glycolipids useful as immunoadjuvants |
Luigi
Panza |
12- Oct- 07 |
10- Oct -08 |
15- Apr- 14 |
US8697140 |
Virucidal
disinfectant |
B.
Braun Medical AG |
28- Jan- 05 |
28- May -09 |
15- Apr- 14 |
US8697088 |
VLPs
derived from cells that do not express a viral matrix or core protein |
Novavax,
Inc. |
25- May- 07 |
27- May -08 |
15- Apr- 14 |
US8697087 |
Influenza
vaccines including combinations of particulate adjuvants and
immunopotentiators |
Novartis
AG |
4- Nov-
05 |
6- Nov -06 |
15- Apr- 14 |
US8691837 |
Substituted
imidazo ring systems and methods |
3M
Innovative Properties Company |
25- Nov- 03 |
24- Nov -04 |
8- Apr-
14 |
US8691826 |
Compounds |
Chiesi
Farmaceutici S.p.A. |
14- Sep- 11 |
13- Sep -12 |
8- Apr-
14 |
US8691781 |
Compositions
for treating respiratory viral infections and their use |
Sirnaomics,
Inc. |
5- Nov-
04 |
4- Nov -05 |
8- Apr-
14 |
US8691777 |
Combination
therapy |
Emory
University |
27- Jan- 11 |
25- Jan -12 |
8- Apr-
14 |
US8686152 |
4,4-disubstituted
piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1) |
Janssen
Pharmaceutica NV |
10- Mar- 10 |
9- Mar -11 |
1- Apr-
14 |
US8682619 |
Device
including altered microorganisms, and methods and systems of use |
The
Invention Science Fund I, LLC |
14- Dec- 05 |
28- May -10 |
25- Mar -14 |
US8679839 |
Cell
line from rousettus as host cell for pathogen amplification |
Probiogen
AG |
4- Mar-
08 |
4- Mar -09 |
25- Mar -14 |
US8678184 |
Methods
for producing vaccine adjuvants |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
25- Mar -14 |
US8678002 |
Devices
and methods for decreasing human pathogen transmission |
Filligent
Limited |
26- Jun- 07 |
25- Jun -08 |
25- Mar -14 |
US8673983 |
Melanins
synthesized chemically or via enzyme catalysis |
Loyola
University Chicago |
21- Dec- 07 |
22- Dec -08 |
18- Mar -14 |
US8673932 |
Oxime
substituted imidazo-containing compounds |
3M
Innovative Properties Company |
12- Aug- 03 |
12- Aug -04 |
18- Mar -14 |
US8673907 |
Pharmaceutically
acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)
propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their
use in therapy |
AstraZeneca
AB |
17- Dec- 07 |
16- Dec -08 |
18- Mar -14 |
US8673904 |
Epoxide
inhibitors of cysteine proteases |
The Board
of Trustees of the Leland Stanford Junior University |
13- Jun- 06 |
13- Jun -07 |
18- Mar -14 |
US8673558 |
Luciferase
biosensor |
Promega
Corporation |
10- Oct- 03 |
24- Apr -12 |
18- Mar -14 |
US8673331 |
Composition
with sterilizing activity against bacteria, fungus and viruses, application
thereof and method for preparation thereof |
GP&E |
18- Nov- 11 |
18- Nov -11 |
18- Mar -14 |
US8669263 |
Use
of TAM receptor inhibitors as antimicrobials |
Salk
Institute for Biological Studies |
9- Nov-
07 |
8- Mar -13 |
11- Mar -14 |
US8669262 |
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-
pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra
zine-2-carboxamide |
Parion
Sciences, Inc. |
27- Jun- 11 |
26- Jun -12 |
11- Mar -14 |
US8669240 |
Biological
specimen collection and transport system and method of use |
Longhorn
Vaccines & Diagnostics, LLC |
1- Oct-
07 |
19- Mar -13 |
11- Mar -14 |
US8664274 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arena viruses |
Siga
Technologies, Inc. |
6- Dec- 04 |
6- Jul- 11 |
4- Mar -14 |
US8664218 |
Pharmaceutical
compounds |
Astex
Therapeutics Ltd. |
11- Apr- 08 |
30- Jan -13 |
4- Mar -14 |
US8664188 |
siRNA
compositions and methods for potently inhibiting viral infection |
Xiangxue
Group (Hong Kong) Company Limited |
11- Dec- 08 |
11- Dec -09 |
4- Mar -14 |
US8663922 |
Systems
and methods for detecting multiple optical signals |
Gen-Probe
Incorporated |
10- Mar- 05 |
1- Jun -10 |
4- Mar -14 |
US8658767 |
Lipidated
polyepitope vaccines |
National
Health Research Institutes |
15- Nov- 10 |
15- Nov -11 |
25- Feb -14 |
US8658697 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arenaviruses |
Siga
Technologies, Inc. |
6- Dec- 04 |
26- Oct -10 |
25- Feb -14 |
US8658666 |
Substituted
imidazoquinolines and imidazonaphthyridines |
3M
Innovative Properties Company |
11- Feb- 05 |
10- Feb -06 |
25- Feb -14 |
US8658178 |
Carbon
nanotube compositions and methods of use thereof |
Yale
University |
19- Mar- 08 |
19- Mar -09 |
25- Feb -14 |
US8653252 |
Short
interfering RNA (siRNA) analogues |
Santaris
Pharma A/S |
21- Mar- 03 |
22- Mar -04 |
18- Feb -14 |
US8653084 |
Hydrobenzamide
derivatives as inhibitors of Hsp90 |
Astex
Therapeutics Ltd. |
12- Oct- 06 |
12- Oct -07 |
18- Feb -14 |
US8653034 |
Compositions
and methods comprising phosphatidylethanolamine- binding peptide derivatives |
Board
of Regents, The University of Texas System |
15- Jul-02 |
8- May -08 |
18- Feb -14 |
US8652836 |
Defective
ribosomal products in blebs (DRibbles) and methods of use to stimulate an
immune response |
Providence
Health System |
29- Jul-05 |
27- Jul- 06 |
18- Feb -14 |
US8652782 |
Compositions
and methods for detecting, identifying and quantitating
mycobacterial-specific nucleic acids |
Longhorn
Vaccines & Diagnostics, LLC |
12- Sep- 06 |
26- Apr -11 |
18- Feb -14 |
US8652533 |
Durable
biocides and disinfectants |
Mitsui
Norin Co., Ltd. |
7-Jul- 04 |
5- Jul- 05 |
18- Feb -14 |
US8648076 |
Cysteine
protease inhibitors and their therapeutic applications |
Hybrigenics
SA |
5- Aug-
05 |
26- Jul- 06 |
11- Feb -14 |
US8647676 |
Antimicrobial
composition from copepods |
Nofima
Ingrediens |
28- Oct- 08 |
28- Oct -09 |
11- Feb -14 |
US8642596 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arena viruses |
Siga
Technologies, Inc. |
6- Dec- 04 |
6- Dec -05 |
4- Feb -14 |
US8642260 |
Single
quantum-dot based aptameric nanosensors |
The
Research Foundation of the City University of New York |
21- Oct- 08 |
21- Oct -09 |
4- Feb -14 |
US8633322 |
Alkynyl
derivatives useful as DPP-1 inhibitors |
Janssen
Pharmaceutica NV |
29- Oct- 09 |
28- Oct -10 |
21- Jan- 14 |
US8633308 |
Compounds
for preventing or treating viral infections and methods of use thereof |
The
Governors of The University of Alberta |
28- Feb- 07 |
27- Feb -08 |
21- Jan- 14 |
US8632764 |
Directed
evolution and in vivo panning of virus vectors |
University
of North Carolina at Chapel Hill |
30- Apr- 08 |
29- Apr -09 |
21- Jan- 14 |
US8629283 |
Compounds
that modulate negative-sense, single-stranded RNA virus replication and uses
thereof |
Icahn
School of Medicine at Mount Sinai |
6- Mar-
08 |
6- Mar -09 |
14- Jan- 14 |
US8629271 |
Compounds |
AstraZeneca
AB |
6- Feb-
08 |
2- Apr -12 |
14- Jan- 14 |
US8629098 |
Compositions
and methods for adoptive and active immunotherapy |
Yale
University |
15- Jan- 08 |
14- Jan -09 |
14- Jan- 14 |
US8628786 |
Polychlorinated
biphenyls and squalene-containing adjuvants |
Novartis
AG |
28- Dec- 07 |
2- Dec -11 |
14- Jan- 14 |
US8624011 |
Vaccines
and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid
molecules encoding the same, and methods for using the same |
The
Trustees of the University of Pennsylvania |
14- Sep- 09 |
14- Sep -10 |
7- Jan- 14 |
US8623419 |
Technology
for preparation of macromolecular microspheres |
Ansun
Biopharma, Inc. |
24- Jan- 06 |
4- Nov -11 |
7- Jan-
14 |
US8623382 |
Immunogenic
compositions for inducing an immune response to HIV |
Wyeth
LLC |
17- Jun- 04 |
18- Jan -11 |
7- Jan-
14 |
US8623364 |
Antigenic
GM-CSF peptides and antibodies to GM-CSF |
Morphotek,
Inc. |
8- Feb-
06 |
24- Oct -12 |
7- Jan-
14 |
US8617838 |
Fluorescent
proteins and related methods and compounds |
University
of Massachusetts |
20- Sep- 04 |
20- Sep -05 |
31- Dec -13 |
US8615368 |
Method
for determining the amount of an analyte in a sample |
Gen-Probe
Incorporated |
10- Mar- 05 |
10- Mar -06 |
24- Dec -13 |
US8609370 |
Highly
active glycoproteins-process conditions and an efficient method for their
production |
Glycotope
GmbH |
13- Feb- 04 |
14- Feb -05 |
17- Dec -13 |
US8609101 |
Granulocyte-macrophage
colony-stimulating factor (GM-CSF) neutralizing antibodies |
Theraclone
Sciences, Inc. |
23- Apr- 09 |
23- Apr -10 |
17- Dec -13 |
US8604215 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
22- Mar -10 |
10- Dec -13 |
US8603469 |
Methods
of treating cancer with human monoclonal antibodies against interleukin 8 |
Genmab
A/S |
16- Dec- 02 |
27- Dec -11 |
10- Dec -13 |
US8599383 |
Optical
cytometry |
The
Regents of the University of California |
6- May-
09 |
6- May -09 |
3- Dec -13 |
US8598192 |
Hydroxylamine
substituted imidazoquinolines |
3M
Innovative Properties Company |
14- Nov- 03 |
12- Nov -04 |
3- Dec -13 |
US8598134 |
RNAi
modulation of RSV, PIV and other respiratory viruses and uses thereof |
South
Alabama Medical Science Foundation |
22- Oct- 04 |
23- Jul- 10 |
3- Dec -13 |
US8598116 |
Treatment
of influenza virus infection |
Educational
Fund and Autoimmune Technologies, LLC |
4- Nov-
03 |
29- May -12 |
3- Dec -13 |
US8598106 |
Anti-microbial
composition exhibiting residual anti-microbial properties on a surface |
Byotrol
PLC |
17- Sep- 07 |
5- Jul- 11 |
3- Dec -13 |
US8597650 |
Methods
for treating rheumatoid arthritis with anti-bile salt- stimulated lipase
(BSSL) antibodies |
HERNELL
OLLE |
8- Apr-
09 |
6- Apr -10 |
3- Dec -13 |
US8592567 |
Vaccines
and immunotherapeutics using codon-optimized IL-15 and methods for using the
same |
The
Trustees of the University of Pennsylvania |
13- Jan- 06 |
3- May -12 |
26- Nov -13 |
US8592391 |
Method
for therapeutic, clinical and veterinary use poly-ICLC |
SALAZAR
ANDRES |
1-Jul- 03 |
17- Oct -08 |
26- Nov -13 |
US8586770 |
Unsaturated
steroid compounds |
Harbor
Therapeutics, Inc. |
29- Sep- 04 |
18- Feb -11 |
19- Nov -13 |
US8586364 |
Cells and
methodology to generate non-segmented negative-strand RNA viruses |
Institut
Pasteur |
22- Dec- 06 |
21- Dec -07 |
19- Nov -13 |
US8586363 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
10- Dec -10 |
19- Nov -13 |
US8581584 |
Membrane
proteins, mechanisms of action and uses thereof |
Florida
State University Research Foundation |
26- May- 10 |
26- May -11 |
12- Nov -13 |
US8580927 |
Engineered
antibody constant domain molecules |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
31- Jan- 08 |
30- Jan -09 |
12- Nov -13 |
US8580268 |
CpG
oligonucleotide analogs containing hydrophobic T analogs with enhanced
immunostimulatory activity |
Coley
Pharmaceutical GmbH |
27- Sep- 06 |
27- Sep -07 |
12- Nov -13 |
US8569283 |
Compounds
and compositions as c-Kit kinase inhibitors |
LIU
XIAODONG |
1- Sep-
11 |
29- Aug -12 |
29- Oct- 13 |
US8562996 |
RSV-specific
binding molecules and means for producing them |
MedImmune
Limited |
1- Jun-
07 |
30- May -08 |
22- Oct- 13 |
US8562943 |
Quality
control methods for oil-in-water emulsions containing squalene |
Novartis
AG |
8- Nov-
06 |
6- Nov -07 |
22- Oct- 13 |
US8560339 |
System
and method to predict the global spread of infectious agents via commercial
air travel |
Kamran
Khan |
2- Apr-
07 |
2- Apr -08 |
15- Oct- 13 |
US8557767 |
Synthetic
apolipoprotein E mimicking polypeptides and methods of use |
UAB
Research Foundation |
28- Aug- 07 |
27- Aug -08 |
15- Oct- 13 |
US8557248 |
Methods
and compositions for treating malaria |
Cyvax,
Inc. |
9- Aug-
10 |
9- Aug -11 |
15- Oct- 13 |
US8552051 |
Use
of pharmaceutical compositions containing mesembrenone |
H.
L. Hall & Sons Limited |
20- Mar- 09 |
16- Mar -10 |
8- Oct-
13 |
US8552032 |
Bicyclic
derivatives useful as inhibitors of DPP-1 |
Janssen
Pharmaceutica NV |
18- Dec- 09 |
16- Dec -10 |
8- Oct-
13 |
US8551968 |
Methods
for generation of antibodies |
National
Jewish Health |
13- Mar- 07 |
13- Mar -08 |
8- Oct-
13 |
US8551756 |
Avian
influenza chimeric VLPS |
Novavax,
Inc. |
11- Jul-03 |
19- Jan -10 |
8- Oct-
13 |
US8551750 |
Device
including bone cage and method for treatment of disease in a subject |
The
Invention Science Fund I, LLC |
23- Apr- 09 |
28- Jul- 09 |
8- Oct-
13 |
US8551749 |
Device
including bone cage and method for treatment of disease in a subject |
The
Invention Science Fund I, LLC |
23- Apr- 09 |
23- Apr -09 |
8- Oct-
13 |
US8551738 |
Systems
and methods for rapid identification of nucleic acid variants |
Ibis
Biosciences, Inc. |
21- Jul-05 |
11- Nov -09 |
8- Oct-
13 |
US8551469 |
Treatment
of tumors and viral diseases with recombinant interferon alpha |
Superlab
Far East Limited |
28- Feb- 01 |
6- Oct -08 |
8- Oct-
13 |
US8546432 |
Tetrazolones
as inhibitors of fatty acid synthase |
Infinity
Pharmaceuticals, Inc. |
5- May-
10 |
5- May -11 |
1- Oct-
13 |
US8546383 |
Chiral
fused [1,2]imidazo[4,5-c] ring compounds |
3M
Innovative Properties Company |
30- Dec- 04 |
25- May -12 |
1- Oct-
13 |
US8546082 |
Methods
for identification of sepsis-causing bacteria |
Ibis
Biosciences, Inc. |
11- Sep- 03 |
25- May -07 |
1- Oct-
13 |
US8541568 |
Compositions
and methods using siRNA molecules for treatment of gliomas |
BIGNER
DARELL D |
24- May- 08 |
26- May -09 |
24- Sep -13 |
US8541457 |
Aminothiazole
derivatives as human stearoyl-CoA desaturase inhibitors |
Xenon
Pharmaceuticals Inc. |
3- Jun-
05 |
5- Jun -06 |
24- Sep -13 |
US8541438 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
21- Dec -10 |
24- Sep -13 |
US8541221 |
Primate
T-lymphotropic viruses |
Johns
Hopkins University |
21- Feb- 05 |
1- Jul- 10 |
24- Sep -13 |
US8541003 |
Vectors
expressing SARS immunogens, compositions containing such vectors or expression
products thereof, methods and assays for making and using |
Protein
Sciences Corporation |
20- Jun- 03 |
21- Jun -04 |
24- Sep -13 |
US8529968 |
Decontaminating
composition having simultaneously bactericidal, fungicidal and virocidal properties,
methods for obtaining and using said composition |
Hightech
Bio-Activities Holding GmbH |
29- Mar- 04 |
29- Mar -05 |
10- Sep -13 |
US8524715 |
Phenoxyacetic
acid derivatives useful for treating respiratory diseases |
Astrazeneca
AB |
23- Nov- 04 |
22- Nov -05 |
3- Sep -13 |
US8524488 |
Methods
and devices for determining a cell characteristic, and applications employing
the same |
The
Regents of the University of California |
10- Sep- 02 |
9- Mar -05 |
3- Sep -13 |
US8524241 |
Fusion
proteins comprising a fragment of Vibrio cholerae exotoxin A |
The
General Hospital Corporation |
20- Jul-07 |
18- Jul- 08 |
3- Sep -13 |
US8519106 |
Monoclonal
human tumor-specific antibody |
University
of Zurich |
13- Mar- 07 |
13- Mar -08 |
27- Aug -13 |
US8507545 |
Cytotoxic
T cell activator comprising EP4 agonist |
National
University Corporation, Hamamatsu University School of Medicine |
8- May-
07 |
7- May -08 |
13- Aug -13 |
US8507544 |
Bi-aryl
amide compounds as CRTh2 receptor modulators |
Astrazeneca
AB |
5-Jul- 07 |
3- Jul- 08 |
13- Aug -13 |
US8507455 |
Folate
conjugates |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
4- Dec -08 |
13- Aug -13 |
US8506968 |
SARS
vaccine compositions and methods of making and using them |
Eli
Lilly and Company |
29- Jun- 00 |
28- Dec -09 |
13- Aug -13 |
US8506966 |
Adjuvanted
influenza vaccines for pediatric use |
Novartis
AG |
22- Feb- 08 |
20- Feb -09 |
13- Aug -13 |
US8501746 |
Organic
compounds |
Novartis
AG |
5- Jun-
06 |
4- Jun -07 |
6- Aug -13 |
US8501699 |
Bicyclic
nucleosides and nucleotides as therapeutic agents |
Biota
Scientific Management Pty Ltd |
3-Jul- 08 |
7- Sep -12 |
6- Aug -13 |
US8501461 |
System
for performing multi-formatted assays |
Gen-Probe
Incorporated |
10- Mar- 05 |
3- Dec -09 |
6- Aug -13 |
US8497405 |
Process
for dispersing vaporous hydrogen peroxide |
STERIS
Inc. |
6- Mar-
07 |
28- Feb -13 |
30- Jul- 13 |
US8497112 |
Method
for producing viral vaccines |
Baxter
Healthcare SA |
28- Aug- 07 |
28- Aug -08 |
30- Jul- 13 |
US8494781 |
Systems
and methods for identifying replikin scaffolds and uses of said replikin
scaffolds |
BOGOCH
ELENORE S |
6- Jun-
03 |
10- Dec -10 |
23- Jul- 13 |
US8492329 |
Bioactive
peptides and methods of using same |
Compugen
Ltd. |
12- Jul-07 |
11- Jul- 08 |
23- Jul- 13 |
US8486959 |
Dibenzo[f,h]isoquinoline
derivatives |
National
Health Research Institutes |
14- Jan- 10 |
14- Jan -11 |
16- Jul- 13 |
US8486678 |
Pharmaceutical
compositions for the treatment of virus infection |
Kineta
Two, LLC |
23- Nov- 05 |
1- Feb -12 |
16- Jul- 13 |
US8486619 |
Arrayed
imaging reflectometry (air) sensor chip comprising influenza hemagglutinin
(HA) polypeptides suitable for the detection of antiviral immune responses |
University
of Rochester |
2- May- 08 |
1- May -09 |
16- Jul- 13 |
US8486420 |
Live
virus vaccines |
Children's
Hospital, Inc. |
15- Feb- 05 |
15- Feb -06 |
16- Jul- 13 |
US8481547 |
Substituted
benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 |
Janssen
Pharmaceutica NV |
18- Dec- 09 |
16- Dec -10 |
9- Jul- 13 |
US8481270 |
Method
for chromogenic detection of two or more target molecules in a single sample |
Ventana
Medical Systems, Inc. |
22- Aug- 08 |
21- Aug -09 |
9- Jul- 13 |
US8481255 |
Scytovirin
domain 1 related polypeptides |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
25- May- 05 |
30- Sep -11 |
9- Jul- 13 |
US8476292 |
Amide
and carbamate derivatives of N-{2-[4-amino-2-
(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1- dimethylethyl}methanesulfonamide
and methods |
3M
Innovative Properties Company |
9- Sep- 05 |
8- Sep -06 |
2- Jul- 13 |
US8476288 |
Salts
756 |
AstraZeneca
AB |
21- May- 09 |
20- May -10 |
2- Jul- 13 |
US8476265 |
Compounds-801 |
AstraZeneca
AB |
30- Jul-10 |
14- Sep -12 |
2- Jul- 13 |
US8470771 |
Method
and medicament for inhibiting the infection of influenza virus |
Institute
of Microbiology, Chinese Academy of Sciences |
14- Nov- 07 |
18- Dec -07 |
25- Jun- 13 |
US8470769 |
Method of
treatment of bacterial infection by administration of poly- lysine |
Novabiotics,
Ltd. |
18- Aug- 04 |
30- Nov -11 |
25- Jun- 13 |
US8470346 |
Anti-viral
pharmaceutical compositions |
Mast
Therapeutics, Inc. |
10- Dec- 03 |
19- May -11 |
25- Jun- 13 |
US8470335 |
Recombinant
SARS-CoV nsp12 and the use of thereof and the method for producing it |
Industry-Academic
Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation
Foundation |
13- Jun- 08 |
13- Jun -08 |
25- Jun- 13 |
US8466284 |
Some
2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
Astra
Zeneca AB |
6- Nov-
07 |
5- Nov -08 |
18- Jun- 13 |
US8466167 |
Compounds
and compositions as TLR activity modulators |
IRM
LLC |
3- Mar-
08 |
27- Feb -09 |
18- Jun- 13 |
US8466124 |
RNA
sequence motifs in the context of defined internucleotide linkages inducing
specific immune modulatory profiles |
Coley
Pharmaceutical GmbH |
13- Aug- 07 |
12- Jun -12 |
18- Jun- 13 |
US8465751 |
Cna—B
domain antigens in vaccines against gram positive bacteria |
Novartis
AG |
12- Jan- 09 |
12- Jan -10 |
18- Jun- 13 |
US8461125 |
Compositions
and methods to treat asthma |
The
Children's Hospital of Philadelphia |
14- Feb- 08 |
13- Aug -10 |
11- Jun- 13 |
US8460914 |
Decreasing
potential iatrogenic risks associated with vaccines and vaccine antigens |
Novartis
AG |
9- Sep-
04 |
10- Jan -13 |
11- Jun- 13 |
US8460605 |
Decontaminant
dispenser suitable for use as a projectile |
STERIS
Inc. |
6- Mar-
07 |
20- Feb -08 |
11- Jun- 13 |
US8455483 |
Compounds—801 |
AstraZeneca
AB |
31- Jul-09 |
30- Jul- 10 |
4- Jun-
13 |
US8450471 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
22- Mar -12 |
28- May -13 |
US8450467 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
14- Dec -11 |
28- May -13 |
US8450350 |
Triazoles
as inhibitors of fatty acid synthase |
Infinity
Pharmaceuticals, Inc. |
5- May-
10 |
5- May -11 |
28- May -13 |
US8450284 |
Coiled-coil
lipopeptide helical bundles and synthetic virus-like particles |
Universitaet
Zuerich |
9- Dec-
06 |
6- Dec -07 |
28- May -13 |
US8450055 |
Malaria
antigen screening method |
The
United States of America as Represented by the Secretary of the Navy |
31- Aug- 05 |
25- Aug -06 |
28- May -13 |
US8445650 |
Mutant
botulinum neurotoxin serotype A polypeptide and uses thereof |
Thomas
Jefferson University |
25- Sep- 07 |
25- Sep -08 |
21- May -13 |
US8445447 |
B7-DC
variants immunogenic compositions and methods of use thereof |
The
Johns Hopkins University |
13- Jul-07 |
7- Mar -12 |
21- May -13 |
US8444961 |
RNA virus
infection inhibitor, method for inhibition of infection by RNA virus, RNA
virus infection-inhibiting product, and use as RNA virus infection inhibitor |
Sekisui
Chemical Co., Ltd. |
16- Jun- 09 |
16- Jun -10 |
21- May -13 |
US8440704 |
Quercetin-containing
compositions |
Quercegen
Pharmaceuticals LLC |
17- Jul-06 |
16- Dec -09 |
14- May -13 |
US8440649 |
Phenanthroindolizidine
analogues |
National
Health Research Institutes |
24- Feb- 09 |
11- Feb -10 |
14- May -13 |
US8440642 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
1- Sep -11 |
14- May -13 |
US8440432 |
Tal
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
22- Mar -12 |
14- May -13 |
US8440431 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
22- Mar -12 |
14- May -13 |
US8440408 |
Animal
protein-free media for cultivation of cells |
Baxter
Healthcare S.A. |
29- Oct- 04 |
10- Dec -10 |
14- May -13 |
US8436178 |
Imidazoquinolines
with immuno-modulating properties |
AstraZeneca
AB |
8- May-
07 |
6- May -08 |
7- May -13 |
US8436024 |
2-pyridone
compounds |
Astrazeneca
AB |
2- Oct-
09 |
1- Oct -10 |
7- May -13 |
US8431160 |
Microparticles
containing biodegradable polymer and cationic polysaccharide for use in
immunogenic compositions |
Novartis
AG |
24- Feb- 06 |
24- Feb -07 |
30- Apr- 13 |
US8431134 |
Use of a
pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a
pathogen |
The
United States of America as represented by the Secretary of the Department of
Health and Human Services,
Centers for Disease Control and Prevention |
31- Jul-08 |
31- Jul- 09 |
30- Apr- 13 |
US8426565 |
Dendritic
cell marker and uses thereof |
Walter
and Eliza Hall Institute of Medical Research |
30- Aug- 07 |
29- Aug -08 |
23- Apr- 13 |
US8420798 |
Method
for producing nucleic acid probes |
Ventana
Medical Systems, Inc. |
1- Sep-
06 |
31- Aug -07 |
16- Apr- 13 |
US8420784 |
Interleukin
10 receptor, (IL-10R) antibodies |
Kyowa
Hakko Kirin Co., Ltd. |
27- May- 08 |
27- May -09 |
16- Apr- 13 |
US8420096 |
Cell-penetrating
SOCS polypeptides that inhibit cytokine-induced signaling |
Vanderbilt
University |
4- Mar-
04 |
4- Mar -05 |
16- Apr- 13 |
US8420094 |
Fusion
proteins comprising a fragment of Vibrio cholerae exotoxin A |
The
General Hospital Corporation |
20- Jul-07 |
18- Jul- 08 |
16- Apr- 13 |
US8415394 |
Biphenyloxyacetic
acid derivatives for the treatment of respiratory disease |
Astrazeneca
AB |
6- Oct-
05 |
21- Dec -11 |
9- Apr-
13 |
US8415361 |
Use
of TAM receptor inhibitors as antimicrobials |
The
Salk Institute for Biological Studies |
9- Nov- 07 |
7- Nov -08 |
9- Apr-
13 |
US8415330 |
Biological
specimen collection and transport system and method of use |
Longhorn
Vaccines & Diagnostics, LLC |
1- Oct-
07 |
1- Oct -12 |
9- Apr-
13 |
US8415309 |
Bicyclic
nucleosides and nucleotides as therapeutic agents |
Biota
Scientific Managment Pty Ltd |
1-Jul- 09 |
11- Jan -12 |
9- Apr-
13 |
US8415118 |
Porcine
DC-SIGN, ICAM-3 and LSECtin and uses thereof |
Virginia
Tech Intellectual Properties, Inc. |
29- Oct- 07 |
29- Oct -08 |
9- Apr-
13 |
US8415102 |
Methods
and computer systems for identifying target-specific sequences for use in
nanoreporters |
NanoString
Technologies, Inc. |
10- Apr- 07 |
10- Apr -08 |
9- Apr-
13 |
US8410149 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arenaviruses |
Siga
Technologies Inc. |
6- Dec- 04 |
28- Oct -10 |
2- Apr- 13 |
US8410114 |
2-pyrazinone
derivatives for the treatment of disease or condition in which inhibition of
neutrophil elastase activity is beneficial |
AstraZeneca
AB |
8- May-
06 |
6- Jan -12 |
2- Apr-
13 |
US8409589 |
Mutant
forms of streptolysin O |
Novartis
AG |
21- Dec- 07 |
14- Sep -11 |
2- Apr-
13 |
US8399651 |
Nucleic
acids encoding GAS57 mutant antigens |
Novartis
AG |
12- Sep- 07 |
10- Sep -12 |
19- Mar -13 |
US8398992 |
Methods
and compositions for polytopic vaccination |
Polytopos
LLC |
29- Apr- 05 |
22- Dec -11 |
19- Mar -13 |
US8394986 |
Phenoxiacetic
acid derivatives |
AstraZeneca
AB |
21- Aug- 03 |
26- Jul- 11 |
12- Mar -13 |
US8394945 |
Compositions
for use in identification of bacteria |
Ibis
Biosciences, Inc. |
11- Sep- 03 |
7- Mar -07 |
12- Mar -13 |
US8394386 |
Sequential
delivery of immunogenic molecules via adenovirus and adeno-associated
virus-mediated administrations |
The
Trustees of the University of Pennsylvania |
28- Apr- 04 |
27- Apr -05 |
12- Mar -13 |
US7829712 |
Pyridazine
derivatives for inhibiting human stearoyl-CoA-desaturase |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
9- Nov -10 |
US7829707 |
Pyrrolo
[3,2-d]pyrimidin-4-one derivatives and their use in therapy |
AstraZeneca
AB |
6- Dec-
04 |
5- Dec -05 |
9- Nov -10 |
US7829302 |
Method
for detecting the specificity of activated lymphocyte |
HU
JUN |
8- Dec-
03 |
7- Dec -04 |
9- Nov -10 |
US7820210 |
Methods
and apparatus to prevent, treat, and cure the symptoms of nausea caused by
chemotherapy treatments of human cancers |
Inhalation,
Inc. |
3- Apr- 00 |
18- Mar -08 |
26- Oct- 10 |
US7812135 |
GITR-binding
antibodies |
TOLERRX,
Inc. |
25- Mar- 05 |
27- Mar -06 |
12- Oct- 10 |
US7803918 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
Amsterdam
Institute of Viral Genomics B.V. |
18- Aug- 03 |
18- Aug -04 |
28- Sep -10 |
US7803796 |
Homopiperazine
compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot
structure of SARS coronavirus |
Sungkyunkwan
University Foundation For Corporate Collaboration |
22- Dec- 06 |
20- Dec -07 |
28- Sep -10 |
US7803765 |
Methods
of constructing biodiverse gene fragment libraries and biological modulators
isolated therefrom |
Phylogica
Limited |
20- Feb- 04 |
20- Feb -04 |
28- Sep -10 |
US7799800 |
Lipid-modified
immune response modifiers |
3M
Innovative Properties Company |
30- Oct- 03 |
12- Aug -04 |
21- Sep -10 |
US7794998 |
Primate
T-lymphotropic viruses |
Johns
Hopkins University |
21- Feb- 05 |
24- Feb -07 |
14- Sep -10 |
US7794659 |
Signal
measuring system having a movable signal measuring device |
Gen-Probe
Incorporated |
10- Mar- 05 |
10- Mar -06 |
14- Sep -10 |
US7790878 |
RNAi
modulation of RSV, PIV and other respiratory viruses and uses thereof |
Alnylam
Pharmaceuticals, Inc. |
22- Oct- 04 |
25- Jun -09 |
7- Sep -10 |
US7790449 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing the same, and uses
therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
6- Sep -07 |
7- Sep -10 |
US7790159 |
Methods, combinations
and kits for treating viral infections using immunoconjugates and antibodies
to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
7- Sep -10 |
US7786290 |
Double-stranded
ribonucleic acid with increased effectiveness in an organism |
Alnylam
Pharmaceuticals, Inc. |
13- Jun- 03 |
14- Jun -04 |
31- Aug -10 |
US7785775 |
Human
virus causing severe acute respiratory syndrome (SARS) and uses thereof |
Versitech
Limited |
24- Mar- 03 |
8- Jun -07 |
31- Aug -10 |
US7785612 |
Polyamino
acid for use as adjuvant |
Masanori
Baba |
20- Apr- 05 |
19- Apr -06 |
31- Aug -10 |
US7781226 |
Particle
on membrane assay system |
The
Board of Regents of the University of Texas System |
27- Feb- 04 |
22- Dec -04 |
24- Aug -10 |
US7781203 |
Supports
for assaying analytes and methods of making and using thereof |
Corning
Incorporated |
29- Dec- 05 |
7- Jun -06 |
24- Aug -10 |
US7777036 |
Heterocyclic
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
17- Aug -10 |
US7777022 |
Bioinformatically
detectable group of novel regulatory viral and viral associated
oligonucleotides and uses thereof |
Rosetta
Genomics, Ltd. |
26- Nov- 02 |
26- May -04 |
17- Aug -10 |
US7776521 |
Coronavirus
isolated from humans |
The
United States of America as represented by the Secretary of the Department of Health and
Human Services, Centers for Disease Control and Prevention |
25- Apr- 03 |
14- May -07 |
17- Aug -10 |
US7767817 |
Water
soluble boronic acid fluorescent reporter compounds and methods of use
thereof |
FANG
HAO |
5- Sep-
03 |
7- Sep -04 |
3- Aug -10 |
US7767677 |
Heterocyclic
derivatives and their use as stearoyl-CoA desaturase inhibitors |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
3- Aug -10 |
US7767658 |
Vaccine
composition |
Aventis
Pasteur SA |
17- Nov- 03 |
9- Jan -08 |
3- Aug -10 |
US7767657 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
16- Aug -06 |
3- Aug -10 |
US7767210 |
RNA
virus vaccines and methods |
The
Board of Regents of the University of Oklahoma |
14- Dec- 05 |
14- Dec -06 |
3- Aug -10 |
US7763618 |
Pyridyl
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
29- Jul-03 |
29- Jul- 04 |
27- Jul- 10 |
US7758868 |
Modified
polymerases and attenuated viruses and methods of use thereof |
The
Penn State Research Foundation |
22- Dec- 06 |
24- Dec -07 |
20- Jul- 10 |
US7754711 |
Pyridazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
9- Feb -05 |
13- Jul- 10 |
US7750123 |
Antibodies
against SARS-CoV and methods of use thereof |
Dana
Farber Cancer Institute, Inc. |
25- Nov- 03 |
24- Nov -04 |
6- Jul- 10 |
US7749445 |
Method
and apparatus for analyzing bioprocess fluids |
BioScale,
Inc. |
2- May-
05 |
19- Dec -06 |
6- Jul- 10 |
US7745486 |
Quercetin-containing
compositions |
Quercegen
Pharma LLC |
17- Jul-06 |
16- Jul- 07 |
29- Jun- 10 |
US7745442 |
Methods
of reducing risk of infection from pathogens |
Parion
Sciences, Inc. |
20- Aug- 03 |
18- Aug -04 |
29- Jun- 10 |
US7745147 |
Methods
and uses of antibodies in the purification of interferon |
ViraNative
AB |
12- Feb- 05 |
13- Feb -06 |
29- Jun- 10 |
US7745119 |
System
for detecting polynucleotides |
Investigen,
Inc. |
20- May- 03 |
21- Nov -05 |
29- Jun- 10 |
US7745118 |
Comparative
genomic resequencing |
Roche
Nimblegen, Inc. |
8- Apr-
04 |
8- Apr -05 |
29- Jun- 10 |
US7741450 |
Antibodies
to GM-CSF |
Morphotek
Inc. |
8- Feb-
06 |
8- Feb -07 |
22- Jun- 10 |
US7741360 |
Bi-aryl
or aryl-heteroaryl substituted indoles |
AstraZeneca
AB |
26- May- 06 |
25- May -07 |
22- Jun- 10 |
US7740858 |
SARS-CoV-specific
B-cell epitope and applications thereof |
National
Taiwan University |
21- Sep- 04 |
21- Sep -04 |
22- Jun- 10 |
US7737135 |
Biphenyloxyacetic
acid derivatives for the treatment of respiratory disease |
AstraZeneca
AB |
24- Aug- 04 |
22- Aug -05 |
15- Jun- 10 |
US7736850 |
Strain
of SARS-associated coronavirus and applications thereof |
Centre
National de la Recherche Scientifique |
2- Dec-
03 |
2- Dec -04 |
15- Jun- 10 |
US7732177 |
Oligoadenylate
Synthetase (OAS) |
Illumigen
Biosciences, Inc. |
23- Nov- 05 |
17- Nov -06 |
8- Jun-
10 |
US7731978 |
Mutant
forms of streptolysin O |
Novartis
AG |
21- Dec- 07 |
19- Dec -08 |
8- Jun-
10 |
US7728110 |
Antibodies
to SARS coronavirus |
Amgen,
Inc. |
19- May- 06 |
21- May -07 |
1- Jun-
10 |
US7725565 |
System
and method for detecting, collecting, analyzing, and communicating event
related information |
Georgetown
University |
25- Feb- 08 |
19- Nov -08 |
25- May -10 |
US7723570 |
Edible
vaccines expressed in soybeans |
SoyMeds,
Inc. |
12- Oct- 04 |
12- Oct -05 |
25- May -10 |
US7723041 |
Assay for
SARS coronavirus by amplification and detection of the replicase sequence |
Becton,
Dickinson and Company |
12- Sep- 03 |
3- Feb -09 |
25- May -10 |
US7722886 |
Compositions
and methods for treatment of severe acute respiratory syndrome (SARS) |
Wyeth |
20- May- 04 |
20- May -04 |
25- May -10 |
US7714109 |
Combinations
and kits for cancer treatment using selected antibodies to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
11- May -10 |
US7713515 |
Methods
and compositions for use in diagnosing and characterizing diseases involving
abnormal apoptosis |
R.E.D.
Laboratories N.V. |
27- May- 03 |
26- May -04 |
11- May -10 |
US7709521 |
Substituted
indole derivatives for pharmaceutical compositions for treating respiratory
diseases |
AstraZeneca
AB |
18- Aug- 03 |
16- Aug -04 |
4- May -10 |
US7709511 |
Benzothiazolone
derivatives |
AstraZeneca
AB |
9- Aug-
05 |
3- Aug -06 |
4- May -10 |
US7709188 |
Multi-allelic
detection of SARS-associated coronavirus |
Birch
Biomedical Research LLC |
22- Aug- 03 |
13- Aug -04 |
4- May -10 |
US7700782 |
Compounds
569 |
AstraZeneca
AB |
19- Dec- 07 |
19- Dec -07 |
20- Apr- 10 |
US7700728 |
Use of
chimeric receptors in a screening assay for identifying agonists and
antagonists of cell receptors |
Schering
Corporation |
24- Mar- 05 |
24- Mar -06 |
20- Apr- 10 |
US7700727 |
Compositions
and kits for detecting pathogen infection |
Biokit,
S.A. |
23- Dec- 03 |
27- Apr -05 |
20- Apr- 10 |
US7700273 |
Peptidomimetics
that mimic a conformational-dependent neutralizing epitope of the human
immunodeficiency virus (HIV) CCR5 coreceptor |
The
United States of America as represented by the Department of Health and Human
Services |
9- Apr- 04 |
11- Apr -05 |
20- Apr- 10 |
US7700120 |
Adjuvancy
and immune potentiating properties of natural products of Onchocerca volvulus |
New
York Blood Center |
15- Jun- 04 |
15- Jun -05 |
20- Apr- 10 |
US7696406 |
Expression
of a recombinant transgene |
Board
of Trustees Operating Michigan State University |
3-Jul- 03 |
2- Jul- 04 |
13- Apr- 10 |
US7696330 |
Binding
molecules against SARS-coronavirus and uses thereof |
Crucell
Holland B.V. |
22- Jul-03 |
20- Jan -06 |
13- Apr- 10 |
US7691877 |
Pharmaceuticals |
Pfizer
Inc. |
17- Feb- 06 |
16- Feb -07 |
6- Apr-
10 |
US7691646 |
Hazardous
substance removing method, hazardous substance removing material used therein
such as air filter, mask, wipe sheet, and the like, and storage method
thereof |
Daikin
Industries, Ltd. |
28- Mar- 03 |
21- Nov -08 |
6- Apr- 10 |
US7691599 |
Mammalian
genes involved in viral infection and tumor suppression |
Zirus,
Inc. |
2- May-
02 |
2- May -03 |
6- Apr-
10 |
US7691390 |
Viral
protein |
CHANG
MING-FU |
2- Mar-
04 |
19- Sep -07 |
6- Apr-
10 |
US7687535 |
Substituted
3-sulfur indoles |
AstraZeneca
AB |
27- May- 03 |
25- May -04 |
30- Mar -10 |
US7687475 |
RNA
interference in respiratory epithelial cells |
University
of Iowa Research Foundation |
9-Jul- 04 |
16- Oct -07 |
30- Mar -10 |
US7682688 |
Microporous
materials, methods, and articles for localizing and quantifying analytes |
University
of Utah Research Foundation |
26- Nov- 02 |
20- Nov -03 |
23- Mar -10 |
US7678774 |
Treating
severe acute respiratory syndrome |
Hemispherx
Biopharma |
16- May- 03 |
26- Jan -07 |
16- Mar -10 |
US7678386 |
Liposomes
coated with selected antibodies that bind to aminophospholipids |
Board
of Regents the University of Texas |
15- Jul-02 |
15- Aug -03 |
16- Mar -10 |
US7674795 |
Fluorene
derivatives, composition containing said derivatives and the use thereof |
Aventis
Pharma SA |
19- May- 05 |
14- Nov -07 |
9- Mar -10 |
US7670807 |
RNA-dependent
DNA polymerase from Geobacillus stearothermophilus |
East
Tennessee State Univ. Research Foundation |
10- Mar- 04 |
10- Mar -04 |
2- Mar -10 |
US7670565 |
Building
decontamination with vaporous hydrogen peroxide |
Steris
Inc |
31- Jan- 03 |
3- Mar -08 |
2- Mar -10 |
US7666996 |
Casein
derived peptides and uses thereof |
Peptera
Pharmaceuticals Ltd |
1- Mar-
00 |
1- Mar -04 |
23- Feb -10 |
US7666592 |
Methods
for concurrent identification and quantification of an unknown bioagent |
Ibis
Biosciences, Inc. |
18- Feb- 04 |
17- Feb -05 |
23- Feb -10 |
US7662860 |
3D-structure
model of SARS coronavirus 3CL protease and anti- SARS drugs |
Shanghai
Institute of Materia Medica, Chinese Academy of Sciences |
4- Jun-
03 |
2- Dec -05 |
16- Feb -10 |
US7648997 |
Hydroxylamine
substituted imidazoquinolines |
Coley
Pharmaceutical Group, Inc. |
12- Aug- 03 |
12- Aug -04 |
19- Jan- 10 |
US7648844 |
Method
and apparatus for detection of analyte using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
19- Jan- 10 |
US7645881 |
Methods
for treating hepatitis C |
PTC
Therapeutics, Inc. |
22- Jul-04 |
14- Jul- 05 |
12- Jan- 10 |
US7642350 |
Purine
derivatives |
Pfizer
Limited |
4- May-
05 |
3- May -06 |
5- Jan-
10 |
US7636637 |
Variable
length probe selection |
Roche
NimbleGen, Inc. |
18- Jun- 04 |
20- Jun -05 |
22- Dec -09 |
US7635557 |
Enzymatic
diagnostic test for SARS and other viral diseases |
MND
Diagnostic Ltd. |
23- Jun- 03 |
23- Jun -04 |
22- Dec -09 |
US7635485 |
Method
of accelerated vaccination against Ebola viruses |
The
United States of America as represented by the Department of Health and Human
Services |
1- Aug-
03 |
17- Jan -06 |
22- Dec -09 |
US7632638 |
Methods
and apparatus for detecting viruses using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
15- Dec -09 |
US7629443 |
Neutralizing
monoclonal antibodies against severe acute respiratory syndrome-associated
coronavirus |
New
York Blood Center, Inc. |
2- Jun-
04 |
8- Feb -06 |
8- Dec -09 |
US7629385 |
Sphingolipid-derived
pharmaceutical compositions |
Jado
Technologies GmbH |
29- Jun- 04 |
29- Jun -05 |
8- Dec -09 |
US7629137 |
Methods
and apparatus for detecting bacteria using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
8- Dec -09 |
US7629114 |
Method of
collecting nasopharyngeal cells and secretions for diagnosis of viral upper
respiratory infections and screening for nasopharyngeal cancer |
World
Sense Technology Limited |
26- Aug- 03 |
20- Aug -04 |
8- Dec -09 |
US7625563 |
Cancer
treatment methods using selected immunoconjugates for binding to
aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
1- Dec -09 |
US7625492 |
Charge-based
water filtration systems |
The
University of Wyoming Research Corporation |
28- Jan- 03 |
28- Jan -04 |
1- Dec -09 |
US7625428 |
Bioagent
air filtration systems |
The
University of Wyoming Research Corporation |
28- Jan- 03 |
28- Jan -04 |
1- Dec -09 |
US7623997 |
Computer-implemented
biological sequence identifier system and method |
The
United States of America as represented by the Secretary of the Navy |
2-Jul- 04 |
6- Jun -06 |
24- Nov -09 |
US7622559 |
Human
monoclonal antibodies against interleukin 8 (IL-8) |
Genmab
A/S |
16- Dec- 02 |
27- Jun -07 |
24- Nov -09 |
US7622125 |
Polycistronic
HIV vector constructs |
Novartis
Vaccines and Diagnostics, Inc. |
5- May-
04 |
5- May -05 |
24- Nov -09 |
US7622118 |
Cancer
treatment methods using selected antibodies to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
24- Nov -09 |
US7622112 |
Anti-SARS
monoclonal antibodies |
Not
Available |
5- Dec-
03 |
6- Dec -04 |
24- Nov -09 |
US7619067 |
Evolved
interferon-alpha polypeptides |
Maxygen,
Inc. |
18- May- 05 |
17- May -06 |
17- Nov -09 |
US7618802 |
Compositions
of coronaviruses with a recombination-resistant genome |
The
University of North Carolina at Chapel Hill |
21- Jul-03 |
19- Jan -06 |
17- Nov -09 |
US7618788 |
Proteome
epitope tags and methods of use thereof in protein modification analysis |
Millipore
Corporation |
10- May- 02 |
5- Feb -04 |
17- Nov -09 |
US7618635 |
Super-antigen
fusion proteins and the use thereof |
Healthbanks
Biotech Co., Ltd. |
21- Jul-04 |
19- Jul- 05 |
17- Nov -09 |
US7615381 |
Method
and apparatus for detecting estradiol and metabolites thereof using an
acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
10- Nov -09 |
US7615223 |
Selected
immunoconjugates for binding to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
10- Nov -09 |
US7611908 |
Method
and apparatus for therapeutic drug monitoring using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
3- Nov -09 |
US7611704 |
Compositions
and methods for treating viral infections using antibodies and immunoconjugates
to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
3- Nov -09 |
US7605161 |
Pyridyl
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
20- Oct- 09 |
US7605135 |
Baicalin
as a treatment for SARS infection |
The
University of Hong Kong |
10- Nov- 03 |
8- Nov -04 |
20- Oct- 09 |
US7604960 |
Transient
protein expression methods |
Crucell
Holland B.V. |
15- Apr- 99 |
1- Jun -07 |
20- Oct- 09 |
US7604801 |
Methods
for detecting parvovirus infections |
The
Research Foundation of State University of New York |
5- May-
03 |
16- Oct -08 |
20- Oct- 09 |
US7598382 |
Aryl
substituted imidazoquinolines |
Coley
Pharmaceutical Group, Inc. |
20- Dec- 02 |
13- Jan -06 |
6- Oct-
09 |
US7598094 |
Methods
and apparatus for detecting cardiac injury markers using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
6- Oct-
09 |
US7598072 |
Assay
to detect viral uncoating |
Wisconsin
Alumni Research Foundation |
9- Dec-
03 |
8- Dec -04 |
6- Oct-
09 |
US7597936 |
Method
of producing a pigmented composite microporous material |
University
of Utah Research Foundation |
26- Nov- 02 |
26- May -04 |
6- Oct-
09 |
US7595381 |
Method
for detecting SARS coronavirus |
Eiken
Kagaku Kabushiki Kaisha |
27- Jun- 03 |
10- Jun -08 |
29- Sep -09 |
US7595163 |
Method
for detecting SARS coronavirus |
Eiken
Kagaku Kabushiki Kaisha |
27- Jun- 03 |
10- Jun -08 |
29- Sep -09 |
US7592343 |
Pyridazine-piperazine
compounds and their use as stearoyl-CoA desaturase inhibitors |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
22- Sep -09 |
US7592322 |
RNAi
modulation of RSV, PIV and other respiratory viruses and uses thereof |
Alnylam
Pharmaceuticals, Inc. |
22- Oct- 04 |
14- Jun -05 |
22- Sep -09 |
US7592008 |
Membrane
scaffold proteins |
The Board
of Trustees of the University of Illinois, a body corporate and politic of
the State of Illinois |
20- Nov- 00 |
11- Jan -05 |
22- Sep -09 |
US7589092 |
Prodrugs
of heteroaryl compounds |
Koronis
Pharmaceuticals, Incorporated |
20- Jun- 03 |
27- Dec -06 |
15- Sep -09 |
US7585647 |
Nucleic
acid encoding recombinant interferon |
WEI
GUANGWEN |
28- Aug- 03 |
26- Aug -04 |
8- Sep -09 |
US7582740 |
Methods
and kits for detecting SARS-associated coronavirus |
The
Trustees of Columbia University In the City of New York |
17- Apr- 03 |
23- Jan -04 |
1- Sep -09 |
US7582621 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
16- Feb -06 |
1- Sep -09 |
US7579396 |
Polymer
composite |
Eastman
Kodak Company |
31- Jan- 07 |
31- Jan -07 |
25- Aug -09 |
US7579359 |
1-alkoxy
1H-imidazo ring systems and methods |
3M
Innovative Properties Company |
2- Sep-
04 |
1- Sep -05 |
25- Aug -09 |
US7572621 |
Detection,
characterization and treatment of viral infection and methods thereof |
Canadian
Blood Services |
9- Apr-
03 |
11- Oct -05 |
11- Aug -09 |
US7572448 |
Combined
cancer treatment methods using selected antibodies to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
11- Aug -09 |
US7572442 |
Selected
antibody compositions for binding to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Jul- 03 |
11- Aug -09 |
US7569536 |
Method
for controlling SR protein phosphorylation, and antiviral agents whose active
ingredients comprise agents that control SR protein activity |
Masatoshi
Hagiwara |
26- Dec- 03 |
24- Dec -04 |
4- Aug -09 |
US7569384 |
Albumin
fusion proteins |
Human
Genome Sciences, Inc. |
9- Feb-
04 |
8- Aug -06 |
4- Aug -09 |
US7550140 |
Antibody
to the human OX40 receptor |
Crucell
Holland B.V. |
13- Jun- 02 |
13- Jun -03 |
23- Jun- 09 |
US7547698 |
Bicyclic
heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase
(SCD) |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
16- Jun- 09 |
US7547516 |
Method
for reducing the presence of amplification inhibitors in a reaction
receptacle |
Gen-Probe
Incorporated |
10- Mar- 05 |
10- Mar -06 |
16- Jun- 09 |
US7547512 |
High-throughput
diagnostic assay for the human virus causing severe acute respiratory
syndrome (SARS) |
The
University of Hong Kong |
24- Mar- 03 |
24- Mar -04 |
16- Jun- 09 |
US7544697 |
Pyrazolopyridines
and analogs thereof |
Coley
Pharmaceutical Group, Inc. |
3- Oct-
03 |
1- Apr -05 |
9- Jun-
09 |
US7541436 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
4- May -07 |
2- Jun-
09 |
US7541163 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
14- Aug -07 |
2- Jun-
09 |
US7531630 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
13- Sep -06 |
12- May -09 |
US7531324 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
13- Sep -06 |
12- May -09 |
US7521424 |
Albumin
fusion proteins |
Human
Genome Sciences, Inc. |
22- Jan- 03 |
7- Jul- 05 |
21- Apr- 09 |
US7521185 |
Assay for
SARS coronavirus by amplification and detection of the replicase sequence |
Becton,
Dickinson and Company |
12- Sep- 03 |
13- Sep -04 |
21- Apr- 09 |
US7514436 |
Pyridazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
7- Apr-
09 |
US7511124 |
Compositions
comprising phosphatidylethanolamine-binding peptides linked to anti-viral
agents |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
31- Mar -09 |
US7504384 |
Use
of lipid conjugates in the treatment of infection |
Yissum
Research Development Company of the Hebrew University of Jerusalem |
10- Jan- 00 |
8- Sep -05 |
17- Mar -09 |
US7504382 |
Protease
inhibitors for coronaviruses and SARS-CoV and the use thereof |
Cytovia,
Inc. |
6- May-
03 |
6- May -04 |
17- Mar -09 |
US7504205 |
Uncharacterized
ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for
SARS therapy |
The
Burnham Institute |
17- May- 04 |
17- May -05 |
17- Mar -09 |
US7504097 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
17- Mar -09 |
US7498409 |
Screening
assay for TLR7, TLR8 and TLR9 agonists and antagonists |
Schering
Corporation |
24- Mar- 05 |
23- Mar -06 |
3- Mar -09 |
US7498152 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
3- Mar -09 |
US7495011 |
Anti-coronavirus
drug |
aRigen
Pharmaceuticals, Inc. |
15- Jul-03 |
14- Jul- 04 |
24- Feb -09 |
US7491793 |
Influenza
virus inhibiting peptides |
The
Administrators of the Tulane Educational Fund |
4- Nov-
03 |
3- Nov -04 |
17- Feb -09 |
US7491706 |
Artificial
cpg single-stranded oligodeoxynucleotide and antiviral use thereof |
Changchun
Huapu Biotechnology Co., Ltd. |
25- Jul-03 |
26- Jul- 04 |
17- Feb -09 |
US7491508 |
Methods
of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
The
Trustees of the University of Pennsylvania |
20- Jun- 03 |
15- Jun -04 |
17- Feb -09 |
US7491489 |
Synthetic
peptide targeting critical sites on the SARS-associated coronavirus spike
protein responsible for viral infection and method of use thereof |
The
University of Hong Knog |
22- Nov- 04 |
28- Oct -05 |
17- Feb -09 |
US7491397 |
Receptor
binding polypeptides |
National
Health Research Institutes |
9- Jan- 04 |
10- Jan -05 |
17- Feb -09 |
US7488801 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
10- Feb -09 |
US7488589 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
10- Feb -09 |
US7488473 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
10- Feb -09 |
US7485432 |
Selective
modulation of TLR-mediated biological activity |
3M
Innovative Properties Company |
27- Feb- 03 |
27- Feb -04 |
3- Feb -09 |
US7482334 |
Therapeutic
treatment methods |
Hollis-Eden
Pharmaceuticals, Inc. |
28- Aug- 02 |
12- Feb -07 |
27- Jan- 09 |
US7482149 |
Inhibition
of SARS coronavirus infection with clinically approved antiviral drugs |
Genome
Institute of Singapore |
9- Jun-
03 |
9- Jun -04 |
27- Jan- 09 |
US7479484 |
Peptides
and peptidomimetics having immune-modulating, anti- inflammatory, and
anti-viral activity |
Takeda
Pharmaceutical Company Limited |
25- Jun- 03 |
25- Jun -04 |
20- Jan- 09 |
US7470666 |
Use of
Ulinastatin and its pharmaceutical composition for treating severe acute
respiratory syndrome |
Guangdong
Techpool Biochem. Pharma. Co., Ltd. |
26- May- 03 |
25- May -04 |
30- Dec -08 |
US7470548 |
Hazardous
substance removing method, hazardous substance removing material used therein
such as air filter, mask, wipe sheet, and the like, and storage method
thereof |
Daikin
Industries, Ltd. |
28- Mar- 03 |
26- Mar -04 |
30- Dec -08 |
US7468418 |
Compositions
for enhancing transport of molecules into cells |
AVI
BioPharma., Inc. |
29- Apr- 03 |
29- Apr -04 |
23- Dec -08 |
US7465836 |
Hydrolytically-resistant
boron-containing therapeutics and methods of use |
Anacor
Pharmaceuticals, Inc. |
16- Jun- 03 |
15- Jun -04 |
16- Dec -08 |
US7462615 |
Inhibitors
of cysteine proteases, the pharmaceutical compositions thereof and their
therapeutic applications |
Hybrigenics
SA |
8- Dec-
05 |
8- Dec -05 |
9- Dec -08 |
US7460960 |
Proteome
epitope tags and methods of use thereof in protein modification analysis |
Epitome
Biosystems, Inc. |
10- May- 02 |
13- Nov -03 |
2- Dec -08 |
US7456180 |
Piperazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
25- Nov -08 |
US7455833 |
Methods
and compositions for treating viral infections using antibodies and immunoconjugates
to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
25- Nov -08 |
US7452542 |
Live
attenuated coronavirus vaccines |
Vanderbilt
University |
21- May- 04 |
23- May -05 |
18- Nov -08 |
US7445889 |
Methods
for detecting parvovirus infections |
The
Research Foundation of State University of New York |
5- May-
03 |
5- May -04 |
4- Nov -08 |
US7442761 |
Replikin
peptides and uses thereof |
BOGOCH
ELENORE S |
6- Jun-
03 |
4- Jun -04 |
28- Oct- 08 |
US7442508 |
Methods
for detection and production of influenza viruses |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
28- Apr -06 |
28- Oct- 08 |
US7439349 |
Method
for preparation of large volume batches of poly-ICLC with increased
biological potency; therapeutic, clinical and veterinary uses thereof |
Not
Available |
3-Jul- 02 |
1- Jul- 03 |
21- Oct- 08 |
US7439052 |
Method
of making modified immunodeficiency virus particles |
Lipid
Sciences |
29- Jun- 00 |
10- Apr -06 |
21- Oct- 08 |
US7435588 |
Systems
for detection and production of respiratory, herpes and enteric viruses |
Diagnostic
Hybrids, Inc. |
20- Sep- 05 |
28- Apr -06 |
14- Oct- 08 |
US7435538 |
High
throughput screening method of drug for physiologically active protein |
CellFree
Sciences Co., Ltd. |
8- Sep-
03 |
8- Sep -04 |
14- Oct- 08 |
US7432045 |
Method
of inhibiting influenza infection with antiviral peptides |
Wisconsin
Alumni Research Foundation |
1- Dec-
03 |
1- Dec -04 |
7- Oct-
08 |
US7429656 |
Inhibition
of SARS-associated coronavirus (SCoV) infection and replication by RNA
interference |
The
University of Hong Kong |
19- May- 03 |
14- Jun -06 |
30- Sep -08 |
US7427479 |
Methods
and kits for identifying target nucleotides in mixed populations |
Applera
Corporation |
30- Apr- 04 |
29- Apr -05 |
23- Sep -08 |
US7424370 |
Computational
method for identifying adhesin and adhesin-like proteins of therapeutic
potential |
Council
of Scientific and Industrial Research |
20- Jul-04 |
7- Feb -05 |
9- Sep -08 |
US7407663 |
Modified
immunodeficiency virus particles |
Lipid
Sciences, Inc. |
29- Jun- 00 |
20- Jun -03 |
5- Aug -08 |
US7407662 |
Modified
viral particles with immunogenic properties and reduced lipid content |
Lipid
Sciences, Inc. |
29- Jun- 00 |
21- Jun -04 |
5- Aug -08 |
US7405207 |
Nebulizer
formulations of dehydroepiandrosterone and methods of treating asthma or
chronic obstructive pulmonary disease using compositions thereof |
Epigenesis
Pharmaceuticals, Inc. |
17- Jun- 02 |
17- Jun -03 |
29- Jul- 08 |
US7405046 |
Compositions
and methods for treatment of rhinovirus |
The
Quigley Corporation |
6- Aug-
01 |
27- Oct -06 |
29- Jul- 08 |
US7399588 |
Method
for detecting SARS coronavirus |
Eiken
Kagaku Kabushiki Kaisha |
27- Jun- 03 |
15- Jun -04 |
15- Jul- 08 |
US7396914 |
SARS
nucleic acids, proteins, antibodies, and uses thereof |
University
of Massachusetts |
4- Aug-
03 |
4- Aug -04 |
8- Jul- 08 |
US7393856 |
Anti-viral
uses of borinic acid complexes |
Anacor
Pharmaceuticals, Inc. |
14- Jun- 04 |
14- Jun -05 |
1- Jul- 08 |
US7393638 |
Assay
system and methods for detecting SARS-CV |
AsiaGEN
Corporation |
1-Jul- 03 |
1- Jul- 03 |
1- Jul- 08 |
US7387271 |
Immunostimulatory
combinations |
3M
Innovative Properties Company |
30- Dec- 02 |
30- Dec -03 |
17- Jun- 08 |
US7384909 |
Anti-viral
treatment methods using phosphatidylethanolamine- binding peptides linked to
anti-viral agents |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
10- Jun- 08 |
US7378386 |
Anti-viral
treatment methods using phosphatidylethanolamine- binding peptide derivatives |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
27- May -08 |
US7375210 |
PCR
primer set for detecting severe acute respiratory syndrome
(SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the
same |
Samsung
Electronics Co., Ltd. |
12- Dec- 03 |
24- Nov -04 |
20- May -08 |
US7375202 |
Human
virus causing severe acute respiratory syndrome (SARS) and uses thereof |
The
University of Hong Kong |
24- Mar- 03 |
24- Mar -04 |
20- May -08 |
US7375180 |
Methods
and compositions related to IRM compounds and Toll-like receptor 8 |
3M
Innovative Properties Company |
13- Feb- 03 |
12- Feb -04 |
20- May -08 |
US7374883 |
Method
and kit for the detection of a novel coronoavirus associated with the severe
acute respiratory syndrome (SARS) |
QIAGEN
Diagnostics GmbH |
30- Apr- 03 |
30- Apr -04 |
20- May -08 |
US7371850 |
Method
and composition for reducing expression of ROCK-II |
Myriad
Genetics, Inc. |
20- Aug- 03 |
20- Aug -04 |
13- May -08 |
US7371837 |
Human
virus causing respiratory tract infection and uses thereof |
The
University of Hong Kong |
21- Jul-04 |
16- May -05 |
13- May -08 |
US7371525 |
Compositions
and methods for diagnosing and treating severe acute respiratory syndrome
(SARS) |
The
Chinese University of Hong Kong |
29- Jul-03 |
28- Jul- 04 |
13- May -08 |
US7361747 |
Isolation
and characterization of the precursor virus of human SARS virus:
SARS-associated corona virus-like virus |
The
University of Hong Kong |
22- May- 03 |
24- May -04 |
22- Apr- 08 |
US7361304 |
Building
decontamination with vaporous hydrogen peroxide |
Steris
Inc. |
31- Jan- 03 |
29- Jan -04 |
22- Apr- 08 |
US7358068 |
Antiviral
oligonucleotides |
Replicor,
Inc. |
13- Sep- 02 |
12- Sep -03 |
15- Apr- 08 |
US7354908 |
Materials
and methods for prevention and treatment of RNA viral diseases |
University
of South Florida |
30- Apr- 02 |
30- Apr -03 |
8- Apr-
08 |
US7354551 |
Room
decontamination with hydrogen peroxide vapor |
Steris
Inc |
8-Jul- 04 |
8- Jul- 04 |
8- Apr-
08 |
US7344740 |
Methods
and apparatus to prevent, treat, and cure the symptoms of nausea caused by
chemotherapy treatments of human cancers |
Inhalation,
Inc. |
3- Apr- 00 |
27- Nov -04 |
18- Mar -08 |
US7344720 |
Vaccine
composition |
Sanofi
Pasteur SA |
17- Nov- 03 |
15- Nov -04 |
18- Mar -08 |
US7339051 |
Compositions
and methods for the treatment of severe acute respiratory syndrome (SARS) |
Isis
Pharmaceuticals, Inc. |
28- Apr- 03 |
26- Apr -04 |
4- Mar -08 |
US7335658 |
Pyridazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
26- Feb -08 |
US7332475 |
Preventive
or therapeutic composition for viral infectious disease |
Kyowa
Hakko Kogyo Co., Ltd. |
22- Jul-03 |
22- Jul- 04 |
19- Feb -08 |
US7332294 |
CXCL10-based
diagnosis and treatment of respiratory illnesses |
University
Health Network |
17- Aug- 04 |
17- Aug -04 |
19- Feb -08 |
US7320857 |
Characterization
of the earliest stages of the severe acute respiratory syndrome (SARS) virus
and uses thereof |
Chinese
National Human Genome Center at Shanghai |
9-Jul- 04 |
9- Jul- 04 |
22- Jan- 08 |
US7318918 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
18- May -05 |
15- Jan- 08 |
US7314613 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
19- May -04 |
1- Jan-
08 |
US7312036 |
Compositions
for use in identification of viral hemorrhagic fever viruses |
ISIS
Pharmaceuticals, Inc. |
22- Mar- 04 |
21- Mar -05 |
25- Dec -07 |
US7297786 |
RNA
interference in respiratory epitheial cells |
University
of Iowa Research Foundation |
9-Jul- 04 |
11- Jul- 05 |
20- Nov -07 |
US7291498 |
Methods
of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
The
Trustees of the University of Pennsylvania |
20- Jun- 03 |
20- Jun -03 |
6- Nov -07 |
US7282568 |
Human
monoclonal antibodies against interleukin 8 (IL-8) |
Genmab
A/S |
16- Dec- 02 |
16- Dec -03 |
16- Oct- 07 |
US7282199 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
25- Apr -03 |
16- Oct- 07 |
US7267942 |
Diagnostic
assay for the human virus causing severe acute respiratory syndrome (SARS) |
The
University of Hong Kong |
24- Mar- 03 |
24- Mar -04 |
11- Sep -07 |
US7261867 |
Production
of silver sulfate grains using organo-sulfate or organo- sulfonate additives |
Eastman
Kodak Company |
7- Apr-
06 |
7- Apr -06 |
28- Aug -07 |
US7247303 |
Selected
antibody CDRs for binding to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
24- Jul- 07 |
US7244732 |
Prodrugs
of heteroaryl compounds |
Koronis
Pharmaceuticals, Incorporated |
20- Jun- 03 |
31- Mar -04 |
17- Jul- 07 |
US7223787 |
Prenylation
inhibitors reduce host cell permissiveness to viral replication |
Board
of Regents, The University of Texas System |
21- Oct- 03 |
21- Oct -03 |
29- May -07 |
US7220852 |
Coronavirus
isolated from humans |
The
United States of America as represented by the Secretary of the Department of Health and
Human Services, Centers for Disease Control and Prevention |
25- Apr- 03 |
12- Apr -04 |
22- May -07 |
US7183300 |
Inhibitors
of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and
analogues thereof |
AGARWAL
ATUL |
11- Nov- 04 |
10- Nov -05 |
27- Feb -07 |
US7166435 |
Compositions
and methods for reducing the transmissivity of illnesses |
The
Quigley Corporation |
6- Aug-
01 |
14- Dec -04 |
23- Jan- 07 |
US7163947 |
1-Amino
1H-imidazoquinolines |
3M
Innovative Properties Company |
7- Mar-
03 |
3- Sep -04 |
16- Jan- 07 |
US7151163 |
Antiviral
agents for the treatment, control and prevention of infections by
coronaviruses |
Sequoia
Pharmaceuticals, Inc. |
28- Apr- 03 |
28- Apr -04 |
19- Dec -06 |
US7151091 |
Compositions
and methods for preventing infection |
La
Jolla Biosciences LLC |
20- Sep- 02 |
22- Sep -03 |
19- Dec -06 |
US7148248 |
Method of
treating or inhibiting the development of brain inflammation and sepsis |
NOZAKI
MASAKO |
29- Nov- 02 |
26- Nov -03 |
12- Dec -06 |
US7129223 |
Inhibition
of SARS-associated coronavirus (SCoV) infection and replication by RNA
interference |
The
University of HongKong |
19- May- 03 |
19- May -04 |
31- Oct- 06 |
US7129042 |
Compositions
and methods for detecting severe acute respiratory syndrome coronavirus |
Diagnostic
Hybrids, Inc. |
3- Nov-
03 |
3- Nov -03 |
31- Oct- 06 |
US7115563 |
Composition
and its therapeutic use |
Insignion
Holding Limited |
29- May- 02 |
29- May -03 |
3- Oct-
06 |
US7091214 |
Aryl
substituted Imidazoquinolines |
3M
Innovative Properties Co. |
20- Dec- 02 |
18- Dec -03 |
15- Aug -06 |
US7048953 |
Methods
and apparatus to prevent, treat and cure infections of the human respiratory
system by pathogens causing severe acute respiratory syndrome (SARS) |
Inhalation,
Inc. |
3- Apr- 00 |
2- May -03 |
23- May -06 |
US7023593 |
Apparatus
for forming nano-grating device |
Industrial
Technology Research Institute |
28- Nov- 03 |
17- Mar -04 |
4- Apr-
06 |
US6946291 |
Mixed
cell diagnostic systems |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
30- Mar -04 |
20- Sep -05 |
US20200176
079 |
METHODS
AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES |
Not
Available |
19- Jul-17 |
18- Jul- 18 |
4- Jun-
20 |
US20200173
925 |
MICROSCOPIC
BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC
BODY DETECTION DEVICE |
JAPAN
SCIENCE AND TECHNOLOGY AGENCY |
29- Mar- 17 |
28- Mar -18 |
4- Jun- 20 |
US20200172
883 |
COMPOSITIONS
FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS |
Not
Available |
19- Nov- 09 |
13- Sep -19 |
4- Jun-
20 |
US20200172
879 |
DHFR
TUNABLE PROTEIN REGULATION |
Not
Available |
3- Mar-
17 |
2- Sep -19 |
4- Jun-
20 |
US20200172
600 |
RSV
F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
15- Jul-09 |
16- Aug -17 |
4- Jun-
20 |
US20200172
513 |
DIHYDROPYRIMIDINYL
BENZAZEPINE CARBOXAMIDE COMPOUNDS |
Hoffmann-La
Roche Inc. |
12- Jun- 16 |
5- Feb -20 |
4- Jun-
20 |
US20200172
480 |
CONJUGATES
OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Jul-12 |
5- Feb -20 |
4- Jun-
20 |
US20200171
085 |
Method
of Treating Respiratory Tract Infection |
Not
Available |
19- May- 17 |
18- May -18 |
4- Jun-
20 |
US20200171
060 |
FLEX-NUCLEOSIDE
ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES |
Not
Available |
31- Jul-17 |
26- Jan -18 |
4- Jun-
20 |
US20200166
505 |
METHOD
AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID
SAMPLE BY USING NEODYMIUM MAGNETS |
The
U.S.A., as represented by the Secretary, Department of Health and Human
Services |
1- Sep- 15 |
30- Jan -20 |
28- May -20 |
US20200165
632 |
ENHANCING
AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
Spark
Therapeutics, Inc. |
7- Jun-
17 |
6- Jun -18 |
28- May -20 |
US20200165
630 |
COMPOSITIONS
FOR THE TREATMENT OF DISEASE |
Not
Available |
29- Apr- 16 |
28- Apr -17 |
28- May -20 |
US20200165
613 |
VIRUS
LIKE PARTICLE |
The
University of Leeds |
1- Jun-
17 |
31- May -18 |
28- May -20 |
US20200165
594 |
CRISPR
SYSTEM BASED ANTIVIRAL THERAPY |
MASSACHUSETTS
INSTITUTE OF TECHNOLOGY |
7-Jul- 17 |
6- Jul- 18 |
28- May -20 |
US20200165
585 |
NEW
CHIMERIC ENZYMES AND THEIR APPLICATIONS |
Not
Available |
27- Jul-17 |
27- Jul- 18 |
28- May -20 |
US20200165
357 |
CARBONIC
ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF |
Not
Available |
2- Dec-
05 |
21- Oct -19 |
28- May -20 |
US20200164
334 |
MICROSPOTTING
DEVICE |
Not
Available |
18- Apr- 12 |
11- Oct -19 |
28- May -20 |
US20200164
067 |
Methods
and Compositions for Inhibiting Akt3 |
Not
Available |
15- Jan- 16 |
5- Feb -20 |
28- May -20 |
US20200164
058 |
TRIMERIC
S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY
SYNDROME-CORONAVIRUS |
King
Abdulaziz University |
27- Nov- 18 |
27- Nov -18 |
28- May -20 |
US20200164
020 |
PUM
1 PROTEIN AS TARGET FOR VIRUS INHIBITION |
Not
Available |
12- Apr- 17 |
12- Apr -17 |
28- May -20 |
US20200163
878 |
LIPID
NANOPARTICLE MRNA VACCINES |
Not
Available |
26- Oct- 16 |
26- Oct -17 |
28- May -20 |
US20200157
600 |
METHODS
AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION |
Not
Available |
19- Nov- 18 |
19- Nov -18 |
21- May -20 |
US20200157
222 |
ANTI-PD-L1
ANTIBODIES AND USES THEREOF |
Not
Available |
29- Mar- 18 |
29- Mar -19 |
21- May -20 |
US20200157
221 |
ONCOLYTIC
VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES |
Not
Available |
30- Jun- 16 |
28- Jan -20 |
21- May -20 |
US20200155
704 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
30- Jan -20 |
21- May -20 |
US20200155
699 |
MODIFIED
VIRUS-LIKE PARTICLES OF CMV |
Not
Available |
22- Oct- 14 |
26- Nov -19 |
21- May -20 |
US20200155
667 |
VACCINE
COMPOSITIONS |
Not
Available |
27- Jul-17 |
24- Jan -20 |
21- May -20 |
US20200155
664 |
INFLUENZA
VACCINES WITH REDUCED AMOUNTS OF SQUALENE |
Not
Available |
10- Feb- 09 |
26- Jun -19 |
21- May -20 |
US20200155
662 |
COMBINATION
IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS |
Not
Available |
26- May- 17 |
25- May -18 |
21- May -20 |
US20200155
660 |
COMPOSITIONS
AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY |
Not
Available |
23- Sep- 15 |
22- Nov -19 |
21- May -20 |
US20200155
646 |
EV576 For
Use in the Treatment of Viral Infections of the Respiratory Tract |
Volution
Immuno Pharmaceuticals SA |
8- Jan- 10 |
7- Jun -19 |
21- May -20 |
US20200149
062 |
ENGINEERED
TSC2 |
Not
Available |
14- Jul-17 |
13- Jul- 18 |
14- May -20 |
US20200149
048 |
Transbiotic
Regulation of Bacterial Gene Expression |
Not
Available |
22- May- 17 |
22- May -18 |
14- May -20 |
US20200148
749 |
ANTIBODIES
AND PROCESSES FOR PREPARING THE SAME |
Not
Available |
16- May- 08 |
10- Oct -19 |
14- May -20 |
US20200147
203 |
VACCINATION
OF IMMUNOCOMPROMISED SUBJECTS |
Not
Available |
26- Sep- 14 |
10- Jan -20 |
14- May -20 |
US20200147
193 |
COMPOSITIONS
AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS |
Not
Available |
2- Jun- 17 |
2- Jun -18 |
14- May -20 |
US20200147
171 |
COMPOSITIONS
OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST
CANCERS, INFECTIONS DISEASES AND DISORDERS |
Not
Available |
18- Sep- 18 |
18- Sep -19 |
14- May -20 |
US20200140
547 |
MULTIFUNCTIONAL
ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE |
Not
Available |
26- May- 17 |
25- May -18 |
7- May -20 |
US20200140
493 |
Engineering
Virus-like Nanocarriers for Biomolecule Delivery |
Not
Available |
26- Oct- 18 |
25- Oct -19 |
7- May -20 |
US20200140
398 |
HUMAN
HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS |
AZIENDA
OSPEDALIERA UNIVERSITARIA SENESE |
13- Feb- 15 |
6- Jan -20 |
7- May -20 |
US20200138
937 |
Genetically
Attenuated Nucleic Acid Vaccine |
Not
Available |
2- Jun-
17 |
1- Jun -18 |
7- May -20 |
US20200138
936 |
Phenotypically
Wild-Type and Genetically Attenuated Viruses |
Not
Available |
2- Jun-
17 |
1- Jun -18 |
7- May -20 |
US20200138
818 |
METHODS
OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB |
Not
Available |
7- Nov-
18 |
6- Nov -19 |
7- May -20 |
US20200138
780 |
METHODS
FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C |
Not
Available |
14- Mar- 13 |
19- Dec -19 |
7- May -20 |
US20200131
518 |
CONTROL
OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE |
Not
Available |
14- Mar- 17 |
14- Mar -18 |
30- Apr- 20 |
US20200129
487 |
CHEMOTHERAPY
FOR CANCER USING AZABICYCLO COMPOUND |
TAIHO
PHARMACEUTICAL CO., LTD. |
30- Jun- 17 |
29- Jun -18 |
30- Apr- 20 |
US20200127
954 |
RNA
TARGETING METHODS AND COMPOSITIONS |
Salk
Institute for Biological Studies |
22- Aug- 17 |
31- Dec -18 |
23- Apr- 20 |
US20200124
599 |
ACCURATE,
RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING
SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL |
CELLEMEDY
CO., LTD |
13- Apr- 17 |
13- Apr -18 |
23- Apr- 20 |
US20200123
233 |
AMINO
ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND
POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
Ablynx
N.V. |
5- Jun- 08 |
1- Aug -19 |
23- Apr- 20 |
US20200123
205 |
Inhibition
Of TCR Signaling With Peptide Variants |
Not
Available |
22- Oct- 18 |
18- Dec -19 |
23- Apr- 20 |
US20200123
203 |
COMPOSITIONS
COMPRISING CURONS AND USES THEREOF |
FLAGSHIP
PIONEERING INNOVATIONS V, INC. |
13- Jun- 17 |
13- Jun -18 |
23- Apr- 20 |
US20200115
448 |
CELLS
EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS
AND USES THEREOF |
Not
Available |
26- Apr- 17 |
22- Oct -19 |
16- Apr- 20 |
US20200115
434 |
ANTIBODY/T-CELL
RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF |
Not
Available |
23- Oct- 15 |
29- Oct -19 |
16- Apr- 20 |
US20200113
996 |
CHIMERIC
VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF
IMMUNE RESPONSES |
Not
Available |
23- Jun- 17 |
21- Jun -18 |
16- Apr- 20 |
US20200113
967 |
PEPTIDES
AND USES THEREFOR AS ANTIVIRAL AGENTS |
Not
Available |
26- May- 17 |
26- May -17 |
16- Apr- 20 |
US20200113
831 |
LIPOSOMES
HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 11 |
16- Dec -19 |
16- Apr- 20 |
US20200113
830 |
PEGYLATED
LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA |
GLAXOSMITHKLINE
BIOLOGICALS S.A. |
31- Aug- 11 |
16- Dec -19 |
16- Apr- 20 |
US20200109
403 |
IN
VIVO DELIVERY OF OLIGONUCLEOTIDES |
Not
Available |
12- Dec- 11 |
18- Dec -19 |
9- Apr-
20 |
US20200108
136 |
METHODS
AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES |
Not
Available |
6- Apr-
07 |
22- Nov -19 |
9- Apr-
20 |
US20200102
558 |
TRANSKINGDOM
PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY |
Not
Available |
3- Apr-
17 |
3- Oct -19 |
2- Apr-
20 |
US20200102
550 |
TAL
EFFECTOR-MEDIATED DNA MODIFICATION |
Not
Available |
10- Dec- 09 |
28- Aug -19 |
2- Apr-
20 |
US20200102
544 |
POXVIRUS-PLASMODIUM
RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND
METHODS OF MAKING AND USING THE SAME |
Not
Available |
30- Dec- 13 |
11- Sep -19 |
2- Apr- 20 |
US20200102
362 |
TUMOR
NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING
AND BIOACTIVITY |
Not
Available |
6- Apr-
17 |
5- Apr -18 |
2- Apr-
20 |
US20200102
292 |
SUBSTITUTED
BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF |
Not
Available |
3-Jul- 13 |
10- Jul- 19 |
2- Apr-
20 |
US20200101
158 |
ANTI-TIGIT
ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF |
Not
Available |
1- Oct-
15 |
22- Oct -19 |
2- Apr-
20 |
US20200101
153 |
MVA-BN
AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN |
Not
Available |
6- Apr-
17 |
6- Apr -18 |
2- Apr-
20 |
US20200101
142 |
PDE5
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
Not
Available |
12- Jun- 17 |
12- Jun -18 |
2- Apr-
20 |
US20200101
119 |
METHODS
OF TREATMENT OF INFECTIONS USING BACTERIA |
Not
Available |
27- Sep- 18 |
26- Sep -19 |
2- Apr-
20 |
US20200101
087 |
PHARMACEUTICAL
COMPOSITIONS AND METHODS |
Not
Available |
3- Aug-
15 |
21- Nov -19 |
2- Apr-
20 |
US20200100
480 |
TRAIT
SELECTION IN AVIANS |
Not
Available |
31- May- 17 |
31- May -18 |
2- Apr-
20 |
US20200095
324 |
ANTI-TIGIT
ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF |
Not
Available |
30- Mar- 17 |
30- Mar -18 |
26- Mar -20 |
US20200093
919 |
MODIFIED
PEDV SPIKE PROTEIN |
Not
Available |
20- Sep- 18 |
18- Sep -19 |
26- Mar -20 |
US20200093
909 |
PLASMODIUM
SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND
ANTIBODIES BINDING TO |
Not
Available |
19- Apr- 17 |
19- Apr -18 |
26- Mar -20 |
US20200093
855 |
ENHANCED
IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE |
Not
Available |
11- Sep- 17 |
3- Jun -19 |
26- Mar -20 |
US20200093
841 |
Broad
Spectrum Antiviral and Methods of Use |
Not
Available |
17- Apr- 06 |
30- Apr -19 |
26- Mar -20 |
US20200087
655 |
PURIFICATION
OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES |
Not
Available |
14- Jul-15 |
22- Nov -19 |
19- Mar -20 |
US20200087
646 |
OPTIMIZED
HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE |
Not
Available |
31- May- 17 |
31- May -18 |
19- Mar -20 |
US20200087
630 |
INFLUENZA
VIRUS AND TYPE 1 DIABETES |
Istituto
Zooprofilattico Sperimentale delle Venezie |
10- Oct- 12 |
25- Jul- 19 |
19- Mar -20 |
US20200087
359 |
GRIFFITHSIN
MUTANTS |
The
United States of America,as represented by the Secretary,Department of Health
and Human Services |
10- Feb- 15 |
27- Nov -19 |
19- Mar -20 |
US20200087
313 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
29- Jul-11 |
25- Apr -19 |
19- Mar -20 |
US20200087
298 |
Imidazo[4,5-c]
Ring Compounds Containing Guanidine Substituted Benzamide Groups |
Not
Available |
1- Mar-
17 |
27- Feb -18 |
19- Mar -20 |
US20200087
280 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
25- Nov -19 |
19- Mar -20 |
US20200086
324 |
DEVICES
AND METHODS FOR NUCLEIC ACID EXTRACTION |
Not
Available |
30- Jun- 16 |
27- Dec -18 |
19- Mar -20 |
US20200085
984 |
APPARATUS,
METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS |
THE
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
7- Mar-
11 |
25- Nov -19 |
19- Mar -20 |
US20200085
947 |
VISTA
MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER |
Not
Available |
7- Sep-
12 |
14- May -19 |
19- Mar -20 |
US20200085
943 |
PHARMACEUTICAL
COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE
PROTEIN OR PEPTIDE ANTIGEN |
CureVac
AG |
31- Jan- 12 |
29- Aug -19 |
19- Mar -20 |
US20200085
872 |
IMMUNE
CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS |
Not
Available |
19- Apr- 17 |
19- Apr -18 |
19- Mar -20 |
US20200085
852 |
EPIDERMAL
MRNA VACCINE |
Not
Available |
5- Aug-
15 |
5- Aug -16 |
19- Mar -20 |
US20200085
756 |
NANOPARTICLE
VACCINE ADJUVANT AND METHODS OF USE THEREOF |
Not
Available |
14- Sep- 18 |
12- Jul- 19 |
19- Mar -20 |
US20200080
141 |
METHODS
AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS |
Not
Available |
11- Dec- 13 |
19- Nov -19 |
12- Mar -20 |
US20200080
111 |
Methods
for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome
Editing and Compositions Thereof |
Not
Available |
18- Sep- 15 |
19- Sep -16 |
12- Mar -20 |
US20200079
820 |
DERIVATIVES
OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE |
Hangzhou
DAC Biotech Co., Ltd. |
20- Apr- 16 |
20- Apr -16 |
12- Mar -20 |
US20200079
781 |
Substituted
2,4 diamino-quinoline as new medicament for fibrosis, autophagy and
cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases |
Not
Available |
5- Sep- 18 |
1- Aug -19 |
12- Mar -20 |
US20200078
335 |
COMPOSITIONS
AND METHODS TO REDUCE PATHOGENESIS |
Not
Available |
1- May-
17 |
1- May -18 |
12- Mar -20 |
US20200072
836 |
MEDIA
ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF |
Not
Available |
5- May-
14 |
2- Apr -19 |
5- Mar -20 |
US20200071
723 |
RNA-BASED
DELIVERY SYSTEMS WITH LEVELS OF CONTROL |
Not
Available |
30- Aug- 18 |
29- Aug -19 |
5- Mar -20 |
US20200071
421 |
BISPECIFIC
ANTIBODY |
Not
Available |
20- Nov- 13 |
8- Apr -19 |
5- Mar -20 |
US20200069
814 |
CONJUGATION
OF A CYTOTOXIC DRUG WITH BIS-LINKAGE |
Hangzhou
DAC Biotech Co., Ltd. |
6- Apr-
17 |
6- Apr -17 |
5- Mar -20 |
US20200062
764 |
ALKYL
PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME |
Not
Available |
17- Nov- 16 |
17- Nov -17 |
27- Feb -20 |
US20200061
187 |
METHODS
FOR PREPARING SQUALENE |
Not
Available |
12- May- 10 |
4- Nov -19 |
27- Feb -20 |
US20200061
185 |
PREFUSION
CORONAVIRUS SPIKE PROTEINS AND THEIR USE |
The
Scripps Research Institute |
25- Oct- 16 |
25- Oct -17 |
27- Feb -20 |
US20200060
981 |
CATIONIC
NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES |
Not
Available |
9- Dec-
16 |
11- Dec -17 |
27- Feb -20 |
US20200056
221 |
METHODS
FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA |
Not
Available |
8- Nov-
13 |
25- Oct -19 |
20- Feb -20 |
US20200056
159 |
NOVEL
ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR |
Not
Available |
28- Feb- 17 |
27- Feb -18 |
20- Feb -20 |
US20200055
927 |
MAST CELL
STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION |
Not
Available |
8- Sep-
16 |
25- Oct -19 |
20- Feb -20 |
US20200055
926 |
MAST CELL
STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION |
Not
Available |
8- Sep-
16 |
25- Oct -19 |
20- Feb -20 |
US20200054
731 |
IMMUNOMODULATORY
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
7- Jan- 14 |
15- Jul- 19 |
20- Feb -20 |
US20200054
660 |
DNA
METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY |
St.
Jude Children's Research Hospital |
9- Dec-
16 |
7- Dec -17 |
20- Feb -20 |
US20200054
259 |
HIGH
DENSITY ANALOG MULTIPEXING |
EnLiSense,
LLC |
17- Aug- 18 |
16- Aug -19 |
20- Feb -20 |
US20200048
722 |
METHODS
FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL,
VIRAL, AND PROTOZOAN NUCLEIC ACIDS |
Not
Available |
8- May- 15 |
24- Aug -19 |
13- Feb -20 |
US20200048
649 |
VIRUS-LIKE
PARTICLES AND USES THEREOF |
Not
Available |
13- Mar- 17 |
13- Mar -18 |
13- Feb -20 |
US20200048
636 |
IMMUNISATION
OF LARGE MAMMALS WITH LOW DOSES OF RNA |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
18- Oct -19 |
13- Feb -20 |
US20200046
865 |
DECONTAMINATION
DEVICE AND METHOD USING ULTRASONIC CAVITATION |
Not
Available |
29- Dec- 17 |
22- Aug -19 |
13- Feb -20 |
US20200046
826 |
METHODS
AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS |
Academia
Sinica |
27- Mar- 09 |
4- Jun -19 |
13- Feb -20 |
US20200046
692 |
SPECIFIC
AKT3 INHIBITOR AND USES THEREOF |
Not
Available |
15- Jan- 16 |
2- Oct -19 |
13- Feb -20 |
US20200040
408 |
HANDHELD
NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION |
Not
Available |
8- Feb-
16 |
6- May -19 |
6- Feb -20 |
US20200040
042 |
CHIMERIC
MOLECULES AND USES THEREOF |
Not
Available |
30- Mar- 17 |
29- Mar -18 |
6- Feb -20 |
US20200038
871 |
DEVICES,
PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE,
EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE,
LIGASE, POLYMERASE, AND SEQUENCING REACTIONS |
Not
Available |
29- Mar- 17 |
29- Mar -18 |
6- Feb -20 |
US20200038
373 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
9- May-
12 |
16- May -19 |
6- Feb -20 |
US20200033
343 |
EXOSOME-MEDIATED
DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES |
Not
Available |
6- Oct-
08 |
14- Oct -19 |
30- Jan- 20 |
US20200032
255 |
METHODS
AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES |
Not
Available |
26- Jan- 07 |
6- Mar -19 |
30- Jan- 20 |
US20200031
871 |
NOVEL
DEPSIPEPTIDES AND USES THEREOF |
Not
Available |
4- Apr-
17 |
30- Mar -18 |
30- Jan- 20 |
US20200031
819 |
COMPOSITIONS
AND METHODS FOR INHIBITING KINASES |
Not
Available |
23- Apr- 15 |
26- Jun -19 |
30- Jan- 20 |
US20200030
441 |
Lipidated
Immune Response Modifier Compound Compositions, Formulations, and Methods |
Not
Available |
17- Aug- 10 |
8- Jul- 19 |
30- Jan- 20 |
US20200030
432 |
ZOONOTIC
DISEASE RNA VACCINES |
ModernaTX,
Inc. |
17- Mar- 17 |
16- Mar -18 |
30- Jan- 20 |
US20200030
422 |
COMBINATION
OF VACCINATION AND OX40 AGONISTS |
CureVac
AG |
9- Sep-
16 |
15- Apr -19 |
30- Jan- 20 |
US20200024
616 |
NOVEL
RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC
TROPISM |
Not
Available |
30- Mar- 18 |
29- Mar -19 |
23- Jan- 20 |
US20200024
310 |
NOVEL
DEPSIPEPTIDE AND USES THEREOF |
Not
Available |
3- Dec-
12 |
1- Aug -19 |
23- Jan- 20 |
US20200020
420 |
Method
for Establishing Machine Learning Model for Predicting Toxicity of siRNA to
Certain Type of Cells and Application Thereof |
Not
Available |
8- Dec- 16 |
7- Dec -17 |
16- Jan- 20 |
US20200017
926 |
CELL-FREE
NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF |
Not
Available |
7- Nov-
13 |
28- Aug -19 |
16- Jan- 20 |
US20200017
832 |
COMPOSITIONS
FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS,
METHODS AND USES THEREOF |
Not
Available |
5- Apr- 17 |
5- Apr -18 |
16- Jan- 20 |
US20200017
588 |
MODULAR
TETRAVALENT BISPECIFIC ANTIBODY PLATFORM |
Not
Available |
14- Oct- 16 |
16- Oct -17 |
16- Jan- 20 |
US20200017
554 |
SELF-ASSEMBLING
PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINS |
Not
Available |
23- Mar- 17 |
22- Mar -18 |
16- Jan- 20 |
US20200017
514 |
ADAMANTANE
DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION |
Not
Available |
12- Jul-18 |
12- Jul- 18 |
16- Jan- 20 |
US20200017
455 |
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS |
Not
Available |
24- Jan- 14 |
19- Mar -19 |
16- Jan- 20 |
US20200016
589 |
LOADING
VIALS |
Not
Available |
10- Nov- 11 |
24- Sep -19 |
16- Jan- 20 |
US20200016
286 |
Production
of Immune-Response-Stimulating Aerosols By Non- Thermal Plasma Treatment Of
Airborne Pathogens |
Not
Available |
13- Jul-18 |
12- Jul- 19 |
16- Jan- 20 |
US20200016
280 |
Compositions
For Enhancing Transport Of Molecules Into Cells |
Not
Available |
29- Apr- 03 |
9- Apr -19 |
16- Jan- 20 |
US20200016
161 |
METHODS
FOR TREATING VIRAL DISORDERS |
TRUSTEES
OF BOSTON UNIVERSITY |
24- Sep- 09 |
22- Jul- 19 |
16- Jan- 20 |
US20200010
883 |
METHODS
AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS |
Not
Available |
9- Oct-
15 |
7- Jun -19 |
9- Jan-
20 |
US20200010
519 |
NUCLEASE
FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE
INTEGRATION |
Not
Available |
10- Mar- 17 |
9- Mar -18 |
9- Jan-
20 |
US20200009
244 |
NANOPARTICLE
VACCINES WITH NOVEL STRUCTURAL COMPONENTS |
Not
Available |
13- Jun- 18 |
13- Jun -19 |
9- Jan-
20 |
US20200002
674 |
ERYTHROID
CELLS COMPRISING PHENYLALANINE HYDROXYLASE |
Not
Available |
18- Nov- 13 |
16- Sep -19 |
2- Jan-
20 |
US20200000
931 |
SYNTHETIC
NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS |
Not
Available |
15- Jul-16 |
10- Apr -19 |
2- Jan-
20 |
US20190391
150 |
COMPOSITIONS
AND METHODS FOR CAPTURING EXOSOMES |
Not
Available |
1- May-
15 |
10- Sep -19 |
26- Dec -19 |
US20190390
249 |
BIOLOGICAL
SPECIMEN COLLECTION AND TRANSPORT SYSTEM |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
19- Jun -17 |
26- Dec -19 |
US20190390
229 |
GENE
EDITING REAGENTS WITH REDUCED TOXICITY |
Not
Available |
21- Apr- 16 |
20- Apr -17 |
26- Dec -19 |
US20190390
179 |
SYNTHETIC
REVERSE TRANSCRIPTASES AND USES THEREOF |
Not
Available |
12- Apr- 16 |
12- Apr -17 |
26- Dec -19 |
US20190390
176 |
NOVEL
RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL
MUSCLE TROPISM |
Not
Available |
2- Dec- 15 |
3- Jul- 19 |
26- Dec -19 |
US20190389
816 |
ANTIVIRAL
COMPOUNDS AND METHODS |
Biotron
Limited |
26- Jun- 03 |
29- Aug -19 |
26- Dec -19 |
US20190388
473 |
METHODS
AND COMPOSITIONS FOR IMMUNOMODULATION |
Not
Available |
1- Apr-
14 |
30- Aug -19 |
26- Dec -19 |
US20190382
799 |
VIRAL
METHODS OF MAKING GENETICALLY MODIFIED CELLS |
Not
Available |
27- Oct- 16 |
19- Apr -19 |
19- Dec -19 |
US20190382
433 |
GLYCOLIPIDS
AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY |
THE
UNIVERSITY OF NOTTINGHAM |
4- Apr-
14 |
25- Jul- 19 |
19- Dec -19 |
US20190381
180 |
HYBRID
CARRIERS FOR NUCLEIC ACID CARGO |
Not
Available |
9- Jun-
16 |
9- Jun -17 |
19- Dec -19 |
US20190381
162 |
PAN
FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING |
Not
Available |
28- Mar- 16 |
27- Mar -17 |
19- Dec -19 |
US20190381
155 |
COMBINATION
OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY |
CureVac
AG |
22- Feb- 13 |
29- Aug -19 |
19- Dec -19 |
US20190380
995 |
PREVENTION
AND TREATMENT OF VIRAL INFECTIONS |
Not
Available |
2- Jun-
16 |
3- Jul- 19 |
19- Dec -19 |
US20190380
891 |
MOBILE
CLINICS |
Baylor
College of Medicine |
12- Nov- 14 |
28- Aug -19 |
19- Dec -19 |
US20190376
151 |
MODIFIED
OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING
NUCLEIC ACIDS |